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ABSTRACT 
 
Childhood maltreatment increases the risk of developing major depressive disorder (MDD) and 
post-traumatic stress disorder (PTSD) later in life. Dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis, a regulator of the body’s stress response, has been associated with exposure 
to childhood maltreatment, MDD, and PTSD. Additional work has shown that a history of 
childhood maltreatment, MDD, and PTSD is associated with altered DNA methylation levels within 
key HPA axis genes. Despite this well-known association, the molecular mechanism(s) 
contributing to the increased risk of developing mental illness, specifically MDD or PTSD, 
following exposure to childhood maltreatment remain poorly understood. Therefore, the goal of 
my dissertation is to further elucidate the biologic mechanisms contributing to the relationship 
among childhood maltreatment, MDD, and PTSD by focusing on DNA methylation and gene 
expression. Chapter 2 investigates whether childhood maltreatment and MDD have a joint or 
potentially interacting effect on NR3C1, the glucocorticoid receptor, promoter region DNA 
methylation using whole blood. A secondary analysis examines the potential functional effect on 
downstream gene expression levels. Chapter 3 examines whether blood-derived DNA 
methylation of FKBP5, another HPA axis gene, mediates the relationship between childhood 
maltreatment and MDD, and whether DNA methylation subsequently influences FKBP5 gene 
expression. In Chapter 4, the genome-scale blood-based transcriptomic profiles of childhood 
maltreatment and PTSD are characterized and compared for overlap. Chapter 5 characterizes 
the genome-scale DNA methylation profiles associated with MDD in post-mortem brain. Results 
reveal that, despite clear evidence for a long-lasting biologic embedding of CM exposure, the 
subsequent impact of MDD and PTSD during adulthood is characterized by genomic signatures 
that are largely distinct from those associated with early life adversity. Taken together, these 
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studies contribute to our current understanding of the biologic impact of childhood maltreatment, 
MDD, and PTSD on DNA methylation and gene expression levels.  
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CHAPTER  1: A GENERAL INTRODUCTION TO THE RELATIONSHIP BETWEEN EARLY 
LIFE ADVERSITY AND MENTAL ILLNESS 
 
ABSTRACT 
There is a well-documented link between exposure to early life adversity (ELA) and poor mental 
health later in life. More specifically, childhood maltreatment is known to increase the susceptibility 
to both major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) during 
adulthood. Childhood maltreatment, or more broadly ELA, MDD, and PTSD, have all been 
associated with dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, a key regulator of 
the body’s stress response. Despite the established link between ELA and increased susceptibility 
to MDD and PTSD, the molecular mechanisms contributing to this relationship are poorly 
understood. In order to gain a deeper understanding of this relationship and the biologic 
mechanisms contributing to it, we must first understand the impact of each exposure on different 
biologic systems and processes. The biologic systems and processes that will be reviewed 
include: the HPA axis, stress-related mental disorders, dysregulation of the HPA axis, epigenetics 
as a potential mediator of mental illness, and gene expression. Despite the observable 
association between childhood maltreatment, MDD, and PTSD on HPA axis reactivity, DNA 
methylation, and gene expression, many studies have examined these exposures separately. 
Examination of these exposures separately is a good first step to understanding the biologic 
impact of the individual exposure, however it does not provide insight into the relationship 
between these exposures. Therefore, further work is necessary to deepen our understanding of 
the relationship between childhood maltreatment, MDD, and PTSD.  
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Current estimates from the National Survey of Children’s Exposure to Violence (NatSCEV) 
indicate lifetime exposure to childhood maltreatment is 24.9% within the US (Finkelhor et al., 
2015). Following exposure to childhood maltreatment, the risk or susceptibility for mental illness 
dramatically increases (Afifi et al., 2008; Hussey et al., 2006; Kendler et al., 2004; MacMillan et 
al., 2001; Nanni et al., 2012); among women reporting childhood sexual abuse, 39.3% go on to 
experience lifetime depression (Kessler et al., 1994), compared with 21.3% in the general 
population (Molnar et al., 2001). Similarly, whereas 48.5% of women and 51.2% of men meet the 
criteria of at least one lifetime mood, anxiety or substance disorder, substantially more- 78% of 
women and 82% of men- do so among those reporting child sexual abuse (Molnar et al., 2001). 
Data from the National Comorbidity Survey Replication (NCS-R) dataset confirms and extends 
these findings by assessing the population attributable fraction for psychiatric disorders among 
adults in reference to early life adversity (ELA). Among women, 22% to 32% of mood, anxiety and 
substance abuse disorders are attributable to ELA; among men, the range is 20% to 24% (Afifi et 
al., 2008). This suggests there is an underlying mechanism(s) that link ELA to the development 
of mental illness later in life, pointing to the critical importance of investigating the potential biologic 
mechanisms mediating this well-established relationship. For that reason, one logical starting 
point to further examine the relationship between ELA and mental illness is the stress response 
that is regulated by the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous 
system. 
1.1. THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS AND STRESS  
The HPA axis is the master regulator of the body’s stress response (Van Voorhees and 
Scarpa, 2004). Activation of the HPA axis occurs when the central nervous system (CNS) 
perceives an outside stressor as a threat, triggering a cascade starting with the release of 
corticotropin releasing hormone (CRH) from the hypothalamus, which results in the release of 
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adrenocorticotropic hormone (ACTH) from the pituitary, and ending with the release of the 
glucocorticoid cortisol from the adrenal glands into the bloodstream. The CNS also activates the 
sympathetic nervous system (SNS), generating norepinephrine and epinephrine and upregulating 
inflammatory cytokines. In healthy individuals, glucocorticoids, such as the stress hormone 
cortisol, function to modulate transcription of immune response genes (Irwin and Cole, 2011; 
Yang et al., 2012). Regulation of the HPA axis occurs through negative feedback. There are two 
mechanisms of negative feedback that regulate the stress response: a long and an ultra-short 
feedback loop. The long feedback loop works to tamp down the stress response when high levels 
of cortisol are detected by the hippocampus, resulting in the reduction of CRH released by the 
hypothalamus (Binder, 2009; Binder et al., 2008; Davies et al., 2002; Yang et al., 2012). The 
second mechanism is an ultra-short intracellular feedback loop involving the protein product of 
FKBP5, FK506 binding protein 5. FKBP5 modulates the ability of cortisol to bind to the 
glucocorticoid receptor when present in the chaperone complex; when cortisol successfully binds 
to the glucocorticoid receptor, FKBP5 dissociates from the complex (Binder, 2009). The activated 
glucocorticoid receptor forms a homodimer, then translocates into the nucleus (Binder et al., 2008; 
Yang et al., 2012) where it binds to glucocorticoid response elements and acts as a transcription 
factor, initiating transcription of FKBP5 and recruitment of other transcription factors (Figure 1.1). 
FKBP5 is a negative regulator of glucocorticoid sensitivity: when bound to the chaperone 
complex. FKBP5 decreases the binding affinity of cortisol to the GR resulting in decreased 
efficiency for the complex to translocate into the nucleus, contributing to a downregulation of the 
stress response in local environments (Appel et al., 2011; Binder, 2009; Binder et al., 2008; Yang 
et al., 2012).  
In healthy individuals, when an acute stressor is perceived and the HPA axis is activated, 
behavioral and physiologic changes occur together allowing the individual to adapt to the stressor 
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and, ultimately, increase chances of survival. The behavioral and physiologic changes involve 
careful control or regulation of aspects of both the central and peripheral stress response to 
ensure an appropriate reaction occurs. Activation of the stress response is characterized by 
physiologic changes that can increase or inhibit various functions. The physiologic processes that 
are increased during acute stress include: rate of respiration, blood pressure, heart rate, and the 
breakdown of fats into available energy (Charmandari et al., 2005; Chrousos, 2009; Chrousos 
and Gold, 1992). Conversely, acute stress suppresses or slows down the digestive system, 
growth, reproduction, inflammation, and immune response (Charmandari et al., 2005; Chrousos, 
2009; Chrousos and Gold, 1992). Another effect of acute stress is the redirection of oxygen and 
nutrients to the CNS or the site of the stressor. Together, these physiologic changes provide the 
body with more available energy during the stressful event, by suppressing several high energy 
systems. As previously mentioned, the stress response results in behavioral changes as well, 
including enhanced cognition and memory function, heightened focus and vigilance, heightened 
arousal and alertness, increased analgesia, increased body temperature, suppressed appetite, 
and suppressed reproduction (Charmandari et al., 2005; Chrousos and Gold, 1992). Taken 
together, these short-term behavioral and physiologic changes allow the individual to better 
respond to the stressor, by increasing cognitive functions, memory formation, and available 
energy without adverse consequences to the individual. 
Dysregulation of the stress response, however, can occur as a result of chronic stress, 
resulting in hyper- or hypoactivation of the HPA axis (Charmandari et al., 2005; Van Voorhees 
and Scarpa, 2004). Hyperactivation or increased activity of the HPA axis is characterized by 
increased or prolonged secretion of CRH and/or glucocorticoids (i.e. cortisol) (Charmandari et al., 
2005). In contrast, hypoactivation or decreased activity of the HPA axis is characterized by 
reduced secretion of CRH and cortisol (Charmandari et al., 2005). Dysregulation of the stress 
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response, through both hyper- and hypo- activation of the HPA axis, can result in the development 
of various disorders as a consequence of prolonged increased or reduced CRH and glucocorticoid 
exposure.  
Dysregulation of immune function can arise as a consequence of the dysregulated stress 
response, as activation of the HPA axis modulates inflammation and immune response via 
glucocorticoids such as cortisol, while the SNS regulates the production of inflammatory cytokines 
via norepinephrine and epinephrine. When activated, the SNS produces epinephrine and 
norepinephrine which upregulate pro-inflammatory cytokines (Irwin and Cole, 2011). Conversely, 
the end product of HPA axis activation is cortisol, which suppresses the immune response by 
down regulating the production of pro-inflammatory cytokines, with the goal of reducing potential 
tissue damage caused by inflammation (Charmandari et al., 2005; Irwin and Cole, 2011). It is 
thought that chronic or prolonged exposure to stress alters sensitivity to glucocorticoids and 
inflammatory cytokines, resulting in a lack of regulation of the HPA axis as well as immune 
function and response. It is through this joint mechanism of altered immune function resulting 
from HPA axis and SNS dysregulation that susceptibility to hypertension, autoimmune disorders, 
cardiovascular diseases, diabetes, and cancer among others is increased (Coussens and Werb, 
2002; Ishihara and Hirano, 2002; Ridker, 2007; Savoia and Schiffrin, 2006). Furthermore, there 
is a growing body of evidence linking increased levels of inflammatory cytokines with mood and 
anxiety disorders such as major depressive disorder (MDD) and post-traumatic stress disorder 
(PTSD) (Dowlati et al., 2010; Gill et al., 2009; Hoge et al., 2009; Irwin and Cole, 2011; Miller et 
al., 2013; Piletz et al., 2009). Perhaps not surprisingly, MDD, PTSD, and related mood-anxiety 
disorders are often comorbid with these inflammatory conditions, with rates as high as up to 25% 
(Boscarino, 2004) percent. 
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1.2. STRESS RELATED MENTAL DISORDERS  
MDD is a debilitating mental illness with a lifetime prevalence estimated to be 16.2% within 
the US according to the NCS-R (Kessler et al., 2003). Moreover, the lifetime prevalence of MDD 
is much higher in women compared to men, 21% and 12%, respectively (Kessler et al., 1993). 
There is also an increased prevalence of co-morbidity for anxiety, substance abuse, and 
personality disorders (Hirschfeld, 2001; Melartin et al., 2002). Diagnostic criteria for MDD 
according to the Diagnostics Statistical Manual IV (DSM-IV) requires possession of at least 5 of 
the 9 symptoms with persistence of symptoms occurring for two or more weeks. MDD diagnostic 
symptoms include: depressed or irritable mood and/or decreased interest or pleasure, concurrent 
with significant weight change (≥5%), change in sleep (hypersomnia or insomnia), change in 
activity level (psychomotor agitation or retardation), fatigue or loss of energy, feelings of 
worthlessness or guilt, diminished ability to concentrate, and lastly, suicidal thoughts or ideations 
(Association, 2000, 2013). 
PTSD is an anxiety disorder that can result following exposure to a traumatic event. In the US, 
it is estimated that 40-90% of the population has been exposed to or has experienced a traumatic 
event (Green et al., 2000). Despite the high rate of exposure to traumatic events, current 
estimates of lifetime PTSD prevalence sit at 6.8% in the US (Kessler and Wang, 2008). 
Additionally, there is a high rate of co-morbid disorders among those with PTSD, including MDD 
(Breslau et al., 2000), substance abuse (Breslau et al., 2003), and cardiovascular disease (as 
reviewed in (Coughlin, 2011)) to name a few. Diagnostic criteria for PTSD according to DSM-IV 
include exposure to a traumatic event, either experienced or witnessed by the individual, 
characterized by intense feelings of fear, helplessness, or horror and must involve the threat or 
actuality of death, serious injury, or physical integrity of oneself or others. Additional diagnostic 
criteria include: persistent re-experiencing of the traumatic event, avoidance of stimuli associated 
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with the trauma, increased arousal, persistence of the above symptoms for at least 1 month, and 
disturbances causing clinically significant distress or impairment in social, occupational, or other 
areas of functioning (Association, 2000).  
 
1.3. DYSREGULATION OF THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS  
Dysregulation of the stress response can occur from chronic exposure to stress and result 
in the increased prevalence of stress-related mental illnesses and inflammatory diseases. This 
work highlights the effect of environmental exposures on HPA axis function. To further our 
understanding of the impact of environmental exposures, it is important to understand how 
different exposures (childhood maltreatment, MDD, and PTSD) impact HPA axis functioning. 
Foundational rodent studies demonstrated the importance of early life environment, specifically 
maternal behavior, on shaping offspring HPA axis reactivity over the life course. High level of 
maternal care has been associated with reduced plasma ACTH and corticosterone (i.e. the rodent 
equivalent of cortisol) levels in the offspring when exposed to an acute stressor (Liu et al., 1997), 
suggesting high maternal care levels are associated with reduced HPA axis reactivity in offspring. 
The initial findings from this work were extended through cross-fostering experiments that showed 
rat pup stress reactivity resembled the dam it was reared by, not the dam it was born to (Weaver 
et al., 2004), further underscoring the importance of early environment in shaping HPA axis 
reactivity. Additionally, other rodent studies have demonstrated the ability of chronic stress and 
chronic exposure to glucocorticoids to alter HPA axis activity (as reviewed in (Gudsnuk and 
Champagne, 2012)). Taken together these studies provide insight into how HPA axis reactivity is 
shaped throughout the lifetime.  
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In humans, dysregulation of the HPA axis has been associated with exposure to ELA 
(Guerry and Hastings, 2011; Klaassens et al., 2009; Kuhlman et al., 2015; Van Voorhees and 
Scarpa, 2004) as well as mental illnesses such as depression (Belvederi Murri et al., 2014; Espejo 
et al., 2007), major depression (Lamers et al., 2013; Morris et al., 2017; Stetler and Miller, 2011; 
Verduijn et al., 2015), and PTSD (de Kloet et al., 2006; Ehlert et al., 2001). In studies focusing on 
the impact of ELA or childhood maltreatment, results regarding HPA axis hormone levels have 
been mixed between studies comprised of adolescents or adults with a history of ELA exposure. 
Studies comprised of an adolescent sample population have reported increased afternoon cortisol 
levels in participants with a history of childhood maltreatment (Hart et al., 1996; Kaufman, 1991). 
Additionally, increased basal cortisol was observed in maltreated children compared to the non-
maltreated controls (Debellis et al., 1994). In adults, studies examining basal cortisol levels have 
reported no difference among ELA exposed and non-ELA exposed groups (Klaassens et al., 
2009), while blunted cortisol and ACTH levels were observed in studies administering the Trier 
social stress test (TSST) (Carpenter et al., 2007; Elzinga et al., 2008; Meinlschmidt and Heim, 
2005) or combined dexamethasone/corticotropin releasing hormone (Dex/CRH) challenge test 
(Klaassens et al., 2009). In contrast, others have reported increased cortisol and/or ACTH 
following the TSST (Heim et al., 2000) or combined Dex/CRH challenge test (Heim et al., 2008; 
Tyrka et al., 2008) in samples with ELA exposure. Given the apparent opposite effect of ELA on 
cortisol levels in adolescents and adults, it is important to consider potential factors contributing 
to this difference, such as population of the study (adolescents vs adults) or the type, timing, 
severity, and frequency of ELA. One study by Kuhlman et al. (Kuhlman et al., 2015), examined 
the impact of timing of ELA on HPA axis reactivity in an adolescent-aged sample, specifically 
focusing on exposure during infancy (defined as within 1st year) and exposure after infancy 
(defined as after 1st year) (Kuhlman et al., 2015). They found exposure to traumatic events during 
infancy was associated with slower downregulation of cortisol following exposure to acute stress 
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compared to participants exposed to adversities later in childhood. This effect of slower recovery 
following acute stress was also observed in participants with a higher total number of traumatic 
events (Kuhlman et al., 2015). Their results suggest both timing and frequency of traumatic events 
impact HPA axis reactivity. The observed differences between adolescent and adult cortisol levels 
may be related to the age of trauma exposure and how ELA or trauma impact HPA axis function 
at different stages of development. Despite discrepancies in study designs and reported findings, 
these studies provide strong evidence of the long-term impact ELA has on HPA axis reactivity. 
Many studies examining basal cortisol levels in children and adolescents with MDD report 
no significant difference between MDD cases and controls (as reviewed in (Guerry and Hastings, 
2011)). This finding in children and adolescents is contrary to the adult literature which has 
robustly shown increased basal cortisol in participants with MDD (Vreeburg et al., 2009) and 
depression (Dienes et al., 2013; Stetler and Miller, 2011) compared to controls. A large meta-
analysis spanning 40 years of research and encompassing 361 studies found increased levels of 
cortisol following dexamethasone suppression test (DST) and increased ACTH in MDD cases 
compared to controls (Stetler and Miller, 2011). Another meta-analysis of adults 60 and over 
reported significant differences between MDD cases and controls in respect to basal cortisol 
levels throughout the day and cortisol post DST, but no significant differences in ACTH or CRH 
levels (Belvederi Murri et al., 2014). These results differ from studies where administration of the 
DST in children and adolescents resulted in increased cortisol production following DST (as 
reviewed in (Guerry and Hastings, 2011)). Additionally, there is evidence for a genotype effect on 
HPA axis reactivity within FKBP5: significantly increased cortisol and ACTH levels were observed 
following the DST for MDD participants with the FKBP5 risk “T” allele (rs1360780) compared to 
controls (Menke et al., 2013). Following up on this work, another study reported a significant 
genotype dependent increase in plasma cortisol concentrations following the TSST specific to 
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control participants with the TT “risk” genotype of rs1360780, but reported no effect in the remitted 
MDD participants (Hohne et al., 2015). Overall these results suggest increased cortisol and ACTH 
levels in adult individuals with MDD compared to controls, which is thought to be indicative of 
decreased cortisol sensitivity resulting in an inability to properly downregulate the stress 
response.  
Within PTSD, reported findings of HPA axis reactivity are fairly inconsistent, as many 
studies report conflicting or non-significant results. Several studies have reported reduced levels 
(Labonte et al., 2014; Yehuda et al., 2015b) and no-difference (Metzger et al., 2008; Simeon et 
al., 2007) in cortisol levels in individuals with PTSD compared to controls. Additionally, a large 
meta-analysis of 37 studies with reported cortisol measurements from various sources (urine, 
saliva, plasma, and serum) reported no significant difference in cortisol levels between the PTSD 
and non-PTSD groups. However, a significant reduction in serum/plasma cortisol levels was 
associated with PTSD when the studies were subset to include only non-trauma exposed controls  
(Meewisse et al., 2007). The results of this meta-analysis suggests the make-up of the control 
group (trauma exposed or non-trauma exposed) may impact findings. Additionally, this study 
suggests lower cortisol levels are related to trauma exposure rather than PTSD. Interestingly, a 
large study found reduced plasma cortisol levels were associated with current PTSD in Vietnam 
“theater” veterans, but not in Vietnam “theater” veterans with lifetime PTSD when compared to 
Vietnam era veterans who did not serve in Vietnam (Boscarino, 1996). This study suggests there 
may be an effect of disorder status (current, remitted, lifetime) on HPA axis reactivity. Decreased 
cortisol levels were observed in participants with PTSD compared to healthy controls following 
the TSST (Zaba et al., 2015) and DST (Yehuda et al., 2015b; Yehuda et al., 1993) (reviewed in 
(de Kloet et al., 2006)). Additionally, other studies have reported no significant difference in 
cortisol levels between PTSD cases compared to controls following administration of TSST 
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(MacMillan et al., 2009; Roelofs et al., 2009; Simeon et al., 2007) or DST (Simeon et al., 2007). 
These inconsistent findings make it challenging to draw conclusions regarding HPA axis 
dysregulation in PTSD. Some researchers suggest the lower cortisol levels associated with PTSD 
indicate enhanced feedback inhibition, meaning increased sensitivity to cortisol (as reviewed in 
(Ehlert et al., 2001)), while others suggest the low cortisol levels observed in individuals with 
PTSD is related to the impact of ELA or early life trauma (as reviewed in (Pervanidou and 
Chrousos, 2012)). ELA or early life trauma is thought to have a greater impact of HPA axis function 
and reactivity due to the plasticity of the developing brain during early life. This notion of lower 
cortisol associated with early life trauma expands on the finding by Meewisse et al. (Meewisse et 
al., 2007), suggesting the observed low cortisol levels are more related to trauma exposure than 
PTSD. Nevertheless, more work is needed to confirm how the HPA axis is dysregulated by PTSD 
and trauma in general, and if there are disorder status-related differences.  
As indicated above, there are inconsistent findings regarding HPA axis reactivity in relation 
to ELA, MDD, and PTSD. These inconsistencies may result from the design of the study, 
including: demographics or make-up of the population, disorder status (current, remitted, lifetime 
PTSD), selected controls, time points of sample collection, method of hormone detection (urine, 
saliva, serum, or plasma), and the amount of hormone administered (high or low dose) to test 
stress reactivity. All of these factors may contribute to the inconsistent findings reported in studies. 
Another potential contributor to the discrepancy in results may pertain to the heterogeneity of the 
disorder. MDD and PTSD are both heterogeneous disorders, meaning the presentation of 
symptoms and symptom severity can vary greatly among those diagnosed. Despite the 
differences in reported results, these studies showcase the impact lived experiences and chronic 
stress exposure have on HPA axis activity, indicating the HPA axis plays a role in the 
manifestation of disorders such as MDD and PTSD. Despite this established link, it is important 
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to investigate other biologic mechanisms that may be mediating the relationship between ELA 
and mental illness; one plausible mechanism is via epigenetics and downstream gene expression.  
 
1.4. EPIGENETICS AS A POTENTIAL MEDIATOR OF MENTAL ILLNESS  
Epigenetics can be broadly defined as biologic mechanisms which alter gene regulation and 
expression without affecting the underlying DNA sequence. Epigenetic modifications are 
influenced by age, environmental and social exposures, and disease (Fraga et al., 2005; Gudsnuk 
and Champagne, 2012; Robertson, 2005; Weaver et al., 2004). Epigenetic factors are distinct 
from genetic mutations (insertions, deletions, or single nucleotide polymorphisms (SNPs)) that 
are permanent changes to the DNA sequence or genetic code. There are several types of 
epigenetic modifications including histone modifications, non-coding RNA, and DNA methylation 
(Kim et al., 2009; Whitelaw and Whitelaw, 2006) (Figure 1.2). Histone modifications are a diverse 
group of covalent post-translational modifications specifically acting on the histone protein. 
Modifications to the histone protein include methylation, phosphorylation, acetylation, 
ubiquitylation, and sumoylation all of which impact chromatin structure and can make DNA more 
or less accessible to transcription factors (Kouzarides, 2007). Non-coding RNAs are made up of 
two groups, short non-coding RNA (<30nt) and long non-coding RNA (>200nt), which regulate 
gene expression at the transcriptional and post-transcriptional level. Non-coding RNAs can impact 
heterochromatin formation, histone modifications, DNA methylation targeting, and gene silencing 
(Kaikkonen et al., 2011).  
Of particular interest is DNA methylation, which is characterized by the addition of a methyl 
group, -CH3, to the 5’ position of cytosine by a covalent bond, typically when cytosine is coupled 
to guanine on the same strand of DNA. DNA methylation is stable over time (Heijmans et al., 
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2008; Tyrka et al., 2008), tissue specific (Aguilera et al., 2010), and responsive to environmental 
exposures (Fraga et al., 2005). DNA methylation when present at certain genomic regions can 
alter transcriptional activity. Specifically, the presence of methylation within the promoter or at the 
transcription factor binding site of a gene usually results in reduced gene expression (Brenet et 
al., 2011). Because of its responsiveness to social exposures (Essex et al., 2013; Fraga et al., 
2005; Weaver et al., 2004), DNA methylation is an attractive mechanism to study how lived 
experiences or environmental exposures “get under the skin”, i.e. how they manifest biologically. 
Additionally, DNA methylation is a powerful tool that can assist in elucidating the interplay 
between environmental exposures and physiologic consequence(s).  
There are two main approaches for examining DNA methylation levels: locus-specific and 
genome-scale. The locus-specific approach is customizable or application specific and allows for 
the selective targeting of certain sections of a gene. The use of a locus-specific approach to 
examine DNA methylation levels represents a knowledge-driven or hypothesis-driven approach. 
A genome-scale approach allows for a more thorough examination of DNA methylation as multiple 
genomic regions and genes are targeted simultaneously. This approach allows for the 
simultaneous discovery of multiple genes associated with the outcome of interest. Genome-scale 
approaches represent a hypothesis-generating or an exploratory analysis, as the researcher does 
not need a specific hypothesis for this analysis. Additionally, results from genome-scale studies 
can be used as a tool to inform the more targeted locus-specific approach. 
Building off the work demonstrating the impact of early life environment on HPA axis reactivity, 
DNA methylation of key HPA axis genes were examined to further our understanding of how 
environmental exposures “get under the skin”.  Initial work in rodents revealed level of maternal 
care early in life not only impacted future rat pup behavior, but also was associated with significant 
alterations to DNA methylation levels of a key HPA axis gene, Nr3c1, which persisted into 
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adulthood and modified physiologic stress reactivity. Furthermore, cross fostering rat pups 
between the high and low nurturing dams revealed these epigenetic differences were not 
inherited, but rather were influenced by environmental exposures (Weaver et al., 2004). In other 
studies, which have focused on HPA axis gene Fkbp5, decreased DNA methylation levels were 
observed following exposure to increased levels of glucocorticoids in a neuronal cell line (Yang 
et al., 2012) and in neuronal (i.e. hippocampal (Klengel et al., 2013; Yang et al., 2012)) and 
peripheral (i.e. blood (Klengel et al., 2013; Lee et al., 2010; Lee et al., 2011)) tissues, as well as 
in additional cells relevant to the HPA axis (i.e. pituitary cells (Yang et al., 2012)). A similar rodent 
study demonstrated decreased DNA methylation levels in Fkbp5 when exposed to increased 
corticosterone levels (Lee et al., 2010). Moreover, glucocorticoid-induced DNA methylation 
changes persist long after cessation of glucocorticoid exposure (Klengel et al., 2013; Lee et al., 
2010; Lee et al., 2011), suggesting that stress-induced glucocorticoid cascades have long lasting 
consequences on HPA axis function that may be accompanied by behavioral (mal)adaptations 
(Klengel et al., 2013; Mehta and Binder, 2012).  
In humans, early epigenetic studies have examined monozygotic twins as they have identical 
genomes and shared early life environments. Despite these commonalities, monozygotic twins 
may develop discordant diseases during their lifetime, making them a unique group in which to 
study aging and disease. An initial study of monozygotic twins spanning a wide age range 
revealed younger twins have more DNA methylation patterns in common and as twins aged, their 
methylation patterns began to diverge (Fraga et al., 2005). This study highlights the importance 
of environment and how different phenotypes can be generated from identical genotypes. 
Additional work in humans has looked at the impact of prenatal exposure to famine, and found 
epigenetic differences among siblings who were exposed to famine conditions during gestation 
compared to their non-famine exposed siblings (Heijmans et al., 2008). These examples highlight 
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the utility of focusing on DNA methylation in studies that seek to characterize the biologic impact 
of environmental exposures.  
 
1.5. EPIGENETIC DIFFERENCES ASSOCIATED WITH CHILDHOOD MALTREATMENT  
There is a strong body of work showing ELA, more specifically childhood maltreatment, is 
associated with altered DNA methylation levels in the HPA axis gene NR3C1, the glucocorticoid 
receptor (Klaassens et al., 2009; McGowan et al., 2009; Oberlander et al., 2008; Schiene-Fischer 
and Yu, 2001; Weaver et al., 2004), and FKBP5, FK506 binding protein 5 (Klengel et al., 2013; 
Tyrka et al., 2015). Foundational rodent studies revealed maternal care early in life is associated 
with alterations in HPA axis gene Nr3c1 DNA methylation levels, which persist into adulthood and 
modify physiologic stress reactivity, demonstrating epigenetic factors are not exclusively inherited 
as previously thought, they are however, influenced by environmental exposures (Weaver et al., 
2004). Similarly, in humans, maternal depressed/anxious mood during the third trimester was 
associated with increased NR3C1 DNA methylation at the predicted NGFI-A binding site in cord 
derived-blood, and with increased cortisol responses 3 months postnatally (Oberlander et al., 
2008). Subsequent studies found maternal experiences during pregnancy have also been 
associated with differences in NR3C1 DNA methylation levels in offspring blood (Hompes et al., 
2013; Radtke et al., 2011; Smith et al., 2011b). Other studies in humans have further examined 
the impact of childhood maltreatment and other ELAs on DNA methylation levels of HPA axis 
genes NR3C1 and FKBP5 compared to non-childhood maltreatment exposed controls in studies 
examining both blood and post-mortem brain samples (Klengel et al., 2013; Labonte et al., 2012b; 
Martin-Blanco et al., 2014; McGowan et al., 2009; Non et al., 2016; Perroud et al., 2011; Romens 
et al., 2015; Tyrka et al., 2012; Tyrka et al., 2015). These studies have found childhood 
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maltreatment is associated with increased DNA methylation of NR3C1 and decreased DNA 
methylation of FKBP5 when compared to non-maltreated controls.  
Comparatively fewer studies have examined the impact of childhood maltreatment on 
DNA methylation by employing a genome-scale approach. Distinct DNA methylation profiles have 
been associated with childhood maltreatment exposure compared to controls in buccal cells (Cecil 
et al., 2016), saliva (Weder et al., 2014), blood (Suderman et al., 2014), and hippocampal tissue 
(Labonte et al., 2012a). Three additional studies have examined childhood maltreatment in the 
context of psychiatric disorders including borderline personality disorder (Prados et al., 2015), 
PTSD (Mehta et al., 2013), and depression (Weder et al., 2014) in blood and brain derived DNA. 
Taken together, these studies emphasize the long lasting, detectable impact of ELA and 
childhood maltreatment on DNA methylation both at the locus-specific and broader genome-scale 
levels. 
 
1.6. EPIGENETIC DIFFERENCES ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER 
(MDD)  
 
 As with childhood maltreatment, there is strong evidence linking MDD with altered DNA 
methylation, both at the locus-specific and at the genome-scale levels. At the locus-specific level, 
a significant impact of MDD on blood-derived DNA methylation levels in NR3C1 has been 
reported, although there are conflicting reports regarding the direction of effect across studies 
(Bustamante et al., 2016; Na et al., 2014; Nantharat et al., 2015; Roy et al., 2017).  Some studies, 
including our own previous work, have reported decreased DNA methylation in participants with 
a history of MDD compared to controls with no history of MDD (Bustamante et al., 2016; Na et 
al., 2014). Conversely, other studies have found significantly increased DNA methylation 
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associated with MDD compared to controls with no history of MDD (Nantharat et al., 2015; Roy 
et al., 2017). Additionally, another study reported no significant difference in NR3C1 DNA 
methylation levels between MDD cases and controls (Alt et al., 2010) in brain. Studies of other 
HPA axis genes, including FKBP5, are relatively scarce, however significant differences in DNA 
methylation levels in this locus have also been reported (Hohne et al., 2015; Roy et al., 2017) in 
blood. 
 Considerably more work has been done at the genome-scale level with respect to MDD 
(Byrne et al., 2013; Kaut et al., 2015; Malki et al., 2016; Murphy et al., 2017; Numata et al., 2015; 
Oh et al., 2015; Prados et al., 2015; Sabunciyan et al., 2012; Tseng et al., 2014; Walker et al., 
2016a; Walker et al., 2016b). Among these studies, there is a great variety in the sample 
populations used; including familial studies, monozygotic twins, suicide victims, and participants 
with co-morbid mental illnesses. This diversity in samples is not surprising given the high rate of 
co-morbidity of PTSD, borderline personality disorders, bipolar disorder, and suicide among those 
with a history of MDD (Hirschfeld, 2001; Melartin et al., 2002). Additionally, these studies have 
made use of tissues derived from both living individuals (peripheral blood) as well as post-mortem 
tissue (brain). Similar to the locus-specific DNA methylation studies mentioned previously for 
MDD, there is a lack of consensus in reported genome-scale findings, and many studies are 
unable to report findings that are significant following correction for multiple test correction (Byrne 
et al., 2013; Kaut et al., 2015; Murphy et al., 2017; Oh et al., 2015; Sabunciyan et al., 2012; Tseng 
et al., 2014; Walker et al., 2016b). Nevertheless, nominally significant differences have been 
reported, though at this point there remains a lack of consensus in regards to what genes are 
differentially methylated in relation to MDD.  
 Epigenome-scale studies of MDD have primarily focused on the use of peripheral blood 
(Byrne et al., 2013; Malki et al., 2016; Numata et al., 2015; Oh et al., 2015; Prados et al., 2015; 
Tseng et al., 2014; Walker et al., 2016a; Walker et al., 2016b) compared to the more centrally 
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relevant brain tissue (Kaut et al., 2015; Murphy et al., 2017; Oh et al., 2015; Sabunciyan et al., 
2012). One study attempted to identify biomarkers of MDD using a discovery dataset and a test 
dataset and found 363 distinct DNA methylation markers identified with MDD in a discovery 
dataset; when applied to the test dataset 18 markers performed with high accuracy in discerning 
cases from controls in the discriminatory analysis (Numata et al., 2015). Another study found 
decreased DNA methylation patterns in older participants with MDD compared to younger 
participants with MDD (Tseng et al., 2014). Two studies have examined monozygotic twins 
discordant for MDD (Byrne et al., 2013; Malki et al., 2016), however significant findings were only 
reported by Malki et al. (Malki et al., 2016). MDD has also been examined in the context of bipolar 
disorder (Walker et al., 2016a; Walker et al., 2016b) and within the context of both borderline 
personality disorder and childhood maltreatment (Prados et al., 2015). Additionally, differential 
methylation patterns have been reported in post-mortem brain tissues from participants with MDD 
compared to healthy controls (Kaut et al., 2015; Oh et al., 2015; Sabunciyan et al., 2012) and also 
in suicide victims with MDD compared to non-psychiatric sudden death controls (Murphy et al., 
2017). While these studies are more diverse in scope and reported findings, they nevertheless 
provide significant evidence of altered DNA methylation associated with MDD. Despite this strong 
evidence, more work needs to be done to fully understand how epigenetic mechanisms such as 
DNA methylation contribute to MDD.  
 
1.7. EPIGENETIC DIFFERENCES ASSOCIATED WITH POST-TRAUMATIC STRESS 
DISORDER (PTSD) 
 There has been a wide variety of studies examining the epigenetic impact of PTSD on 
HPA axis genes in both blood (Labonte et al., 2014; Perroud et al., 2014; Yehuda et al., 2013; 
Yehuda et al., 2014; Yehuda et al., 2015b) and saliva (Schechter et al., 2015; Vukojevic et al., 
2014). Specifically, in relation to NR3C1, studies have reported decreased DNA methylation 
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associated with lifetime diagnosis of PTSD (Labonte et al., 2014), interpersonal violence-related 
PTSD (Schechter et al., 2015), combat exposed veterans with PTSD (Yehuda et al., 2015b) and 
with increased risk of PTSD in trauma exposed male, but not female, survivors of the Rwandan 
genocide (Vukojevic et al., 2014). Interestingly, in a different study by Perroud et al. (Perroud et 
al., 2014), female survivors of the Rwandan genocide and their offspring had increased NR3C1 
DNA methylation compared to non-genocide exposed controls and their offspring (Perroud et al., 
2014). However, this study did not directly address the relationship between PTSD status and 
NR3C1 DNA methylation levels as they only assessed current PTSD symptom severity and 
depression symptom severity. Similarly, the presence of parental (both maternal and paternal) 
PTSD was associated with decreased NR3C1 DNA methylation in adult offspring of Holocaust 
survivors; however, the presence of paternal PTSD was associated with increased DNA 
methylation (Yehuda et al., 2014). Both of these studies provide evidence for the potential 
intergenerational transmission of traumatic events via DNA methylation. DNA methylation of 
NR3C1 has also been shown to predict PTSD psychotherapy treatment outcome (Yehuda et al., 
2013). Additionally, reduced FKBP5 promoter region DNA methylation levels were associated 
with PTSD recovery following 12 weeks of psychotherapy treatment (Yehuda et al., 2013). These 
studies indicate DNA methylation levels may vary according to PTSD severity and/or 
psychotherapeutic intervention. 
At the genome-scale level, studies have focused exclusively on DNA derived from blood. 
Distinct immune function-related DNA methylation profiles were associated with PTSD compared 
to trauma exposed controls (Uddin et al., 2010), a finding which has received further support (Bam 
et al., 2016; Smith et al., 2011a). Development of PTSD symptoms has been associated with 
telomere lengthening and reversed epigenetic aging (Boks et al., 2015), while another study 
reported accelerated epigenetic aging, based on telomere length (Wolf et al., 2016). Some studies 
report no significant differences between PTSD cases and controls following multiple hypothesis 
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correction (Chen et al., 2016), which may be a result of the small sample size used within the 
study. One study identified a methylation quantitative trait loci (meQTL) associated with PTSD 
risk (Almli et al., 2015). Lastly, distinct epigenome-scale profiles were associated in PTSD 
participants with history of childhood maltreatment and PTSD participants without history of 
childhood maltreatment (Mehta et al., 2013). Interestingly, very little overlap was observed 
between PTSD participants with childhood maltreatment and PTSD participants without childhood 
maltreatment, suggesting exposure to childhood maltreatment in conjunction with PTSD impacts 
different biologic pathways than those impacted in PTSD alone. While these studies provide 
strong support for altered DNA methylation levels in association with PTSD at the locus-specific 
and genome-scale levels, further work needs to be done to fully understand the how epigenetic 
mechanisms contribute to PTSD.  
The literature summarized above provides further, though at times conflicting, support for 
the epigenetic impact of ELA, MDD, and PTSD at the locus-specific and genome-scale levels. 
Despite the strong foundation, further work is needed to fully elucidate how epigenetics, 
specifically DNA methylation, impact the trajectory of mood and anxiety disorders such as MDD 
and PTSD. Additionally, it will be important to investigate what the functional impact of DNA 
methylation is on downstream gene expression at the individual gene level as well as at the 
genome-scale level.  
 
1.8. GENE EXPRESSION  
 To further elucidate the way environmental exposures and lived experiences impact an 
individual biologically, it is important to examine gene expression. Gene expression is the process 
by which DNA is transcribed into RNA, which may later be translated into the gene product or 
protein. Regulation of gene expression is achieved through a variety of mechanisms, including 
epigenetic modifications, which ultimately control the amount of protein that is created and the 
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potential function of the protein. One known regulator of gene expression is DNA methylation. 
The presence of DNA methylation at various genomic regions is known to alter gene expression 
levels. Specifically, increased DNA methylation within the promoter region is associated with a 
decrease in downstream gene expression (Brenet et al., 2011), whereas, DNA methylation at 
other genomic regions, have varying effects on expression (Jones, 2012). Examination of gene 
expression affords the opportunity to observe the potential downstream functional impact of DNA 
methylation. It has been previously suggested that gene expression is regulated by social 
exposures similar to DNA methylation (Cole, 2013). This regulation of gene expression by social 
exposures may provide further insight into the changes that are occurring at the biologic level and 
provide a deeper understanding of how these exposures manifest and impact an individual 
biologically.  
 Similar to DNA methylation studies, there are several ways to measure gene expression 
levels, both at the individual gene level or at the broader genome-scale level. On the individual 
gene level, a specific gene transcript can be targeted for quantification of expressed transcript 
level. This approach is typically used for smaller scale studies and similar to DNA methylation 
approaches, is representative of a knowledge-driven approach. Use of a genome-scale approach 
provides the ability to simultaneously quantify multiple genes and their transcript variants, and 
therefore is an exploratory analysis. This approach allows researchers to gain a better 
understanding of the overall effect an exposure or disease has across all genes.  
 
1.9. ALTERED GENE EXPRESSION ASSOCIATED WITH CHILDHOOD MALTREATMENT 
 The impact of childhood maltreatment on HPA axis genes has been examined, however, 
most studies have focused on NR3C1. Reduced hippocampal gene expression has been reported 
for several transcript variants of NR3C1 in suicide victims with a history of childhood maltreatment 
compared to suicide victims with no history of childhood maltreatment and controls (Labonte et 
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al., 2012b). However, no significant difference in gene expression was observed between any of 
the groups in gene expression from the anterior cingulate gyrus (Labonte et al., 2012b), indicating 
brain region-specificity in transcriptional profiles. A similar study reported reduced NR3C1 gene 
expression levels were associated with abused suicide victims (McGowan et al., 2009). At the 
genome-scale level, distinct differential expression profiles were observed between PTSD cases 
with and without history of childhood maltreatment (Mehta et al., 2013). There are surprisingly few 
studies examining the impact of childhood maltreatment on gene expression. However, similar to 
the Labonte et al study described above (Labonte et al., 2012b) the studies that do exist provide 
support for reduced NR3C1 gene expression following exposure to childhood maltreatment 
(Klengel et al., 2013).  
 
1.10. ALTERED GENE EXPRESSION ASSOCIATED WITH MAJOR DEPRESSIVE 
DISORDER (MDD)  
 MDD diagnosis has been associated with reduced gene expression in blood for NR3C1 
(Roy et al., 2017; Spindola et al., 2017) and FKBP5 (Roy et al., 2017). Additionally, lifetime MDD 
has been associated with differential expression of NR3C1 transcript variants in several brain 
regions compared to controls (Alt et al., 2010). In contrast, studies in blood have reported no 
significant difference in NR3C1 gene expression between MDD cases and controls (Iacob et al., 
2013; Nantharat et al., 2015), and in others a genotype-dependent effect of FKBP5 expression 
was observed in MDD participants with the risk “T” allele carriers (rs1360780) compared to 
controls with the risk “T” allele following dexamethasone challenge (Menke et al., 2013). Following 
up on this work, another group reported a similar genotype-dependent effect of FKBP5 gene 
expression in controls carrying the risk “T” allele compared to controls with the homozygous “C” 
allele following the TSST, however, no difference was observed in the remitted MDD group 
(Hohne et al., 2015). Additionally, genome-scale gene expression studies of MDD have used both 
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blood (Hori et al., 2016; Jansen et al., 2016; Mamdani et al., 2011; Pettai et al., 2016; Spijker et 
al., 2010; Yi et al., 2012) and post-mortem brain tissues (Duric et al., 2013; Forero et al., 2017). 
These genome-scale studies have found distinct expression profiles enriched in immune-related 
genes (Jansen et al., 2016) and synaptic pathways (Duric et al., 2013; Hori et al., 2016). Distinct 
expression profiles have also been associated with MDD compared to controls (Yi et al., 2012), 
with different post-mortem brain regions in participants with MDD (Forero et al., 2017), in 
response to antidepressant treatment (Mamdani et al., 2011; Pettai et al., 2016), and 
lipopolysaccharide stimulation (Spijker et al., 2010). While these studies are diverse in design, a 
significant effect on gene expression was observed for MDD, in several contexts.  
1.11. ALTERED GENE EXPRESSION ASSOCIATED WITH POST-TRAUMATIC STRESS 
DISORDER (PTSD) 
 Considerably more research has been done examining the impact of PTSD compared to 
childhood maltreatment or MDD in blood-based gene expression studies. Lifetime PTSD has 
been associated with increased NR3C1 gene expression of several transcript variants within 
peripheral T lymphocytes compared to controls (Labonte et al., 2014). Interestingly, no difference 
in NR3C1 gene expression was detected for any of the transcript variants tested when comparing 
remitted PTSD and controls (Labonte et al., 2014), and another study reported when decreased 
glucocorticoid receptor-α (GRα) expression levels were associated with PTSD, they also report 
GRα expression levels were inversely correlated with number of traumatic events (Gola et al., 
2014).  A third study reported no difference among PTSD cases and controls (Matic et al., 2013). 
Increased FKBP5 expression has been associated with PTSD-related psychotherapy treatment 
response compared to non-responders (Yehuda et al., 2013) and cognitive behavioral therapy 
compared to controls (Szabo et al., 2014). Reduced FKBP5 expression levels have been 
associated with PTSD compared to trauma exposed controls (Levy-Gigi et al., 2013; Yehuda et 
al., 2009) and increased PTSD symptoms (van Zuiden et al., 2012). At the genome-scale level, 
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many studies of PTSD gene expression are derived from blood (Breen et al., 2015; Glatt et al., 
2013; Logue et al., 2015; Mehta et al., 2011; Mehta et al., 2013; Neylan et al., 2011; O'Donovan 
et al., 2011; Sarapas et al., 2011; Segman et al., 2005; Tylee et al., 2015; Zhou et al., 2014; Zieker 
et al., 2007) compared to brain (Su et al., 2008). Distinct differential expression profiles have been 
identified in participants with PTSD with or without history of childhood maltreatment compared 
to controls (Mehta et al., 2013) and with PTSD symptoms (Mehta et al., 2011). Significant gene 
expression profiles have also been associated with PTSD compared to controls (Logue et al., 
2015; Tylee et al., 2015). Additionally, distinct gene expression profiles related to immune function 
or response have been associated with PTSD (Neylan et al., 2011; O'Donovan et al., 2011; 
Segman et al., 2005; Zieker et al., 2007), combat veterans with PTSD (Breen et al., 2015; Zhou 
et al., 2014), survivors of the World Trade Center attacks with PTSD (Sarapas et al., 2011), and 
with eventual PTSD cases of pre-deployed marines (Glatt et al., 2013). PTSD has also been 
associated with mitochondrial dysregulation (Su et al., 2008). The larger genome-scale studies 
make a strong case for the dysregulation of immune function in participants with PTSD. This 
finding is consistent with previous DNA methylation studies of PTSD (Bam et al., 2016; Smith et 
al., 2011a; Uddin et al., 2010). The locus-specific gene expression studies provide evidence for 
a significant effect of PTSD on gene expression in NR3C1 and FKBP5.  Additionally, there is 
evidence of an effect of treatment response on FKBP5 gene expression levels following therapy 
(psychotherapy or cognitive behavioral therapy) that is opposite to the effect of PTSD. This 
research suggests gene expression levels may be further modulated by therapy-based treatment, 
however further work is needed to fully understand this relationship. Overall, there is a strong 
body of evidence indicating PTSD impacts gene expression levels at specific HPA axis genes 
and at the genome-scale level.  
 
1.12. SUMMARY AND OVERVIEW 
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 Despite the extensive research that has been done to date regarding ELA, MDD, and 
PTSD, the biologic mechanisms contributing to the increased prevalence of mental illness 
following exposure to ELA or other stressful life events remains unclear. Previous studies have 
largely focused on examining the impact of these exposures on HPA axis reactivity, DNA 
methylation and/or gene expression. Additionally, there is an issue with consistency in the 
literature, which can be found in study design, methods used, statistical approaches, data 
analysis, interpretation, presentation of results, etc. These inconsistencies make it challenging to 
compare and contrast the literature and reduce the ability to draw conclusions from previous 
studies. Therefore, more work must be done to tease apart the relationship.  
 The goal of this dissertation is to further elucidate the biologic mechanisms contributing to 
the relationship among childhood maltreatment, MDD, and PTSD by focusing on DNA methylation 
and downstream gene expression. Focusing on both DNA methylation and gene expression at 
the locus-specific and genome-scale levels allows for the biologic impact at specific HPA axis 
genes to be observed and allows for a better perspective of what is occurring at the broader 
genome level. To date, extensive research has been done in regards to childhood maltreatment, 
MDD, and PTSD, however few studies have examined them together. In order to disentangle the 
biologic impact mediating the relationship between ELA and mental illness, these exposures must 
be investigated together.  
The work that follows investigates the relationship between epigenetic and transcriptomic 
mechanisms in regards to childhood maltreatment, MDD, and PTSD. More specifically, in chapter 
2, I report a study that examined whether childhood maltreatment and MDD affect NR3C1 DNA 
methylation in a joint and potentially interacting manner, and whether these DNA methylation 
differences associated with childhood maltreatment and/or MDD contribute to functional 
consequences in NR3C1 gene expression levels.  In chapter 3, I report research that examines 
whether FKBP5 DNA methylation is a plausible biologic mediator of childhood maltreatment for 
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later risk of MDD, and if it subsequently influences FKBP5 gene expression. In chapter 4, I present 
research aimed at characterizing networks of differentially expressed genes associated with 
childhood maltreatment and PTSD. With the ultimate goal of determining the extent of overlap 
among the childhood maltreatment –PTSD associated networks. In chapter 5, I present a study 
that examines the impact of MDD on genome-scale DNA methylation levels from human brain 
tissue. Lastly, in chapter 6, all of the presented work is summarized and tied back into the overall 
goal of the dissertation, to disentangle the role of DNA methylation and downstream gene 
expression in the context of childhood maltreatment, MDD, and PTSD.  
The studies within this dissertation make use of both peripheral tissue, blood (Chapter 2-
4), and central nervous system tissue, brain (Chapter 5), to assess the relationship among 
childhood maltreatment, MDD, and PTSD in DNA methylation and gene expression data. Use of 
central nervous tissue is ideal as it allows for the direct assessment of the potential biologic impact 
of the exposure or disorder of interest. However, peripheral tissues, such as blood can be used 
to identify potential biomarkers of disease risk in a tissue that is easily accessible. Additionally, 
several studies have examined the relationship between genome-scale DNA methylation and 
gene expression in both central and peripheral tissues. These studies demonstrate a degree of 
concordance across blood and brain tissues in both DNA methylation (Farre et al., 2015; Hannon 
et al., 2015; Kaminsky et al., 2012; Walton et al., 2016) and gene expression (Kohane and 
Valtchinov, 2012; Rollins et al., 2010; Sullivan et al., 2006) datasets. These studies provide 
support for the use of blood-based data as potential biomarkers for stress-related conditions. 
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1.13. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.1: Schematic representation of the interaction and function of FKBP5 with the 
glucocorticoid receptor (GR) complex. (1) When FKBP5 is bound to the GR-complex via hsp90, 
the receptor has lower affinity for cortisol. (2) Once cortisol is bound, FKBP5 is exchanged 
against FKBP4 which can then bind dynein. (3) This allows the translocation of the GR-complex 
into the nucleus and DNA binding. (4) The GR can then increase FKBP5 transcription and 
translation via intronic response elements. (5) Increased FKBP5 confers higher GR resistance, 
completing an ultra-short negative feedback loop on GR sensitivity. Reprinted from 
Psychoneuroendocrinology, vol. 34, Binder, E., “The role of FKBP5, a co-chaperone of the 
glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders”, 186-
195, December 2009, with permission from Elsevier. 
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FIGURE 1.2: Epigenetic modifications. Image shows the different types of epigenetic 
modifications (left) and the level of organization they occur (right). Within the boxes (center) are 
visualizations of the epigenetic modification. Figure is from “Beyond the Genome: Epigenetic 
Mechanisms in Lung Remodeling” Hagood, J. Physiology May 2014 and is reprinted with 
permission from the publisher. 
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CHAPTER 2: GLUCOCORTICOID RECEPTOR DNA METHYLATION, CHILDHOOD 
MALTREATMENT AND MAJOR DEPRESSION1 
 
ABSTRACT 
INTRODUCTION: 
Altered DNA methylation (DNAm) levels of hypothalamic-pituitary-adrenal (HPA) axis genes has 
been associated with exposure to childhood maltreatment (CM) and depression; however, it is 
unknown whether CM and depression have joint and potentially interacting effects on the 
glucocorticoid receptor (NR3C1) DNAm. We investigated the impact of CM and lifetime major 
depressive disorder (MDD) on NR3C1 DNAm and gene expression (GE) in 147 adult participants 
from the Detroit Neighborhood Health Study.  
METHODS: 
NR3C1 promoter region DNAm was assessed via pyrosequencing using whole blood-derived 
DNA. Quantitative RT-PCR assays measured GE from leukocyte-derived RNA.  Linear regression 
models were used to examine the relationship among CM, MDD, and DNAm.   
RESULTS: 
Both CM and MDD were significant predictors of NR3C1 DNAm: CM was associated with an 
increase in DNAm in an EGR1 transcription factor binding site (TFBS), whereas MDD was 
associated with a decrease in DNAm downstream of the TFBS. No significant CM-MDD 
interactions were observed. CM alone was associated with significantly lower NR3C1 GE.  
LIMITATIONS: 
Our report of CM is a retrospective self-report of abuse, which may introduce recall bias. DNAm 
was measured in whole blood and may not reflect brain-derived DNAm levels. 
CONCLUSIONS:  
  
1 This chapter is published in its entirety in the Journal of Affective Disorders. This article is reprinted with the 
permission of the publisher and is available from http://www.jad-journal.com/article/S0165-0327(16)30717-0/abstract 
and using DOI:  http://dx.doi.org/10.1016/j.jad.2016.07.038  
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CM and MDD are both associated with altered DNAm levels in the NR3C1 promoter region, 
however the location and direction of effects differ between the two exposures, and the functional 
effects, as measured by GE, appear to be limited to the CM exposure alone. CM exposure may 
be biologically embedded in this key HPA axis gene.
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2.1. INTRODUCTION 
There is a well-established link between early life adversity and poor mental health later 
in life (Afifi et al., 2008; McEwen, 2003). Specifically, childhood maltreatment has been strongly 
associated with the onset of major depression (MDD)  (Kendler et al., 2004; Nemeroff, 2004) and 
other mental illnesses during adulthood, including posttraumatic stress disorder (PTSD) (Green 
et al., 2010), bipolar disorder (Afifi et al., 2008), and anxiety disorders (Kessler et al., 1997). 
Several decades of work in rodents, humans, and non-human primates has demonstrated the 
importance of early environment on the molecular pathways regulating the stress response 
(reviewed in (Klengel et al., 2014)). These studies have largely focused on examining the 
epigenetics of hypothalamic-pituitary-adrenal (HPA) axis genes due to the primary role of the HPA 
axis in regulating the body’s stress response. Dysregulation of the HPA axis results in an altered 
stress response (Nemeroff, 2004), producing an increased risk for mood and anxiety disorders, 
as well as physical disorders such as diabetes and cardiovascular disease (Irwin and Cole, 2011; 
Nemeroff, 2004; Radtke et al., 2011). However, the molecular mechanisms that underlie HPA 
axis dysregulation, and their possible associations with commonly occurring mental disorders 
such as depression remain unclear.  
 DNA methylation is a stable, but modifiable, epigenetic mark that is characterized by a 
chemical alteration to the nucleotides that comprise DNA (Whitelaw and Whitelaw, 2006). This 
chemical modification does not alter the underlying DNA sequence but rather serves to regulate 
chromatin structure and DNA accessibility, often resulting in altered transcription. DNA 
methylation is characterized by the addition of a methyl group, -CH3, to the 5’ position of cytosine 
- typically when cytosine is coupled to guanine on the same strand of DNA – and is stable over 
time (Heijmans et al., 2008; Tyrka et al., 2008), tissue specific (Gama-Sosa et al., 1983), and 
responsive to environmental exposures (Fraga et al., 2005). From a functional perspective, DNA 
methylation of transcription factor binding sites (TFBS) within gene promoter regions typically 
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results in reduced gene expression (Brenet et al., 2011), and, in particular, has been associated 
with early life changes to stress-relevant phenotypes that persist into adulthood (Weaver et al., 
2004). Thus, as a stable, but modifiable, molecular mechanism with functional effects, epigenetic 
regulation is a potential contributor to the etiology of mental disorders resulting from adverse early 
life experiences.  
A substantial body of evidence has shown that early life adversity, in particular childhood 
maltreatment, is associated with DNA methylation differences in HPA axis gene nuclear receptor 
subfamily 3, group member 1 (NR3C1), whose product is commonly known as the glucocorticoid 
receptor (McGowan et al., 2009; Tyrka et al., 2012). The glucocorticoid receptor plays an 
important role in the body’s stress response as it not only binds to the stress hormone cortisol, 
but also modulates the negative feedback of the HPA axis. High levels of cortisol tamp down the 
stress response by reducing corticotropin releasing hormone (CRH), the hormone released by 
the hypothalamus that triggers the stress response cascade (Binder, 2009); this negative 
feedback is facilitated by the binding of cortisol to the glucocorticoid receptor (Binder, 2009). Initial 
rodent studies in NR3C1 demonstrated that early environment, specifically level of maternal care, 
was associated with alterations to NR3C1 DNA methylation, resulting in changes in stress 
sensitivity that last into adulthood (Weaver et al., 2004).  Similarly, in humans, maternal 
depressed/anxious mood during the third trimester was associated with increased NR3C1 DNA 
methylation in a TFBS in cord derived-blood, and with increased infant cortisol responses 3 
months postnatally (Oberlander et al., 2008). Subsequent human studies have confirmed 
exposure to childhood maltreatment and other early life adversities are associated with increased 
NR3C1 DNA methylation measured in both blood and post mortem brain tissue (Labonte et al., 
2012b; Martin-Blanco et al., 2014; McGowan et al., 2009; Tyrka et al., 2012). Maternal 
experiences during pregnancy have also been associated with DNA methylation differences in 
NR3C1 in their offspring, reviewed and summarized in a recent meta-analysis (Palma-Gudiel et 
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al., 2015). These studies underscore the importance of early life environments and, in particular, 
the long-term impact of early life adversity (ELA)-induced changes to DNA methylation on mental 
health.  
Despite the extensive research supporting the link between ELA and altered DNA 
methylation, few studies have examined the link between depression and NR3C1 DNA 
methylation. To date, only two studies have directly examined NR3C1 promoter region DNA 
methylation and MDD. A recent study examined NR3C1 DNA methylation and hippocampal 
volume in a group of participants with MDD compared to healthy controls, finding MDD patients 
had significantly lower levels of DNA methylation within the promoter region of NR3C1 (Na et al., 
2014). Additionally, a second paper examined NR3C1 DNA methylation in a group of participants 
with and without MDD, reporting a significant increase in NR3C1 DNA methylation at a single 
CpG site associated with the disorder (Nantharat et al., 2015). These studies report opposite 
associations between MDD and NR3C1 DNA methylation levels measured in blood; however, the 
relationship among childhood maltreatment, MDD, and NR3C1 DNA methylation was not 
addressed in either work. To address this gap in knowledge, we sought to examine the impact of 
childhood maltreatment and MDD on NR3C1 DNA methylation and gene expression levels among 
adults. We hypothesized that (1) childhood maltreatment and MDD affect NR3C1 DNA 
methylation in a joint and potentially interacting manner, and, secondarily, that (2) DNA 
methylation differences resulting from childhood maltreatment and/or MDD would contribute to 
functional consequences in NR3C1 as measured by gene expression levels.  
  
2.2. METHODS 
2.2.1.  PARTICIPANT SELECTION  
The DNHS was approved by the institutional review boards at the University of Michigan and the 
University of North Carolina at Chapel Hill. Participants (N=152) were selected from the Detroit 
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Neighborhood Health Study (DNHS), a longitudinal, population-based representative sample of 
adult residents from Detroit, MI (Uddin et al., 2010). All participants provided informed consent 
prior to participation in the DNHS. Selection for inclusion within this study was based on the 
availability of whole-blood derived DNA, leukocyte-derived RNA, and complete survey data 
regarding childhood maltreatment and depression histories. In our study population of 152 DNHS 
participants, 94 were female and 58 were male; 26 self-identified as European-American, 116 as 
African-American, and 10 as “other”. The average age was 49.6 years. 
 
2.2.2. CHILDHOOD MALTREATMENT 
Participant survey data regarding childhood maltreatment history were collected via structured 
telephone interviews on the severity, duration, and frequency of each event type. Assessment of 
childhood maltreatment was based on the Conflict Tactics Scale (CTS) (Straus, 1979) and the 
Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 1997), as previously described (Keyes 
et al., 2012; Uddin et al., 2013). CTS items assessed physical and emotional abuse before age 
11, with responses rated on a 5-point scale. CTQ assessed physical and sexual abuse before 
age 18, rating responses on a 3-point scale. The childhood maltreatment score variable is a 
continuous measure ranging from 0-22, as previously described (Keyes et al., 2012; Uddin et al., 
2013). In this study, participants with childhood maltreatment exposure (N=76) were defined as 
any individual belonging to the upper quartile for childhood maltreatment score within the full 
DNHS survey sample (N=1,547). Participants without childhood maltreatment exposure (N=76) 
belonged to the bottom quartile of childhood maltreatment score within the full DNHS survey 
sample.  
 
2.2.3. DEPRESSION MEASURE  
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MDD was assessed using the Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001b) with 
additional questions that assessed timing and duration of symptoms, consistent with DSM-IV 
criteria (American Psychiatric, 1994). The PHQ-9 is a 9-item instrument rating responses on a 4-
point scale ranging from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 
27. The measure has been previously validated (Uddin et al., 2011). MDD was defined as the 
presence of lifetime MDD (cases N=76, controls N=76).   
 
2.2.4. ANTIDEPRESSANT MEDICATION 
Participant medication information was taken during the in-home visit at the time of biologic 
sample collection (see section 2.5). Participants were instructed to provide all current prescribed 
and over the counter medication to the phlebotomist, who recorded the medication name, dosage, 
and frequency each medication was taken. Antidepressant medication use for this study was 
determined based on participant medication information from the appropriate wave. SAS 
Enterprise Guide 7.1 (SAS Institute Incorporated, NC) was used to code medications as 
antidepressants.  
 
2.2.5. SAMPLE PREPARATION 
2.2.5.1. DNA 
Whole blood was collected via venipuncture from study participants during scheduled in home 
visits by a trained phlebotomist. DNA was isolated from whole blood using Qiagen’s QIAamp DNA 
Blood Mini Kit (Qiagen, Valencia, CA) and LifeSciences’s Quickgene DNA Whole Blood Kit (St. 
Petersburg, FL) following the manufacturer’s recommended protocols. DNA concentrations were 
verified using the NanoDrop 1000 (ThermoScientific, Waltham, MA) following the manufacturer’s 
recommended protocol. 
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2.2.5.2. RNA 
RNA was obtained from leukocytes using Leukolock kits following the manufacturer’s alternative 
protocol to preserve total RNA (Ambion, Austin, TX). Quality control criteria was used to ensure 
high quality RNA was obtained, including a RNA integrity number (RIN) ≥5, 28s/18s≥1.0, and 
260/280≥1.7 (Fleige and Pfaffl, 2006; Fleige et al., 2006). RNA sample RIN values and 28s/18s 
ratios were calculated using the 2100 Bioanalyzer (Agilent, Wilmington, DE) to determine RNA 
quality. RNA concentration for each sample was determined using the NanoDrop 1000 
(ThermoScientific).  
 
2.2.5.3. PERIPHERAL BLOOD MONONUCLEAR CELL COUNTS 
 At the time of blood draw, two FICOLL gradient containing 8 ml BD Vacutainers CPTTM with 
sodium citrate (Franklin Lakes, NJ) were used for the collection of peripheral blood mononuclear 
cells (PBMC) samples. Participant tubes were spun in a centrifuge within two hours of collection 
and processed immediately. During processing, mononuclear cells were isolated, assessed for 
viability, and counted using Invitrogen’s Countess automated cell counter (Carlsbad, CA). A small 
number of PBMC samples used in this study were measured using TPP PCV Packed CellVolume 
tubes (Trasadingen, Switzerland) and counted assessed for viability using a hemacytometer 
(Fisher Scientific, Pittsburgh, PA). 
 
2.2.5.4. BISULFITE CONVERSION  
750ng of DNA from each participant was bisulfite converted using Qiagen’s Epitect Bisulfite Kit 
following the manufacturer’s recommended protocol. Negative controls containing RNA/DNA free 
water in place of DNA were included with each bisulfite conversion as a negative control. High 
and low methylation control DNA purchased from Zymo Research (Irvine, CA) were bisulfite 
converted along with the participant samples in order to assess assay performance. 
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2.2.6. PCR AMPLIFICATION & PYROSEQUENCING 
DNA methylation for 13 CpG sites within the promoter region of NR3C1 were assessed via 
pyrosequencing (CHR5: 142,783,655-142,783,501). The 13 CpG sites targeted in our analyses 
encompass a 155bp region and contain an EGR1 TFBS (also known as NGF1-A) (Figure 2.1). 
This locus has been the focus of several other previous studies (McGowan et al., 2009; 
Oberlander et al., 2008; Radtke et al., 2011; Tyrka et al., 2012).  Primers were newly developed 
for this study (see below) using the PyroMark Q24 Assay Design Software 2.0 (Qiagen). 
Validation experiments were carried out according to recommendations in the PyroMark manual 
on all custom assays to ensure high quality primers were used.  PCRs were run in duplicate and 
contained 20ng of bisulfite converted DNA as starting template. No template controls were also 
run in duplicate with each set of PCRs as a negative control. Each primer was also tested using 
bisulfite converted DNA from high and low methylation controls (Zymo). Qiagen’s PyroMark Q24 
Pyrosequencer was used to detect DNA methylation levels following manufacturer’s protocols 
and default settings.  
 
1to4CpG 
Forward PCR primer: 5’-AGTTTTAGAGTGGGTTTGGAG -3’ 
Reverse PCR primer (biotinylated): 5’-ACCACCCAATTTCTCCAATTTCTTTTCTC -3’ 
Sequencing primer:  5’-GAGTGGGTTTGGAGT -3’ 
 
5to13CpG 
Forward PCR primer:  5’-GGGGGAGGGAAGGAGGTA-3’ 
Reverse PCR primer (biotinylated): 5’-CCCCCAACTCCCCAAAAA-3’ 
Sequencing primer:   5’-GGGAGGGAAGGAGGTAG-3’ 
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9to13CpG 
Forward PCR primer:  5’-GGAAGGAGGTAGAGAGAAAAGAAATTGG-3’ 
Reverse PCR primer (biotinylated):  5’-CCCCCAACTCCCCAAAAA -3’ 
Sequencing primer:   5’-GGAGAAATTAGGTTTTTTTAA -3’ 
 
PCR Program: (same for all primer sets) 
Initial    15 minutes 95oC 
Denaturation  30 seconds 94oC 
Annealing   30 seconds 56oC  50 cycles 
Extension  30 seconds 72oC 
Final   10 minutes 72oC 
Hold   4oC indefinitely 
 
2.2.7. REVERSE TRANSCRIPTION & REAL TIME PCR 
To analyze gene expression levels, RNA was reverse transcribed into cDNA following the 
manufacturer’s protocol using the High Capacity Reverse Transcription Kit purchased from 
Applied BioSystems (Foster City, CA). Ready-made Taqman gene expression assays (Applied 
Biosystems) were used to measure relative transcript levels of the target gene NR3C1 
(Hs00353740_m1) and the control gene PGK1 (Hs00943178_g1). The NR3C1 Taqman assay 
specifically targeted the GRα isoform.  Reactions were performed in triplicate for each locus, with 
each replicate tested in a 20μl reaction containing 10ng of participant cDNA. Reactions were run 
on a HT7500 Fast Real Time PCR machine (Applied BioSystems, Foster City, CA) following the 
manufacturer’s recommended protocol for standard reactions. 
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2.2.8. PRIMARY ANALYSES 
Previous studies have reported significant associations between DNA methylation at CpG sites 
1-4 and early life experiences, while CpG sites 5-13 have been grouped together for exploratory 
analyses (McGowan et al., 2009; Oberlander et al., 2008; Tyrka et al., 2012). Additionally, the 
ERG1 TFBS, previously implicated in multiple studies of early-life adversity and NR3C1 DNA 
methylation (Romens et al., 2015; Tyrka et al., 2012; van der Knaap et al., 2014) encompasses 
CpG site 3 and 4, while other TFBS are located within bin 5-13 as identified using the UCSC 
genome browser track “Encode Regulation” ChIP-seq data. The TFBSs within the 5-13CpG 
region have been confirmed in a variety of cell lines including those derived from blood and brain 
tissues. Similar binning approaches have been applied to analyses of stress-related effects on 
other HPA axis genes, in which functionally distinct regions are grouped together in bins (e.g. 
FKBP5; (Klengel et al., 2013; Yehuda et al., 2015a). Therefore, in our study, DNA methylation 
levels were analyzed in two bins, 1-4 and 5-13. Bin 1-4 was created by averaging DNA 
methylation levels within participants across all 4 sites. To create bin 5-13, we pooled data 
generated from both the 5to13CpG and 9to13CpG primer sets, and then averaged DNA 
methylation levels within participants across all 9 sites. Once data collection was complete, the 
full DNA methylation dataset N=152 was examined for normality according to bin (1-4 or 5-13) 
using boxplots, histograms, and the Shapiro-Wilks test of normality in IBM SPSS Statistics for 
Windows, version 22.0 (IBM Corp., Armonk, NY). Extreme outliers (more than 3 interquartile 
ranges from the nearest edge of the boxplot) were removed from the dataset to facilitate normality, 
resulting in a final dataset comprised of N=147. 
 
2.2.8.1. T-TESTS 
Independent samples t-tests were used to test for bivariate associations between childhood 
maltreatment exposure and demographic covariates, as well as MDD and demographic 
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covariates, using IBM SPSS Statistics for Windows version 22.0 (IBM Corp., Armonk, NY). Chi-
squared tests were used to test for associations between childhood maltreatment exposure and 
the demographic variables of sex and race. Similarly, Chi-squared tests were used to test for the 
association between MDD history and sex and race. All statistical tests were two-tailed and results 
were considered significant with an uncorrected p<0.05.  
 
2.2.8.2. REGRESSION  
Linear regressions were performed separately on each bin to test whether childhood maltreatment 
and MDD have joint and potentially interacting relationships on DNA methylation in these regions. 
In addition to our main variables of interest, all regression models included age, sex, race, PBMC 
viability count and antidepressant medication information as covariates. Main effect models were 
run first, followed by interaction models. We addressed the concern of multiple hypothesis testing 
by calculating the false discovery rate (FDR) using the Benjamini Liu method (Benjamini et al., 
2001) for our primary study hypotheses, such that results were accepted as significant when 
pcorrected ≤ 0.012.  
  
2.2.8.3. SECONDARY ANALYSES 
Gene Expression. To examine the potential functional consequences of observed DNA 
methylation differences, we analyzed NR3C1 gene expression values using real-time PCR data. 
Cycle threshold (CT) values for each replicate were averaged to obtain a mean CT value for each 
participant used in our analysis. All data was examined for outliers, and any replicates with a 
standard deviation greater than 0.3 were removed (n=6), and the mean CT was re-calculated 
from remaining data points. Gene expression data were analyzed using the comparative CT 
method (Schmittgen and Livak, 2008), normalizing NR3C1 gene expression against the control 
gene PGK1. Resulting data were analyzed by student’s t-test to compare expression levels 
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according to the main study variables, as warranted by the DNA methylation data, and results 
were accepted as significant if p<0.05. 
 
2.3. RESULTS 
Participants with exposure to childhood maltreatment did not differ significantly from those without 
childhood maltreatment exposure in terms of age, sex, or race (Table 2.1). As expected, 
participants with childhood maltreatment exposure differed from those without such exposure for 
childhood maltreatment score (Table 2.1); in addition, DNA methylation over CpG sites 1-4 was 
significantly higher in those with vs. without childhood maltreatment exposure (Figure 2.2). 
Similarly, MDD cases and controls were significantly different for childhood maltreatment score 
(Table 2.1); in addition, DNA methylation was significantly lower over CpG sites 5-13 in those with 
vs. without MDD (Figure 2.3).  
 
2.3.1. MAIN EFFECT AND INTERACTION OF CHILDHOOD MALTREATMENT AND MDD TO 
PREDICT NR3C1 DNA METHYLATION LEVELS 
2.3.1.1. AVERAGE DNA METHYLATION CpG SITES 1-4 
We first examined whether childhood maltreatment and MDD predict DNA methylation levels in 
our study participants, with DNA methylation averaged at CpGs 1-4 and 5-13, respectively, as the 
outcome (Table 2.2). In the main effects model for the average DNA methylation of CpG sites 1-
4, childhood maltreatment significantly predicted DNA methylation levels at CpG sites 1-4, such 
that participants with childhood maltreatment exposure showed increased DNA methylation 
(β=0.038 SE 0.015, pcorrected=0.001; MDD was not associated with DNA methylation in this 
region (pcorrected=0.019) following FDR adjustment, which attenuated the unadjusted significant 
p-value (p=0.026). Age, sex, race, PBMC, and antidepressant medication were also not 
  
42 
significant in this model (Table 2.2). In addition, the interaction model showed no significant 
synergistic effect of childhood maltreatment and MDD on NR3C1 DNA methylation (Table 2.2). 
 
2.3.1.2. AVERAGE DNA METHYLATION CpG SITES 5-13 
For DNA methylation averaged across CpG sites 5-13, the main effects models revealed that 
MDD significantly predicted lower DNA methylation (β=-1.038 SE 0.315, pcorrected=0.008. 
childhood maltreatment was not associated with DNA methylation in this region 
(pcorrected=0.05). In addition, age, sex, PBMCs, and antidepressant medication were not 
significant in this model (Table 2.2). As with sites 1-4, analyses of sites 5-13 showed no significant 
synergistic effect of childhood maltreatment and MDD on NR3C1 DNA methylation 
(pcorrected=0.05; Table 2.2). 
 
2.3.2. GENE EXPRESSION OF PERIPHERAL LEUKOCYTES 
Results from the regression models suggested independent effects of childhood maltreatment 
and MDD on DNA methylation, thus we chose to separately examine the potential effect of 
childhood maltreatment and MDD on gene expression. T-tests were used to determine significant 
differences in gene expression levels within groups (childhood maltreatment vs No childhood 
maltreatment and MDD vs. No MDD). Results indicated a significant (p=0.037) decrease in fold 
change in the childhood maltreatment group compared to the No childhood maltreatment group; 
no significant expression differences were observed for MDD (p=0.27) (Figure 2.4).  
 
2.4. DISCUSSION  
The overall goal of this study was to investigate the association of childhood maltreatment 
and MDD with DNA methylation and gene expression of the glucocorticoid receptor in an adult 
population. Our primary analyses sought to test whether childhood maltreatment and MDD have 
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a joint and potentially interacting association with NR3C1 DNA methylation. Our secondary 
analyses assessed whether childhood maltreatment and/or MDD-associated differences in 
NR3C1 DNA methylation levels were also associated with differences in gene expression. Results 
from our primary analyses showed that childhood maltreatment exposure was associated with an 
increase in DNA methylation in the upstream region of NR3C1 tested in our assays, i.e. across 
the four CpG sites spanning the EGR1 TFBS. Conversely, MDD was associated with significant 
decreases in DNA methylation in the latter half of the CpG sites examined (i.e. sites 5-13). No 
significant childhood maltreatment x MDD interactions were observed in either region (1-4 or 5-
13), suggesting that there is no effect heterogeneity for childhood maltreatment and MDD on DNA 
methylation within these sites of the NR3C1 promoter region. Taken together, results indicate that 
while childhood maltreatment and MDD are both associated with DNA methylation differences the 
NR3C1 promoter region, the location and direction of effects differ between the two exposures. 
Our finding of increased NR3C1 DNA methylation associated with exposure to childhood 
maltreatment  is consistent with previous literature focusing on either childhood maltreatment 
(Martin-Blanco et al., 2014; McGowan et al., 2009; Tyrka et al., 2012) or early life experiences 
(Oberlander et al., 2008; Radtke et al., 2011). Similarly, our MDD results are also consistent with 
a recent study examining NR3C1 DNA methylation levels which reported decreased DNA 
methylation (Na et al., 2014). It should be noted that one other study that examined NR3C1 
promoter region DNA methylation levels reported a significant increase at their CpG site 7 
(corresponding to CpG site 5 in this study) in MDD cases compared to healthy controls (Nantharat 
et al., 2015). Additionally, only one of their CpG sites overlaps with the region we found to be 
significantly associated with MDD in our study, which is a point of consideration when comparing 
results. However, neither of these studies assessed childhood maltreatment or other adverse life 
events in their population. Despite these findings, our study is distinct from this more recent work 
as we examined the joint and potentially interacting effects of both childhood maltreatment and 
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MDD on NR3C1 DNA methylation. Interestingly, despite this difference in focus from previous 
studies, we did detect significant differences in DNA methylation associated with childhood 
maltreatment and MDD, which are consistent with previous studies that examined these 
outcomes separately.  
To date, research on NR3C1 DNA methylation has largely focused on the importance of 
early life environment (Oberlander et al., 2008; Radtke et al., 2011; Tyrka et al., 2012). Our results, 
however, identify a significant association between MDD and DNA methylation in adults, 
suggesting that NR3C1 DNA methylation levels are potentially more plastic than previously 
thought; early life environment may not be the only critical window where alterations of DNA 
methylation levels can occur within HPA axis genes. Additionally, we did not observe a significant 
interaction between childhood maltreatment and MDD for CpG sites in either of the two bins (1-4 
or 5-13). This finding is somewhat surprising given the strong body of evidence linking childhood 
maltreatment exposure with MDD onset (Kendler et al., 2004; Nemeroff, 2004) and our significant 
association of childhood maltreatment and MDD with DNA methylation levels. The lack of 
significant interaction suggests childhood maltreatment and MDD influence NR3C1 promoter 
region DNA methylation levels independently of one another.   
Our secondary analyses tested whether the observed significant DNA methylation 
differences were reflective of gene expression levels in NR3C1. We found a significant decrease 
in gene expression between individuals with vs. without childhood maltreatment exposure. This 
finding is consistent with previous reports in the literature linking increased DNA methylation 
within the promoter to decreased gene expression (Brenet et al., 2011; McGowan et al., 2009), in 
particular at CpG sites spanning the EGR1 TFBS (Weaver et al., 2007). Despite finding 
significantly lower DNA methylation in the downstream region of NR3C1 CpG sites associated 
with MDD, we did not observe significant gene expression differences associated with MDD 
status; however, MDD does not significantly influence DNA methylation at the EGR1-associated 
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CpG sites, suggesting that its functional consequences (as measured by NR3C1 expression) may 
be limited compared to the effects of childhood maltreatment exposure. This null gene expression 
finding associated with MDD is consistent with a previous study examining DNA methylation and 
gene expression in a group of MDD patients and healthy controls (Nantharat et al., 2015). 
It should be noted that several transcripts of NR3C1 exist as a result of alternative splicing. 
The presence of these different transcripts can result in altered glucocorticoid sensitivity (Lewis-
Tuffin and Cidlowski, 2006; Shahidi et al., 1999). Two of the more prominent products of 
alternative splicing include: glucocorticoid receptor α (GRα) and β (GRβ). Multiple studies have 
reported GRα as the main active isoform (Labonte et al., 2014; Labonte et al., 2012b; Pujols et 
al., 2002) which works to bind glucocorticoids, while GRβ negatively regulates GRα (Hagendorf 
et al., 2005; Oakley et al., 1996; Pujols et al., 2002). GRα is more prevalent in peripheral 
leukocytes and monocytes compared to GRβ (Hagendorf et al., 2005; Pujols et al., 2002), the 
same tissues used in this study to measure relative gene expression and DNA methylation levels 
of NR3C1, respectively. Our Taqman gene expression assay specifically targeted the GRα 
isoform. Taking into account our finding of decreased mRNA expression in those with a history of 
childhood maltreatment, is it likely that GR-α is down regulated among those with this exposure, 
possibly leading to decreased cortisol sensitivity. This notion is supported by a study reporting 
significantly decreased GRα mRNA expression in participants with PTSD compared to healthy 
controls. Of particular relevance to the current work is the finding that decreased GRα expression 
was modulated by a dose-response effect of trauma irrespective of PTSD status, such that those 
with higher trauma loads showed more marked decrease in GRα expression (Gola et al., 2014). 
Of particular importance to this study is the issue of tissue specificity in DNA methylation.  
In this study, we report DNA methylation levels derived from a peripheral tissue, blood, and do 
not assess DNA methylation in brain, as our population is composed of living individuals. 
Nevertheless, several studies have examined post-mortem brain tissue samples and report 
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similar patterns of DNA methylation as those observed in peripheral tissue (Farre et al., 2015; 
McGowan et al., 2009). To assess whether DNA methylation levels within NR3C1 were consistent 
between blood and brain tissues, we visualized our regions of interest (see methods for 
coordinates) using the UCSC genome browser (genome.ucsc.edu) and MARMAL-AID (marmal-
aid.org). NR3C1 DNA methylation levels were similar in both tissues, providing further support 
that the observed changes in blood are potentially a useful biomarker of changes occurring in the 
brain. Additional work in rodents suggests that GR-responsive genes, including NR3C1, show 
concordant gene expression changes in brain and blood in relation to stress-related phenotypes 
(Daskalakis et al., 2014), further supporting the use of select blood-based measures as 
biomarkers of stress-related conditions. 
 
2.4.1. LIMITATIONS 
It is important to note limitations one must consider when interpreting our results. First, the 
childhood maltreatment variable used in our study is a retrospective self-reported measure from 
each individual of abuses occurring before the age of 18. Even though early life experiences have 
been shown to be long lasting and detected into adulthood, self-reported measures may introduce 
recall bias. Previously, retrospective self-reports of childhood maltreatment from adults with 
documented cases were associated with underreporting of physical and sexual abuse (Widom 
and Morris, 1997; Widom and Shepard, 1996). Therefore, our measure of childhood maltreatment 
may well be an underestimate of previous abuse. Second, we report small, yet significant DNA 
methylation changes and observed effect sizes within our data; however, these results are 
consistent with previous childhood maltreatment and depression-related reports of NR3C1 DNA 
methylation (Labonte et al., 2014; Oberlander et al., 2008; Tyrka et al., 2012). In addition, the 
functional effect of childhood maltreatment-associated DNA methylation differences on gene 
expression lends support to the relevance of these small effects. Third, although we controlled for 
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PBMC viability counts, which did not differ among participants with vs. without childhood 
maltreatment or MDD, we were not able to control for differences in white blood cell subsets. Thus 
it is possible that the childhood maltreatment and/or MDD-associated DNA methylation 
differences might be localized to a particular cell type. Fourth, studies have shown that atypical 
and melancholic subtypes of MDD manifest in different biologic pathways (Charmandari et al., 
2005; Lamers et al., 2013); however, in our work we were unable to subdivide our participants 
into atypical or melancholic depression based on the instrument used within the parent study 
preventing a more detailed interpretation of our findings with regard to MDD subtype. Finally, we 
were unable to assess whether our observed DNA methylation and expression differences in 
NR3C1 were also associated with differences in cortisol levels, as such samples were not 
collected in the original parent study. However, related studies suggest that DNA methylation 
differences are indeed associated with differences in cortisol levels (Tyrka et al., 2012), with 
increased NR3C1 DNA methylation associated with reductions in plasma cortisol. 
This study also has many strengths. Our study is unique in that we are testing samples 
from a non-clinical, community-based cohort of adult residents in Detroit, providing the opportunity 
to generalize our results to the larger Detroit population. Additionally, our analyses included 
participant antidepressant medication information: controlling for medication use in analyses is 
imperative to accurately interpret data and results, due to multiple reports of altered epigenetic 
signatures following antidepressant medication use (Melas et al., 2012; Perisic et al., 2010). 
Furthermore, our study extends the current literature, as we simultaneously examined the 
association of childhood maltreatment and MDD on DNA methylation and gene expression levels 
within the same study participants. Finally, we tested study participants for both gene expression 
and DNA methylation levels, allowing us to infer the potential downstream impact of differences 
in DNA methylation levels. 
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2.5. CONCLUSION 
In conclusion, we report significant DNA methylation differences within the promoter region of 
NR3C1 associated with both childhood maltreatment and MDD. We also found a significant 
decrease in NR3C1 gene expression among those exposed to childhood maltreatment, however 
no significant difference in relative gene expression levels was observed in MDD. Future work on 
other HPA axis genes should provide additional insight into the joint and potentially interacting 
effects of childhood maltreatment and MDD on stress-relevant DNA methylation.
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2.6. TABLES AND FIGURES 
TABLE 2.1. Demographic and survey data summary of the study participants. Values indicate the counts or mean ± standard deviation. 
 
 Total N=147 
Measures CM- CM+ 
t-test Χ2 
MDD- MDD+ 
t-test Χ2 
p-value p-value p-value p-value 
Age 49.95±12.68 50.07±12.33 0.953  50.30±13.80 49.63±10.64 0.739  
Sex    0.948    0.672 
Male  28 28   30 26   
Female 46 45   52 39   
Race    0.553    0.915 
European American 15 10   13 12   
African American 55 58   64 49   
Other 4 5   5 4   
PBMC count       
(million cells) 
4.50+1.28 4.55+1.73 0.858  4.47+1.46 4.61+1.58 0.598  
Percent DNA Methylation        
1-4 CpG 2.28±0.82 2.81±1.35 0.005  2.64±0.92 2.43±1.38 0.262  
5-13 CpG 4.46±1.82 4.72±1.84 0.411  5.01±1.75 4.06±1.80 0.002  
CM Score 1.54±1.39 11.01±3.88 <0.001   5.20±4.82 7.57±6.17 0.012   
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TABLE 2.2. Regression results. Linear regression results showing the main effect and interaction models for CpG sites 1-4 and 5-13. 
The β value, 95% confidence interval (CI), uncorrected p-values, and FDR corrected p-values are shown for each variable within the 
model. Age, sex, race, peripheral blood mononuclear cell (PBMC) counts, and antidepressant medication use were included as 
covariates. Bold values indicate the variable is a significant predictor of DNA methylation following adjustment for multiple hypothesis 
testing.  
  Main Effect   Interaction  
  β 95% CI p-Value FDR  β 95% CI p-Value FDR 
  CpG sites 1-4  
CM 0.038 0.009 0.068 0.01 0.012  0.049 0.012 0.087 0.01  
MDD -0.385 -0.722 -0.048 0.026 0.019  -0.267 -0.688 0.153 0.211  
Age -0.005 -0.018 0.008 0.431   -0.005 -0.018 0.008 0.445  
Sex -0.071 -0.392 0.251 0.665   -0.066 -0.388 0.256 0.687  
Race 0.348 0.001 0.695 0.049   0.366 0.016 0.715 0.04  
PBMC (counts) 0.04 -0.064 0.144 0.45   0.043 -0.062 0.147 0.419  
Antidepressant (Y/N) -0.09 -0.604 0.425 0.731   -0.121 -0.64 0.399 0.647  
CM*MDD - - - -   -0.289 -0.903 0.325 0.354 0.05 
  Main Effect   Interaction  
  β 95% CI p-Value FDR  β 95% CI p-Value FDR 
  CpG sites 5-13  
CM 0.023 -0.031 0.078 0.4 0.033  0.041 -0.029 0.11 0.251  
MDD -0.983 -1.611 -0.356 0.002 0.008  -0.794 -1.581 -0.007 0.048  
Age -0.022 -0.046 0.002 0.067   -0.022 -0.046 0.002 0.07  
Sex -0.223 -0.823 0.378 0.465   -0.217 -0.818 0.385 0.477  
Race 0.43 -0.219 1.079 0.193   0.458 -0.196 1.112 0.168  
PBMC (counts) 0.104 -0.091 0.299 0.293   0.108 -0.087 0.304 0.275  
Antidepressant (Y/N) 0.206 -0.754 1.167 0.671   0.155 -0.816 1.126 0.753  
CM*MDD - - - -   -0.456 -1.597 0.685 0.43 0.05 
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FIGURE 2.1: Promoter region of NR3C1 examined within this study (CHR5: 142,783,501-142,783,655 UCSC Genome Browser Build 
2009/hg19). CpG sites tested in this study are depicted in bold green font and are also numbered. The EGR1 transcription factor 
binding site is located at CpG sites 3 and 4 and is denoted by underline. The transcription start site is indicated by “+1”. Lowercase 
nucleotides represent intronic regions, while uppercase nucleotides represent exon 1F. Figure was adapted from “Prenatal exposure 
to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses”, 
Oberlander et al., Epigenetics April 2008 with permission of the publisher (Taylor & Francis Ltd: http://www.tandfonline.com). 
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FIGURE 2.2: Average DNA methylation among participants with vs. without childhood maltreatment (CM) exposure at CpG sites 1-4 
and 5-13 within NR3C1, N=147. * denotes statistical significance (pcorrected<0.012). The error bars represent standard error of the 
mean within each binned CpG region. 
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FIGURE 2.3: Average DNA methylation among participants with vs. without MDD history at CpG sites 1-4 and 5-13 in NR3C1, N=147. 
* denotes statistical significance (pcorrected<0.012). The error bars represent standard error of the mean within each binned CpG 
region. 
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FIGURE 2.4: Fold change of NR3C1 gene expression levels between individuals with vs. without childhood maltreatment (CM) 
exposure and for participants with and without MDD history. Paired T-tests show a significant (p=0.037) decrease in expression among 
CM cases and controls for NR3C1. No significant difference was observed for MDD cases compared to controls. Error bars represent 
standard error.  
 2 This chapter was submitted to Journal of Psychiatric Research and is currently under review. 
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CHAPTER 3: FKBP5 DNA METHYLATION DOES NOT MEDIATE THE ASSOCIATION 
BETWEEN CHILDHOOD MALTREATMENT AND DEPRESSION SYMPTOM SEVERITY IN 
THE DETROIT NEIGHBORHOOD HEALTH STUDY2 
 
ABSTRACT 
Exposure to childhood maltreatment increases the risk of developing mental illness later in life. 
Childhood maltreatment and depression have both been associated with dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis—a key regulator of the body’s stress response. 
Additionally, HPA axis dysregulation has been implicated in the etiology of a range of mental 
illnesses. A substantial body of work has shown history of childhood maltreatment alters DNA 
methylation levels within key HPA axis genes. We therefore investigated whether one of these 
key genes, FKBP5 mediates the relationship between childhood maltreatment and depression, 
and assessed FKBP5 DNA methylation and gene expression within 112 adults from the Detroit 
Neighborhood Health Study (DNHS). DNA methylation was assessed in 4 regions, including the 
upstream promoter, downstream promoter, and two glucocorticoid response elements (GREs) via 
pyrosequencing using whole blood derived DNA; Taqman assays measured relative RNA 
expression from leukocytes. Mediation analyses were conducted using sequential linear 
regression. Childhood maltreatment was significantly associated with depression symptom 
severity (FDR < 0.006), but was not a significant predictor of DNA methylation in any of the four 
loci examined. FKBP5 showed elevated expression levels in participants with vs. without a history 
of depression (p < 0.001); no significant difference in gene expression levels was observed in 
relation to childhood maltreatment (p>0.05). Our results suggest DNA methylation does not 
mediate the childhood maltreatment-depression association in the DNHS.
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3.1. INTRODUCTION 
Adverse early life experiences, such as childhood maltreatment (CM), increase 
susceptibility for developing depression (Hussey et al., 2006; Nanni et al., 2012; Nelson et al., 
2016), post-traumatic stress disorder (PTSD) (Stein et al., 1996), bipolar disorder (Afifi et al., 
2008), and other mental health disorders (MacMillan et al., 2001; Martin-Blanco et al., 2014; 
McGowan et al., 2009) in adulthood. In addition, exposure to CM has been shown to dysregulate 
the hypothalamic-pituitary-adrenal (HPA) axis, a master regulator of the body’s stress response 
(reviewed in (Van Voorhees and Scarpa, 2004)). Substantial work has demonstrated that 
dysregulation of the HPA axis increases the likelihood of developing mood and anxiety disorders 
(Appel et al., 2011; Ceulemans et al., 2011; Espejo et al., 2007; Guerry and Hastings, 2011; 
Nemeroff, 2004). Moreover, it has been well-documented that exposures during early life, 
including CM, impact DNA methylation (5mC) levels within genes of the HPA axis (Martin-Blanco 
et al., 2014; McGowan et al., 2009; Romens et al., 2015; van der Knaap et al., 2014) making the 
HPA axis is a logical starting point for studies examining the epigenetic impact of CM.  
FK506 Binding Protein 5 (FKBP5) is a gene whose product is involved in HPA axis function 
by negatively regulating the stress response. The HPA axis is activated by stress and is regulated 
by two levels of negative feedback: long range and ultra-short intracellular feedback loops. Long 
range feedback occurs when high levels of cortisol in the blood stream are detected by the 
hypothalamus, resulting in decreased excretion of corticotropin releasing hormone (CRH) and 
subsequent tamping down of the stress response (Binder, 2009; Binder et al., 2008; Davies et al., 
2002; Yang et al., 2012). Ultra-short feedback occurs at the cellular level and involves FKBP5, 
which acts as a negative regulator of the glucocorticoid receptor (GR) (Appel et al., 2011; Binder, 
2009; Binder et al., 2008; Yang et al., 2012). The presence of FKBP5, when bound to a multi-
protein chaperone complex in the cytoplasm, lowers the binding affinity between cortisol and the 
GR (Binder, 2009). When cortisol is able to successfully bind to the GR, the GR-cortisol complex 
translocates into the nucleus, where it binds to glucocorticoid response elements (GREs) (Binder 
 57 
et al., 2008; Yang et al., 2012) and acts as a transcription factor to upregulate FKBP5 
transcription. Increased expression of FKBP5 reduces GR sensitivity, leading to more unbound 
cortisol in the cytoplasm and in the blood, thereby activating the long feedback loop (Binder, 
2009). 
Despite FKBP5’s prominent role in the regulation of the stress response, relatively few 
studies have examined the relationship between CM and FKBP5 5mC in humans. Klengel et al.  
(Klengel et al., 2013) examined FKBP5 5mC in participants with a history of childhood trauma 
compared to a control group. They reported significantly decreased 5mC at several glucocorticoid 
response elements (GREs) and a significant interaction between childhood trauma exposure and 
genetic variation at rs1360780 to predict 5mC at intron 7 (Klengel et al., 2013). A second study, 
by Tyrka et al., examined the association of CM and FKBP5 5mC at intron 7 in a cohort of pre-
school aged children, and found significantly decreased FKBP5 5mC of two CpG sites within 
intron 7 and found no significant interaction between SNP rs1360780 and lifetime contextual 
stress on FKBP5 5mC of intron 7 (Tyrka et al., 2015). A third study in children, by Weder et al., 
employed a genome-wide approach using Illumina’s 450K Bead Chip to examine 5mC and more 
broadly the relationship among CM and depression (Weder et al., 2014). They reported significant 
differences among CM cases compared to controls at several CpG sites within FKBP5. However, 
due to the incomplete coverage of the FKBP5 region by the 450K array, the region examined in 
the two earlier studies was not assessed. 
Two additional groups have examined FKBP5 5mC in relation to other stressful life events. 
Hönhe et al. examined the impact of psychosocial stress on FKBP5 5mC and gene expression 
(GE) within the context of major depression history and FKBP5 genotype. They found a significant 
interaction of SNP genotype of rs1360780 and depression status on FKBP5 5mC of intron 7, 
however this finding did not survive multiple test corrections (Hohne et al., 2015). Lastly, Non et 
al. found the length of time in institutionalized care was significantly negatively correlated with 
FKBP5 intron 7 CpG site 1 5mC after correcting for multiple hypothesis testing (Non et al., 2016).  
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These studies reported significantly different FKBP5 5mC associated with either exposure 
to CM or major depression, however none of them directly examined the relationship among CM, 
5mC, and depression—yet, given the demonstrated relationship between CM and 5mC, as well 
as differential 5mC in relation to depression in FKBP5 (Hohne et al., 2015) and other HPA axis 
genes (Na et al., 2014; Nantharat et al., 2015; Tyrka et al., 2012), a plausible relation exists among 
these factors. To address this possibility, we examined whether FKBP5 5mC mediates the 
relationship between CM and depression, and if the altered 5mC subsequently influences GE 
levels of FKBP5. Our primary analyses focused on the introns implicated in previous work as 
being influenced by CM (Klengel et al., 2013; Tyrka et al., 2015), while the FKBP5 promoter region 
analyses reflect a smaller exploratory dataset that tested more canonical influences of 5mC on 
GE. 
 
3.2. METHODS 
3.2.1. PARTICIPANT SELECTION 
The Detroit Neighborhood Health Study (DNHS) was approved by the institutional review board 
at the University of Michigan and the University of North Carolina at Chapel Hill. Participants were 
selected from the DNHS, a longitudinal, population-based representative sample of adult 
residents from Detroit, MI (Goldmann et al., 2011; Uddin et al., 2010). All participants provided 
informed consent prior to participation. Selection for inclusion in this study was based on the 
availability of whole-blood derived DNA, leukocyte-derived RNA, and complete survey data 
regarding CM and depression histories. The full sample (N=112) was tested for intron 2 and intron 
7, and a subset of participants (N=72) were selected for the promoter region assays.  
 
3.2.2. CHILDHOOD MALTREATMENT 
CM history was collected via structured telephone interviews assessing the severity, duration, 
and frequency of each event type. Assessment of CM was based on an adaptation of the Conflict 
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Tactics Scale (CTS) (Straus, 1979) and the Childhood Trauma Questionnaire (CTQ) (Bernstein 
et al., 1997), as previously described (Keyes et al., 2012; Uddin et al., 2013). CTS items assessed 
physical and emotional abuse before age 11, with responses rated on a 5-point scale. CTQ 
assessed physical and sexual abuse before age 18, rating responses on a 3-point scale. In this 
study, a binary variable of CM exposure was used, such that CM exposure (N=56) was defined 
as any individual belonging to the upper quartile for CM score within the full wave 2 DNHS survey 
sample (N=1,588). Participants without exposure to CM (N=56) belonged to the bottom quartile 
of CM score within the full wave 2 DNHS survey sample.  
 
3.2.3. DEPRESSION MEASURE  
Depression symptom severity (depSS) scores were based on participant responses from the 
Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001a), rated on a 4-point scale for each 
of the 9 questions with each question ranging from 0 (not at all) to 3 (nearly every day); and total 
depression severity scores ranging from 0 to 27 as described in (Uddin et al., 2013). Lifetime 
major depressive disorder (MDD) was assessed at each wave of the DNHS using the PHQ-9, 
with additional questions to assess the timing and duration of symptoms, consistent with DSM-IV 
criteria (American Psychiatric, 1994) and previously validated (Uddin et al., 2011). Participant 
depression information was taken from the same wave as the participants’ biospecimens tested 
in the experiments described below. In this study, the continuous measure of depSS was used in 
the regression models. Within the GE analyses MDD was defined as history of lifetime MDD.  
 
3.2.4. ANTIDEPRESSANT MEDICATION 
Participant medication information was obtained during the in-home visit at the time of biologic 
sample collection and has been described previously (Bustamante et al., 2016) and is included in 
the regressions as a covariate.  
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3.2.5 GENOTYPE 
Participant genotype of FKBP5 SNP rs1360780 was imputed from data collected by the Illumina 
HumanOmniExpress BeadChip. PLINK (Purcell et al., 2007) was used to impute the genotype of 
rs1360780 for the DNHS participants. A subset of the study participants (N=100) had available 
genotype information. 
 
3.2.6. SAMPLE PREPARATION 
3.2.6.1. DNA AND RNA COLLECTION 
Whole blood was collected via venipuncture from study participants during scheduled in-home 
visits by a phlebotomist. DNA was isolated from whole blood and concentration was verified via 
Nanodrop 1000 (Thermofisher Scientific, Waltham, MA) as previously described (Bustamante et 
al., 2016). RNA was isolated from leukocytes and subjected to stringent quality control criteria as 
previously described within the DNHS (Bustamante et al., 2016)  
 
3.2.6.2. PERIPHERAL BLOOD MONONUCLEAR CELL COUNTS 
 At the time of blood draw, two, FICOLL gradient containing 8 ml BD Vacutainers CPTTM with 
sodium citrate (Franklin Lakes, NJ) were used for the collection of peripheral blood mononuclear 
cell (PBMC) samples and processed as previously described (Bustamante et al., 2016).  
 
3.2.6.3. BISULFITE CONVERSION  
Using Qiagen’s Epitect Bisulfite Kit, 750ng of participant DNA was bisulfite converted following 
the manufacturer’s recommended protocol. Negative controls containing RNAse/DNAse free 
water in place of DNA were included with each bisulfite conversion. High and low methylation 
control DNA purchased from Zymo Research (Irvine, CA) was bisulfite converted along with the 
participant samples in order to assess assay performance. 
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3.2.7. PCR AMPLIFICATION & PYROSEQUENCING 
5mC upstream of the transcription start site (TSS) (CHR6:35,656,797-35,656,920), downstream 
of the TSS (CHR6:35,655,829-35,655,843), and introns 2 (CHR6:35,558,310-35,558,785) and 7 
(CHR6:35,607,754 -35,608,049) of FKBP5 were assessed via pyrosequencing. These regions 
were targeted in part based on: (i) previous work within FKBP5 (intron 2 and 7: (Klengel et al., 
2013)), and (ii) previous work demonstrating an association between early life adversity and 5mC 
in promoter regions of related HPA axis genes (i.e. NR3C1 (Oberlander et al., 2008; Tyrka et al., 
2012)). All assay files were designed and created using the PyroMark Q24 Assay Design 
Software 2.0 (Qiagen). 5mC of FKBP5’s Intron 2 and 7, which encompass GREs, has been 
previously investigated by (Klengel et al., 2013; Tyrka et al., 2015; Yehuda et al., 2015a) (Figure 
3.1). PCR and pyrosequencing primers for Intron 2 and 7 have been previously described in 
(Klengel et al., 2013). A new sequencing primer for Intron 7 CpG 3 was designed using the same 
PCR primers as described by (Klengel et al., 2013). Two separate loci were examined within the 
FKBP5 promoter region. The first was a ready-made Qiagen assay targeting 3 CpG sites within 
intron 1 and overlapped a CpG island TSS, denoted as downstream promoter (Figure 3.1). The 
second was newly developed using the PyroMark Q24 Assay Design Software 2.0 (Qiagen). The 
newly developed primer set encompassed 11 CpG sites within a transcription factor binding site 
(TFBS), and overlapped a CpG island upstream of the TSS, denoted as upstream promoter 
(Figure 3.1).  
All PCR and sequencing primers were validated according to the recommendations in the 
PyroMark manual to ensure high quality primers were used. Additionally, each primer set was 
tested using commercially available high and low methylation control DNA (Zymo Research) that 
was bisulfite converted on site. Bisulfite converted participant DNA was amplified using Qiagen’s 
PyroMark PCR kit for all four loci of FKBP5 examined in this study. PCRs were run in duplicate 
and contained 20ng of bisulfite converted participant DNA as starting template. No template 
controls were run in duplicate and were included with each set of PCRs as a negative control as 
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they did not contain any DNA. Qiagen’s PyroMark Q24 Pyrosequencer was used to detect 5mC 
levels following manufacturer’s protocols and default settings. 
 
Upstream Promoter Assays: 
Upstream Promoter Primerset_1 
Forward PCR primer (biotinylated): 5’-AGGGTTTAGGGGTTGTTAGT-3’ 
Reverse PCR primer: 5’-TCCACCATCCCTTCTCTATAAC-3’ 
Sequencing primer:  5’-ATAATAAAAACCAAACCTCATTTAC-3’    
Annealing temperature: 58oC 
Targets 9 CpG sites  
 
Upstream Promoter Primerset_2  
Forward PCR primer:  5’-AGGGTTTAGGGGTTGTTAGT-3’ 
Reverse PCR primer (biotinylated): 5’-TTTCCACCATCCCTTCTCTATAAC-3’ 
Sequencing primer:   5’-GTTTATGTAAATGAGGT-3’    
Annealing temperature: 58oC 
Targets 2 CpG sites 
 
Downstream Promoter Assay: 
Assay Name: Hs_FKBP5_01_PM PyroMark CpG assay 
Qiagen Catalogue Number: PM00120946 
Sequencing primer:  5’- CGTTCAGCCGCTTCGG -3’ 
Annealing temperature: 56oC 
Targets 3 CpG sites 
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Intron 7 Assay:  
 
FKBP5 Intron 7 CpG 3 sequencing primer:  5’- AAGTTGTATTTTATTTTTTTAAGGA -3’ 
Annealing temperature: 57oC 
Targets 1 CpG site 
 
PCR Program: (same for all primer sets) 
Initial    15 minutes 95oC 
Denaturation  30 seconds 94oC 
Annealing   30 seconds 55-58oC*  50 cycles 
Extension  30 seconds 72oC 
Final   10 minutes 72oC 
Hold   4oC  
*Annealing temperature varies for each of the PCR primers. 
 
3.2.8. REVERSE TRANSCRIPTION & REAL-TIME PCR 
FKBP5 mRNA expression levels were assessed in participants with available total RNA (N=71). 
Total RNA was reverse transcribed into cDNA following the manufacturer’s protocol using the 
High Capacity Reverse Transcription Kit purchased from Applied BioSystems (Foster City, CA). 
Ready-made Taqman GE assays (Applied Biosystems) were used to measure relative transcript 
levels of the target gene FKBP5 (Hs015610061_m1) and the control gene TATA Binding Protein, 
TBP (Hs00427621_m1) run in separate wells. Reactions were performed in triplicate for each 
participant. Each reaction was 20μl and contained 10ng of participant cDNA for both the test and 
control genes. Reactions were run on the HT7500 Fast Real-Time PCR machine (Applied 
BioSystems, Foster City, CA) following the manufacturer’s recommended protocol. 
 
3.2.9. PYROSEQUENCING DATA ANALYSIS 
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5mC levels were averaged across CpG sites within each of the four tested loci (upstream 
promoter, downstream promoter, intron 2, and intron 7). The distribution of averaged 5mC data 
obtained for each region was evaluated using boxplots, histograms, and tested for normality using 
the Shapiro-Wilk test of normality in IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., 
Armonk, NY).  
 
3.2.10 DEMOGRAPHIC STATISTICS  
Independent samples t-tests were used to test for bivariate associations between CM exposure 
and demographic covariates, as well as depression and demographic covariates. Chi-square 
tests were used to test for associations between CM exposure and the demographic variables of 
sex, race, and genotype. Similarly, Chi-square tests were used to test for the association between 
depression history and sex, race, and genotype. All statistical tests were two-tailed and results 
were considered significant when p < 0.05. Tests were conducted using SPSS version 23.0. 
 
3.2.11. MEDIATION ANALYSES 
5mC, CM, and depSS information for each participant was used to carry out mediation analyses 
using linear regressions (Figure 3.2). The analysis was performed using SPSS version 23.0, 
following criteria outlined in (Baron and Kenny, 1986). Specifically, we assessed whether: (a) CM 
is associated with depSS after controlling for confounders (i.e. age, sex, race, PBMC count, and 
antidepressant medication use); (b) CM is associated with FKBP5 5mC levels, after controlling 
for confounders; (c) if FKBP5 5mC is a predictor of depSS, after controlling for confounders; and 
lastly, if a, b and c were significant, we tested (a’), i.e. if the effect of CM on depSS at FKBP5 
regions is attenuated after controlling for 5mC at those regions, as well as other confounders. All 
regression models included age, sex, self-reported race, peripheral blood mononuclear cell 
(PBMC) count, and antidepressant medication information as covariates. A secondary analysis 
tested the potential interaction between CM and FKBP5 SNP rs1360780 within intron 7, as 
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previously reported in (Klengel et al., 2013; Tyrka et al., 2015), in a subset of individuals with 
available genotype data (n=100). For the model testing for an interaction, the main effect model 
was run first, followed by the interaction model. To address the concern of multiple hypothesis 
testing and potential Type I errors, the false discovery rate (FDR) was calculated as outlined in 
(Benjamini et al., 2001) such that results were accepted as significant when FDR ≤ 0.006. 
Adjusted p-values are indicated by “FDR” and unadjusted p-values are indicated by “p”. 
 
 3.2.12. GENE EXPRESSION  
Cycle threshold (CT) values for each sample were averaged across each replicate to obtain a 
mean CT value for each participant used in our analysis. All data was examined for outliers, and 
any replicates with a standard deviation greater than 0.25 were removed (n=5), and the mean CT 
was re-calculated from the remaining data points (Biosystems, 2016). GE data were analyzed 
using the comparative CT method (Schmittgen and Livak, 2008), normalizing FKBP5 GE against 
the control gene TBP. Normalized data were analyzed using the student’s t-test to compare 
expression levels according to exposure to CM and depression history. In this secondary analysis, 
results were accepted as significant if p<0.05. 
 
3.3. RESULTS 
General descriptive statistics of the study sample are included in Table 3.1. Examination of the 
5mC data revealed no extreme outliers, more than 3 interquartile ranges from the nearest edge 
of the boxplot. Participants with exposure to CM were not significantly different from those without 
CM exposure in terms of age, sex, self-reported race, genotype (rs1360780), PBMC count, or 
percent methylation (Table 3.1). There was a significant difference in CM score and depSS for 
participants with a history of CM exposure compared to those without such exposure (Table 3.1). 
Similarly, those with a history of depression had significantly different CM score and depSS 
compared to those with no reported history of depression (Table 3.1). A subset of the study 
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participants (N=100) had available genotype information; of these, 16 participants were 
homozygous for the T risk allele (i.e. TT), 41 participants were heterozygous CT, and 43 were 
homozygous CC. Participant genotypes were in Hardy-Weinberg equilibrium (p = 0.248). For SNP 
rs1360780, the major allele is C and the minor allele is T. The minor allele frequency according 
to the 1000 genomes project for rs1360780 is 0.3273 (Genomes Project et al., 2015), while in this 
dataset the imputed minor allele frequency among participants is 0.365. 
 
3.3.1. MEDIATION ANALYSIS  
3.3.1.1. UPSTREAM PROMOTER  
We first tested whether CM predicts depSS. CM was the sole significant predictor of depSS in 
this model (β=4.78 SE 1.11 p<0.001 FDR=0.005; Table S1a). The next linear regression model 
tested the relationship between CM and 5mC; neither our primary predictor (i.e. CM) nor any of 
the covariates were significantly associated with 5mC within this locus of the FKBP5 promoter 
region (Table S1b). The next regression model tested whether 5mC predicted depSS; no 
significant predictors or covariates were identified in this model (Table S1c). These results are 
summarized in Figure 3A. 
 
3.3.1.2. DOWNSTREAM PROMOTER  
As with the upstream promoter region results, CM was the sole significant predictor of depSS in 
this model CM (β=4.78 SE 1.11 p<0.001 FDR=0.005; Table S2a). Similarly, there was no 
significant relationship between CM or any of the covariates with 5mC; and, no significant 
predictors were observed in the model examining whether 5mC predicted depSS (Table S2b-c).  
These results are summarized in Figure 3b. 
 
3.3.1.3. INTRON 2 
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In the first model, CM (β=4.47 SE 1.44 p=0.002 FDR=0.006) significantly predicted depSS (Table 
S3a). In the next models, CM was not a significant predictor of FKBP5 Intron 2 5mC (Table S3b), 
nor did FKBP5 intron 2 5mC predict depSS (Table S3c). These results are summarized in Figure 
3C. 
 
3.3.1.4. INTRON 7 
The analyses showed CM significantly predicted depSS (β=4.47 SE 1.44 p=0.002 FDR=0.006; 
Table S4a). Similar to intron 2, CM was not a significant predictor of FKBP5 Intron 7 5mC (Table 
S4b). In the next regression model, intron 7 5mC and other covariates did not significantly predict 
depSS (Table S4c). Inclusion of participant genotype (rs1360780) as an interactor with CM (as 
previously shown (Klengel et al., 2013)), did not alter the reported non-significant findings (Figure 
3.3d; Supplementary Table 3.4). 
 
3.3.2. GENE EXPRESSION OF PERIPHERAL LEUKOCYTES 
FKBP5 GE was examined separately for CM and lifetime MDD to discern the potential impact of 
each exposure. No significant (p>0.05) differences in relative GE levels were observed between 
the CM exposed cases compared to the non-exposed controls. However, when comparing MDD 
cases and controls, we observed a significant increase in relative GE level among those with 
MDD vs. controls (p<0.001) (Figure 3.4).  
 
3.4. DISCUSSION 
Previous studies have highlighted the importance of early life environment in shaping 
mental health outcomes and have provided evidence that adverse early life experiences can 
impact 5mC levels within HPA axis genes. Motivated by this work, we sought to test whether 5mC 
mediates the relationship between CM and depSS in an adult population. We examined four loci 
within FKBP5 (upstream promoter, downstream promoter, intron 2, and intron 7); the latter two 
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loci have previously shown CM-associated 5mC differences. Our results suggest 5mC does not 
mediate the relationship between CM and depSS at any of the four FKBP5 loci examined. 
However, and confirming a large body of previous research in this area (Harkness and Monroe, 
2002; Kessler et al., 1997; MacMillan et al., 2001; Molnar et al., 2001; Wanklyn et al., 2012), a 
significant effect of exposure to CM on depSS was observed. These results highlight the complex 
relationship between CM and depression onset, suggesting multiple factors may contribute to 
disease onset following exposure to CM. 
Further examination of the individual regression analyses of the larger mediation model 
revealed several surprising findings, the first of which is that we did not detect a significant effect 
of CM on FKBP5 5mC within intron 7 that has been reported in other studies (Klengel et al., 2013; 
Tyrka et al., 2015). However, similar to our findings for the promoter region, one previous study 
reported no significant effect of CM on FKBP5 promoter region 5mC (Klengel et al., 2013). The 
second surprising finding is that FKBP5 5mC at any of the 4 loci were not significant predictors of 
depSS. Several studies have shown altered 5mC levels associated with depressive mood (Kahl 
et al., 2016; Nantharat et al., 2015; Oberlander et al., 2008; Tyrka et al., 2016). In addition, 
although the non-significant interaction between CM and genotype (rs1360780) at intron 7 in our 
data stands in contrast to previous work in adults (Klengel et al., 2013), this finding is consistent 
with a study in children (Tyrka et al., 2015). Further investigation is needed to elucidate the 
underlying mechanism between CM and FKBP5 5mC. 
As a secondary analysis, we examined the potential significant functional effect of 
exposure to CM and lifetime MDD on FKBP5 GE levels. No effect of CM exposure was observed 
on FKBP5 GE levels. This finding is consistent with previous work that that examined the 
biological correlates of PTSD in a longitudinal military cohort on FKBP5 GE and included CM as 
a covariate (van Zuiden et al., 2012). Examination of FKBP5 GE levels in relation to lifetime MDD; 
however, revealed a significant increase in expression between those with vs. without a history 
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of the disorder. These findings are consistent with previous studies examining rodent GE of Fkbp5 
in relation to chronic stress (Guidotti et al., 2013) or corticosterone exposure (Lee et al., 2010). 
One human study that compared FKBP5 GE in pre- and post- antidepressant treatment in healthy 
controls and depressed patients reported increased levels of FKBP5 GE at baseline for the 
depressed patients compared to the healthy controls (Cattaneo et al., 2013). Our findings provide 
additional evidence for the potential functional effect of depression on FKBP5 GE. The potential 
functional effect of increased GE levels associated with lifetime MDD may result in decreased 
sensitivity to cortisol, possibly conferring higher GR resistance (Lopez-Duran et al., 2015; Wei et 
al., 2015). In contrast, the non-significant effect of CM on 5mC at any of the four loci suggests 
there is no functional effect of FKBP5 5mC at these loci on FKBP5 GE levels. 
 In the present study we report no significant association between CM and 5mC in FKBP5, 
despite previous reports of an association between these two factors. One potential reason for 
our findings, which do not replicate previous work, may pertain to the structure of our study. The 
population used in this study is drawn from a community-based, population-representative cohort, 
while the Klengel and Tyrka studies were predominantly comprised of participants only from lower 
socioeconomic status. As such the level and types of trauma and/or contextual stressors 
experienced by both cases and controls may differ from our own population and impact results. 
Another potential reason may pertain to the difference in the definition of what constituted CM. 
Selection of CM cases within the Klengel study included histories of both sexual and physical 
abuse, whereas within this study, selection was based off of exposure levels defined by quartile, 
with no requirement regarding the type or number of maltreatment types. The Klengel study also 
reports a significant interaction of childhood trauma and FKBP5 SNP in predicting lifetime PTSD 
status and modified PTS symptom severity. Few studies have examined the impact of PTSD on 
5mC in FKBP5 (Yehuda et al., 2013) and other HPA axis genes (Labonte et al., 2014; Yehuda et 
al., 2015b), therefore it is possible that co-morbid lifetime or current PTSD may be driving some 
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of the reported significant findings in the earlier work. As a result, careful interpretation and 
comparison is required for our own findings as well as those reported by others. 
There are study limitations that should be noted. First, the CM variable used in our study 
is a retrospective self-reported measure of abuses occurring before age 18. Early life experiences 
have been shown to be long lasting and detected into adulthood, however self-reported measures 
may introduce recall bias. Previously, retrospective self-reports of CM from adults with 
documented cases were associated with underreporting of physical and sexual abuse (Widom 
and Morris, 1997; Widom and Shepard, 1996). Therefore, our measure of CM may well be an 
underestimate of previous abuse. Second, we were unable to control for white blood cell subset 
within our study; however, we were able to include PBMC counts in each regression model. 
Notably, there was no significant difference in PBMC counts between participants with vs. without 
exposure to CM or with vs. without a history of depression. Lastly, we were unable to assess 
whether our findings were associated with differences in participant cortisol level, as cortisol was 
not collected within the parent study, the DNHS. Recent work suggests there is a genotype-
dependent cortisol response to stress associated with FKBP5 SNP rs1360780 (Buchmann et al., 
2014; Fujii et al., 2014; Hohne et al., 2015).  
The DNHS is a non-clinical, community-based cohort of adults Detroit, Michigan residents. 
As such, this study provides us the opportunity to generalize our findings to the larger Detroit 
population. Second, our study is unique because antidepressant medication use is a covariate in 
our analyses; inclusion of this variable allows us to adjust for the potential effect of antidepressant 
medication on 5mC levels as previously reported (Melas et al., 2012; Perisic et al., 2010). Third, 
this study adds to the literature by examining the relationship among CM, 5mC, depSS, and GE, 
with additional analyses examining FKBP5 genotype and its potential interaction with CM. Lastly, 
we measured 5mC and GE in a subset of the same study participants, which allowed us to infer 
the potential impact of altered 5mC downstream on FKBP5 GE. 
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In conclusion, we found that 5mC in multiple genomic regions of FKBP5, a regulator of 
GR sensitivity, does not mediate the relationship between CM and depSS. We also found a 
significant increase in FKBP5 GE levels associated with lifetime MDD. We did not however, 
observe any significant difference in relative GE levels related to exposure to CM. Taken together, 
these results suggest other, additional factors beyond DNA methylation likely mediate the 
relationship between CM and depression as detectable in blood.  
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3.5. TABLES AND FIGURES  
TABLE 3.1. Demographic, genetic, and survey data of the study participants. Values indicate the counts or mean ± standard 
deviation. 
      Total N=112       
       
Measures 
Full Study 
Sample 
CM- CM+ 
p value, 
MDD- MDD+ 
p value, 
t-test or Χ2 
t-test or 
Χ2 
Age 50.74±12.96 50.11±13.14 50.14±12.80 0.988 51.50±13.32 47.65±11.91 0.131 
Sex    Χ
2  1   Χ
2  0.257 
Male  50 25 25  30 20  
Female 62 31 31  42 20  
Race    Χ
2 0.697   Χ
2 0.971 
European American 18 8 10  12 6  
African American 86 43 43  55 31  
Other 8 5 3  5 3  
rs1360780    Χ2 0.782   Χ2 0.385 
TT Homozygous 16 9 7  12 4  
CT Heterozygous 41 19 22  23 18  
CC Homozygous 43 22 21  28 15  
Depression Symptom Severity 8.28±7.82 6.13±7.31 10.47±7.78 0.003 3.72±4.98 16.38±4.80 <0.001 
PBMC count (million cells) 4.55±1.49 4.50+1.31 4.60+1.68 0.719 4.46±1.42 4.70±1.61 0.432 
CM Score 6.12±5.43 1.57±1.44 10.66±3.93 <0.001 5.15±4.793 7.85±6.11 0.011 
Percent DNA Methylation        
Average Intron 2 76.4±6.19 76.23±5.94 76.61±6.50 0.764 76.48±6.95 76.30±4.45 0.877 
Average Intron 7 90.24±3.02 89.98±3.14 90.49±2.92 0.397 90.01±2.76 90.62±3.42 0.326 
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TABLE 3.1. (Continued) 
        
Measures 
Full Study 
Sample 
CM- CM+ 
p-value,   
t-test or Χ2 
MDD- MDD+ 
p-value, t-
test or Χ2 
 N=72    
Percent DNA Methylation        
Average Upstream Promoter 4.64±1.67 4.30±1.45 4.75±1.87 0.248    
Average Downstream Promoter 2.8±0.93 2.69±0.91 2.90±0.95 0.353    
Depression Symptom Severity 3.72±4.98 1.44±2.2 6.06±5.91 <0.001    
CM Score 5.15±4.79 0.75±0.77 9.56±2.48       
* Indicated p-values  are derived from t-tests, unless denoted by Χ2, indicating it was derived by chi square test.  
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FIGURE 3.1: Schematic showing the four regions examined within the study indicated by shading upstream promoter 
(CHR6:35,656,797-35,656,920), downstream promoter (CHR6:35,655,829-35,655,843), and introns 2 (CHR6:35,558,310-35,558,785) 
and 7 (CHR6:35,607,754 -35,608,049). All coordinates provided are from the UCSC Genome Browser Build 2009/hg19. The CpG sites 
examined within this study are indicated in uppercase, bold font, and green text. Lower case letters indicate intronic regions. The 
transcription factor binding site is indicated by underlined sequence. 
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FIGURE 3.2: Schematic showing the mediation framework for our analysis. Letters indicate the order the regressions were tested. 
Note analysis “d” was only tested for Intron 7, based on previous work (Klengel et al., 2013).  
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FIGURE 3.3: Summary of the mediation analyses for each region of FKBP5 tested upstream promoter (a), downstream promoter (b), 
intron 2 (c), and Intron 7 (d). Significant results are indicated by bold black text and denoted unadjusted p-value and FDR. Non-
significant results are denoted by gray text and “N.S” for non-significant.  
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FIGURE 3.4: FKBP5 gene expression levels among individuals with (n=35) vs. without (n=36) exposure to childhood maltreatment 
and participants with (n=25) vs. without (n=46) lifetime major depressive disorder history. T-tests showed a significant (p<0.001) 
increase in gene expression levels among major depressive disorder cases compared to controls. Error bars represent standard 
error and asterisk denotes significant p<0.05. 
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CHAPTER 4: ALTERED TRANSCRIPTOMIIC PROFILES ASSOCIATED WITH CHILDHOOD 
MALTREATMENT AND POST-TRAUMATIC STRESS DISORDER 
 
ABSTRACT 
Exposure to childhood maltreatment increases the risk of developing post-traumatic stress 
disorder (PTSD) later in life. Genome-scale studies of childhood maltreatment and PTSD have 
typically examined the impact of these exposures on peripheral expression profiles separately, 
though exceptions do exist. Despite this previous work, the transcriptional profiles of these 
interrelated exposures remain poorly characterized. We employed a systems-biology approach, 
Weighted Gene Co-expression Network Analysis (WGCNA) to investigate the leukocyte 
transcriptome of individuals with varying histories of childhood maltreatment and PTSD. Genome-
scale leukocyte transcriptomic profiles were generated from Illumina’s HT12v4 microarray from 
participants (N=93) from the Detroit Neighborhood Health Study. A replication dataset using 
Illumina’s HT12v3 microarray was identified from the public repository GEO datasets, GSE42002, 
and augmented with additional phenotypic data obtained from the corresponding author of the 
public dataset. Data was pre-processed and analyzed in R version 3.2.5 using packages from 
Bioconductor. The effects of batch and covariates including age, sex, self-reported race, and 
childhood maltreatment (PTSD analyses) or PTSD (childhood maltreatment analyses) were 
removed from the data prior to WGCNA. WGCNA was used to detect co-expression networks 
associated with childhood maltreatment and PTSD, respectively. Gene enrichment analyses were 
performed on modules identified as significant within WGCNA using DAVID. In the discovery 
DNHS dataset, WGCNA revealed one module significantly correlated with childhood 
maltreatment and 6 modules significantly correlated with PTSD. The significant childhood 
maltreatment module was enriched in genes associated with cell cycle regulation, while modules 
significantly associate with PTSD were enriched in genes associated with immune response, 
innate immunity, mitochondrial function, cell cycle, mRNA processing, and transcription. Within 
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the replication analysis, 3 modules were significantly correlated with childhood maltreatment, 
while no modules were significantly correlated with lifetime PTSD. The replication childhood 
maltreatment modules were enriched in genes associated with cell-cell signaling, synaptic 
transmission, and RNA processing. The DNHS-based childhood maltreatment and PTSD 
networks shared a modest overlap in cell cycle-related genes. Interestingly, a small overlap 
between the DNHS-based PTSD and replication childhood maltreatment networks was observed 
for mRNA processing and nucleotide binding. Overall, the WGCNA-generated childhood 
maltreatment and PTSD networks appeared to be unique to each exposure within the discovery 
dataset; additionally, the replication analysis did not replicate the findings of the DNHS-based 
childhood maltreatment or PTSD analyses. Despite the lack of replication, these results provide 
modest additional support for the dysregulation of genes associated with immune function and 
mitochondrial function in individuals with PTSD.  
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4.1. INTRODUCTION 
Recent research indicates 24.9% of the US population has experienced at least one type 
of childhood maltreatment by the age of 18 (Finkelhor et al., 2015). Childhood is a critical 
developmental period where the risk for or resilience to developing mental illness as an adult is 
shaped (Ehlert, 2013; Espejo et al., 2007). More specifically, exposure to childhood maltreatment 
significantly increases the risk of developing post-traumatic stress disorder (PTSD) (Green et al., 
2010; MacMillan et al., 2001; Stein et al., 1996), major depression (Kendler et al., 2004; Nemeroff, 
2004), and bipolar disorder (Afifi et al., 2008) among other mental disorders. PTSD is a debilitating 
psychiatric disorder that can result following exposure to a traumatic event. Current estimates 
suggest between 40-90% of the US population have experienced or been exposed to a traumatic 
event (Green et al., 2000), however, the lifetime prevalence of PTSD is relatively low, 6.8% 
(Kessler and Wang, 2008). In contrast to the general population, men and women who report a 
history of childhood maltreatment are up to 80% more likely to meet criteria for mood and anxiety 
disorders, including PTSD (Duncan et al., 1996; Kessler et al., 1997). Even though environmental 
risk factors associated with PTSD onset both pre- and post-trauma exposure have been identified 
(Koenen et al., 2002; Neigh et al., 2012; Pitman et al., 2012; Trickey et al., 2012), the relationship 
between trauma exposure and PTSD onset is not yet completely understood. In particular, the 
association between childhood maltreatment exposure and subsequent PTSD development 
during adulthood has been well documented (Green et al., 2010; MacMillan et al., 2001; Stein et 
al., 1996), but the biologic mechanisms that underlie these associations have not been well 
characterized. 
Work over the past 10 years has shown that leukocyte gene expression profiles can serve 
as indicators of mental disorders and environmental exposures, even when assessed in 
peripheral tissues (Labonte et al., 2012b; Levy-Gigi et al., 2013; McGowan et al., 2009; Roy et 
al., 2017; Spindola et al., 2017; Yehuda et al., 2009). Whereas previous genome-scale gene 
expression studies of childhood maltreatment are limited, substantially more work has been 
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performed investigating the impact of PTSD on gene expression at the genome-scale level (Breen 
et al., 2015; Glatt et al., 2013; Logue et al., 2015; Neylan et al., 2011; O'Donovan et al., 2011; 
Sarapas et al., 2011; Segman et al., 2005; Tylee et al., 2015; Yehuda et al., 2009; Zhou et al., 
2014; Zieker et al., 2007) in blood. To date, one study has examined the impact of PTSD 
specifically on human brain expression patterns, using a mitochondria-focused gene expression 
microarray (Su et al., 2008), while another study examined PTSD within the context of co-morbid 
depression (Wingo et al., 2015). Much more work has been reported on PTSD-related expression 
profiles in blood: differences in genome-scale gene expression patterns were first observed by 
Segman et al. (Segman et al., 2005) in trauma exposed patients in the emergency room who 
would go on to meet DSM-IV diagnostic criteria for PTSD compared to patients who did not meet 
criteria for PTSD. These identified differences in gene expression were detected four months after 
the emergency room visit (Segman et al., 2005). Since this initial study, others have reported 
significant gene expression differences associated with PTSD cases compared to controls (Logue 
et al., 2015; Tylee et al., 2015) in blood. A strong body of work has consistently shown PTSD is 
associated with altered gene expression levels of genes associated with immune function and 
response in blood, derived from cohorts consisting of civilians (Neylan et al., 2011; O'Donovan et 
al., 2011; Sarapas et al., 2011; Segman et al., 2005; Yehuda et al., 2009; Zieker et al., 2007) and 
military personnel/veterans (Breen et al., 2015; Glatt et al., 2013; Zhou et al., 2014). More 
specifically, these studies report altered expression of genes associated with immune cell function 
(Sarapas et al., 2011; Yehuda et al., 2015a; Zieker et al., 2007), immune activation (Segman et 
al., 2005), immune response (Glatt et al., 2013; Neylan et al., 2011), inflammatory cytokines 
(O'Donovan et al., 2011; Zhou et al., 2014), and increased expression of innate immunity-related 
genes (Breen et al., 2015). These studies highlight the strong and relatively consistent signal 
obtained in studies that have investigated PTSD, as measured by genome-scale gene expression 
data.  
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Despite the well-known association between history of childhood maltreatment and onset 
of PTSD, the transcriptomic (gene expression) impact of both childhood maltreatment and PTSD 
at the genome-scale level has largely been unexplored. An initial study by Mehta et al. (Mehta et 
al., 2013), examined genome-scale DNA methylation and transcriptomic profiles in participants 
with PTSD both with and without a history of childhood maltreatment compared to non-PTSD/non-
childhood maltreatment exposed controls. Mehta found very little overlap in the transcriptomic 
profiles of PTSD participants with childhood maltreatment and PTSD participants without 
childhood maltreatment. To further their understanding of the biologic impact of PTSD and 
childhood maltreatment, DNA methylation and gene expression data were correlated, using only 
those CpG sites that map to genes identified in the differential expression analysis. This 
correlation analysis revealed more significant DNA methylation differences existed in participants 
with PTSD and childhood maltreatment exposure compared to those with PTSD and no childhood 
maltreatment exposure. Despite this seminal work by Mehta, the biologic underpinnings 
pertaining to childhood maltreatment and PTSD remain poorly understood. Moreover, existing 
studies of either childhood maltreatment or PTSD have relied primarily upon standard differential 
analyses to determine expression differences, leaving the functional significance of these 
differences relatively unexplored. To address this gap in knowledge we employed a systems 
biology approach, weighted gene co-expression network analysis (WGCNA), to explore the 
impact of childhood maltreatment and PTSD on the leukocyte transcriptome. The goal of this work 
is to (1) characterize the biologic networks dysregulated by childhood maltreatment and PTSD 
separately and (2) determine the extent of overlap between the childhood maltreatment and PTSD 
associated networks.  
 
4.2. METHODS 
4.2.1. DISCOVERY DATASET 
4.2.1.1. PARTICIPANT SELECTION 
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The Detroit Neighborhood Health Study (DNHS) was approved by the institutional review board 
at the University of Michigan and the University of North Carolina at Chapel Hill. Participants 
(N=129) were selected from the DNHS, a longitudinal, population-based representative sample 
of adult residents from Detroit, MI (Goldmann et al., 2011; Uddin et al., 2010). All participants 
provided informed consent prior to participation in the DNHS. Participant selection for inclusion 
on the Illumina HT-12v4 microarray was based on history of lifetime PTSD, matching cases with 
trauma-exposed controls. The full sample (N=129) was subset for both the PTSD and childhood 
maltreatment analyses to contain the same number of participants, N=93.  
 
4.2.1.2. CHILDHOOD MALTREATMENT 
Participant survey data regarding childhood maltreatment history were collected via structured 
telephone interviews assessing the severity, duration, and frequency of each event type. 
Assessment of childhood maltreatment was based on the Conflict Tactics Scale (CTS) (Straus, 
1979) and the Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 1997), as previously 
described (Keyes et al., 2012; Uddin et al., 2013). CTS items assessed physical and emotional 
abuse before age 11, with responses rated on a 5-point scale. CTQ assessed physical and sexual 
abuse before age 18, rating responses on a 3-point scale. Participant responses were categorized 
into the number of experienced maltreatment types, ranging from 0 (no maltreatment types) to 2 
(2 or more maltreatment types). In this study, exposure to childhood maltreatment is defined by 
the number of types of maltreatment. Participants with childhood maltreatment exposure were 
defined as those with a history of 2 or more types of maltreatment (N=26), and those without 
exposure to childhood were defined as participants with no reported exposure to maltreatment or 
0 types of maltreatment (N=67); participants with 1 type of maltreatment were excluded from the 
analysis.  
 
4.2.1.3. PTSD MEASURE 
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Participant PTSD history was assessed using the PTSD checklist-civilian (PCL-C) (Blanchard et 
al., 1996). The PCL-C is a 17-item self-report measure of PTSD symptoms consistent with the 
DSM-IV symptoms of PTSD (Breslau et al., 1998; Shalev et al., 1998). Additional questions 
assessed the timing, duration, severity of illness, and disability resulting from symptoms. Study 
participants were asked about traumatic events using a list of 19 potentially traumatic events and 
were permitted to describe any other event or situation that was extraordinarily stressful to them. 
PTSD symptoms were assessed by asking the participants to select two traumatic events; first, 
one they regarded as the worst and second a randomly selected event (if the participant 
experienced more than one trauma). Symptoms were assessed separately in relation to the worst 
and the random event. Study participants rated both events on a 5-point scale indicating the extent 
to which the respondent was bothered by a particular symptom resulting from the trauma, ranging 
from 1 (not at all) to 5 (extremely). Lifetime PTSD was classified as those participants who met 
all six DSM-IV criteria for PTSD (American Psychiatric, 1994) in reference to either of the two 
selected traumatic events (cases N=49, controls N=44). Participant lifetime PTSD information 
was taken from the same wave as the participant biospecimen run on the microarray. 
 
4.2.1.4. SAMPLE PREPARATION AND MICROARRAY TESTING 
Whole blood was collected via venipuncture from study participants during scheduled in-home 
visits by a phlebotomist. Participant RNA was obtained from leukocytes using Leukolock kits 
following the manufacturer’s alternative protocol to preserve total RNA (Ambion, Austin, TX). 
Quality control criteria was used to ensure high quality RNA was obtained, including a RNA 
integrity number (RIN) ≥5, 28s/18s≥1.0, and 260/280≥1.7 (Fleige and Pfaffl, 2006; Fleige et al., 
2006). RNA sample RIN values and 28s/18s ratios were calculated using the 2100 Bioanalyzer 
(Agilent, Wilmington, DE) to determine RNA quality. RNA concentration for each sample was 
determined using the NanoDrop 1000 (ThermoScientific). 220ng of participant RNA was supplied 
to the Wayne State University Core facility, Applied Genomics Technology Center (AGTC), for 
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processing on the Illumina HT-12v4 microarray chip (Illumina, San Diego, CA), which interrogates 
over 47,000 probes encompassing roughly 31,000 genes. Briefly, RNA was reverse transcribed 
into cDNA containing a biotin label. The labeled cDNA was then hybridized to the Illumina HT-12 
v4 array and read using the Illumina HiScan technology. Each chip contained 12 case-control 
matched participants on a total of 11 chips. Raw data was imported into Genome Studio (Illumina) 
and examined using the control probe profile. Raw data was then exported to a text file for 
processing.  
 
4.2.1.5. PREPROCESSING MICROARRAYS 
Raw data was imported, preprocessed, and analyzed in R (www.R-project.org) version 3.2.5 
(Team, 2016) using a variety of R packages available in Bioconductor (http://bioconductor.org) 
(Huber et al., 2015). The data was background corrected, transformed using variance stabilizing 
transformation (Huber et al., 2002), quantile normalized, and filtered to remove low and non-
expressed probes using the R packages Limma (Smyth et al., 2005) and Lumi (Du et al., 2008). 
A total of 19,788 transcripts passed the filtering criteria and were included in the downstream 
analyses. Estimates of cellular heterogeneity were created using the R package CellCODE 
(Chikina et al., 2015), separately for childhood maltreatment and PTSD using transcripts that 
passed the filtering criteria. Pre-processed data was examined using principal components 
analysis (PCA) to detect any significant associations between known technical artifacts (chip, 
plate, or batch) and potential study variables (age, sex, self-reported race, childhood 
maltreatment, or PTSD) with calculated PCs. Data was corrected for chip effects and controlled 
for confounders (age, sex, self-reported race, cell estimates, and the co-morbid exposure 
(childhood maltreatment or PTSD)) using the function “RemoveBatchEffects” in the R package 
Limma. PCs were examined at every stage of data QC and pre-processing: Raw data prior to QC, 
post QC, and post data correction. Visualization of PCs confirmed the effects of chip, age, sex, 
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self-reported race, and co-morbid exposure were removed following correction using 
“RemoveBatchEffects”.  
 
4.2.1.6. WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS  
Weighted gene co-expression networks were generated using the R package WGCNA 
(Langfelder and Horvath, 2008), for childhood maltreatment and PTSD separately. 19,788 
transcripts were used as the input for WGCNA and underwent hierarchical clustering to detect 
gene clusters (modules) from correlation patterns observed in the data of each gene. For this 
analysis, WGCNA creates a correlation matrix by performing a Pearson correlation for all possible 
transcript pairs. This matrix was transformed into an adjacency matrix by use of a power function 
(β=4), creating the weighted network. Automatic network construction was used with the function 
“blockwiseModules” with minimum module size set to 30 transcripts. Modules were created using 
mergeCutHeight 0.25, and each cut branch or newly created module was given a unique color 
identifier. Following the creation of modules, each newly created module was then correlated with 
the selected exposure variables of interest, childhood maltreatment or PTSD, using the module 
eigengene (i.e. the first principal component of an individual module, and it is considered to 
representative of the module gene expression profile (Langfelder and Horvath, 2008)). Therefore, 
a positive correlation between module eigengene and exposure of interest is indicative of 
upregulation of genes within the selected module, while a negative correlation is indicative of 
downregulation of genes associated with MDD. 
 
4.2.1.7. GENE ENRICHMENT ANALYSIS 
Modules significantly (p≤0.05) correlated with childhood maltreatment or PTSD were further 
examined via gene enrichment analysis using DAVID version 6.8 (https://david.ncifcrf.gov/) 
(Huang et al., 2007a; Huang et al., 2007b). Briefly, individual probeIDs (transcript identifiers) from 
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each significant module were converted to Entrez gene IDs and used as input for the enrichment 
analysis, using the default parameters in DAVID for analysis.  
 
4.2.1.8. NETWORK VISUALIZATION 
Hub genes (i.e. those with the most connections when subset to the top 150 connections of a 
module) of significant modules for each exposure (childhood maltreatment and PTSD) were 
visualized using external visualization software Cytoscape (http://www.cytoscape.org/) (Shannon 
et al., 2003). 
 
4.2.2. REPLICATION DATASET 
Data for the replication of DNHS findings were accessed from the public repository Gene 
Expression Omnibus Datasets (GEODatasets) (Barrett et al., 2013; Edgar et al., 2002), using the 
search criteria Homo sapiens, gene expression, and childhood maltreatment, and PTSD. 
GSE42002 (Klengel et al., 2013) was selected for the replication analysis and is part of a larger 
study the Grady Trauma Project (GTP) (Binder et al., 2008; Bradley et al., 2008; Gillespie et al., 
2009; Ressler et al., 2011). GSE42002 was generated by Klengel et al. (Klengel et al., 2013), 
using the Illumina HT12v3 microarray and consisted of data from 129 GTP participants. Additional 
phenotypic variables were obtained from the corresponding author listed for GSE42002 for use 
in this analysis. Lifetime PTSD within this replication dataset, was derived using Clinician 
Administered PTSD Scale (CAPS) (see (Klengel et al., 2013) for more information). Additionally, 
childhood maltreatment was assessed using the CTQ, and was further dichotomized into those 
with no-exposure to maltreatment and those with exposure to two or more types of maltreatment 
(Klengel et al., 2013). In this study the dataset was subset to participants with available childhood 
maltreatment and lifetime PTSD variable information, N= 91; participants with missing childhood 
maltreatment and lifetime PTSD information were removed from the analysis. Demographics of 
the 91 participants used in this study are summarized in Table 4.1. Participants with a history of 
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childhood maltreatment did not differ significantly (p>0.05) from those with no history of childhood 
maltreatment in terms of age, sex, or self-reported race. Similarly, participants with a history of 
lifetime PTSD did not differ significantly (p>0.05) from those with no history of PTSD in regards 
to age, sex, or self-reported race (Table 4.1).  
 Normalized and transformed data was downloaded from GEO within R using GEOquery, 
Data was filtered to remove low and non-expressed probes based on detection p-value. A total of 
22,192 probes passed the filtering measures and were included in the replication analysis. 
Estimates of cellular heterogeneity were estimated using the R package CellCODE for childhood 
maltreatment and PTSD separately. Batch effects were estimated using the R package SVA 
(Leek and Storey, 2007) and the method “be”. Data was examined for significant associations 
with technical artifacts (batch) and study variables (age, sex, self-reported race, childhood 
maltreatment, and lifetime PTSD) with calculated PCs. Data was corrected for batch (estimated 
by SVA) effects and controlled for confounders (age, sex, self-reported race, cell estimates, and 
the co-morbid exposure (childhood maltreatment or PTSD) using the function 
“RemoveBatchEffects” in the R package Limma. PCs were examined at every stage of data QC 
and pre-processing, normalized-filtered data and post data correction. Consistent with the 
discovery dataset, visualization of PCs post correction confirmed the effects of chip, age, sex, 
self-reported race, and co-morbid exposure were removed from the data. The chip corrected, 
filtered data was input into WGCNA, analyzed for childhood maltreatment and PTSD separately. 
WGCNA and enrichment analyses were then conducted as described above for the discovery 
dataset. 
 
4.3. RESULTS 
4.3.1. DISCOVERY DATASET 
4.3.1.1. SAMPLE DEMOGRAGHICS  
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In our study population of 91 DNHS participants, 51 were female and 42 were male; 17 
self-identified as European-American or white, 75 as African-American or black, and 1 as “other”. 
The average age was 54.24 years. Further information regarding sample demographic data is 
available in Table 4.2.  
 
4.3.1.2. WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS  
In total, 19 modules were generated for the childhood maltreatment analysis and 17 for 
the lifetime PTSD analysis during the clustering step. Of the generated childhood maltreatment 
modules, one was significantly negatively correlated (p≤0.05) with this exposure (Figure 4.1A). In 
contrast, six modules were significantly correlated (p≤0.05) with lifetime PTSD, with half showing 
positive correlation and half showing negative correlation with this phenotype (Figure 4.1B). 
Positive correlation of modules with the exposure of interest indicates the transcripts within the 
module are over-expressed in cases/exposed group, whereas negative correlation indicates the 
genes are under-expressed in childhood maltreatment-exposed individuals or PTSD cases. 
Gene enrichment analyses were performed on the modules significantly (p≤0.05) 
correlated with childhood maltreatment and PTSD, respectively, to gain a gain a deeper 
understanding of the modules and their functional relevance. One module, grey60 (p=0.03) was 
negatively correlated with childhood maltreatment. Gene enrichment analysis of the grey60 
module revealed 8 annotation clusters with an enrichment score greater than 1 (Supplementary 
Table 4.1). The top 3 annotation clusters were enriched in genes associated with cell cycle, 
mitosis, and DNA replication (Table 4.3). The top 150 gene-gene connections within the childhood 
maltreatment-associated module, grey60, are visualized in Figure 4.3, including the 5 most 
connected genes (KIAA010, PCNA Clamp Associated Factor (alias PCLAF); NCAPG, NON-SMS 
Condensin I Complex Subunit G; CCNB2, Cyclin B2; CDC20, Cell Division Cycle 20; TNFRSF17, 
TNF Receptor Superfamily Member 17), which were associated with DNA repair and cell cycle 
regulation.  
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A summary of the top 3 annotation clusters associated with each of the PTSD-related 
modules is presented in Table 4.4. The top 150 connections for each module significantly 
associated with lifetime PTSD is visualized in Figure 4.4. Briefly, the first PTSD module, grey 
(p=5x10-6), was negatively correlated with PTSD and possessed 19 enrichment clusters with an 
enrichment score above 1 (Supplementary Table 4.2). The grey module was enriched in genes 
associated with transcription, DNA binding, and transcriptional regulation. The 5 most connected 
genes (CCNB2, Cyclin B2; CDC20, Cell Division Cycle 20; KIAA0101, PCNA Clamp Associated 
Factor (alias PCLAF); KIR2DL3, Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and 
Long Cytoplasmic Tail 3; KIR2DL4, Killer Cell Immunoglobulin Like Receptor, Two Ig Domains 
and Long Cytoplasmic Tail 4) were associated with DNA binding and replication (Figure 4.4A). 
The second module, blue (p=0.007), was negatively correlated with PTSD. Gene enrichment 
analysis revealed 64 annotation clusters with an enrichment score greater than 1 (Supplementary 
Table 4.3), with enrichment terms that included ubiquitin conjugation, innate immunity, cell cycle, 
and immune cell response. The 3 most connected genes (ABTB1, Ankyrin Repeat And BTB 
Domain Containing 1; AQP9, Aquaporin 9; NAMPT, Nicotinamide Phosphoribosyltransferase) 
within the blue module were associated with translation, transporter activity and cytokine activity 
(Figure 4.4B). The third module, red (p=0.009), was negatively correlated with PTSD. Gene 
enrichment analysis revealed 23 annotation clusters with an enrichment score above 1 
(Supplementary Table 4.4), with enrichment terms associated with helicase activity, zinc finger 
domains, and immune cell response. The top 5 most connected genes (FBXL10, Lysine 
Demethylase 2B (alias KDM2B); TTC3, Tetratricopeptide Repeat Domain 3; HCFC1, Host Cell 
Factor 1; ZBTB4, Zinc Finger And BTB Domain Containing 4; RCC2, Regulator Of Chromosome 
Condensation 2) within the red module were associated with transcription, ubiquitination, and 
cytokine activity (Figure 4.4C).  
A fourth module, tan (p=9x10-17), was positively correlated with PTSD, 3 annotation 
clusters had an enrichment score greater than 1 (Supplementary Table 4.5). The tan module was 
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enriched in genes associated with mRNA processing and nucleotide binding, which is consistent 
with the 5 most connected genes (TLK1, Tousled Like Kinase 1; PABPC1, Poly(A) Binding Protein 
Cytoplasmic 1; MYL12A, Myosin Light Chain12A; CALML4, Calmodulin Like 4; ADD3, Adducin 
3) (Figure 4.4D). The fifth module, green (p=1x10-7), was positively correlated with PTSD and had 
33 annotation clusters with an enrichment score above 1 (Supplementary Table 4.6). This module 
was enriched in genes associated with mitochondrion, mitochondrial translation, and 
ribonucleoproteins. The 3 most connected genes (ULK1, Unc-51 Like Autophagy Activating 
Kinase 1; NDUFAB1, NADH: Ubiquinone Oxioreductase Subunit AB1; MRPL3, Mitochondrial 
Ribosomal Protein 1) in the green module were associated with protein binding, oxidative 
phosphorylation of the mitochondrial membrane, and mitochondrial RNA binding (Figure 4.4E). 
The last and sixth module, yellow (p=0.005) was positively correlated with PTSD and contained 
42 annotation clusters with an enrichment score above 1 (Supplementary Table 4.7). The yellow 
module was enriched in genes associated with translation, transcription, and glycolysis. The top 
5 yellow genes (CREB1, CAMP Responsive Element Binding Protein 1; DDX51, DEAD-Box 
Helicase 51; CDKN2AIPNL, CDKN2A Interacting Protein N-Terminal Like; CATSPER2, Cation 
Channel Sperm Associated 2; CCBE1, Collagen And Calcium Binding EGF Domains 1) were 
associated with RNA and nucleotide binding and protein binding (Figure 4.4F). 
Terms identified from the gene enrichment analysis for modules significantly correlated 
with either both childhood maltreatment and PTSD were compared for overlap. Comparison of 
these terms yielded an overlap between the childhood maltreatment grey60 module annotation 
cluster 1 and the blue PTSD Module annotation cluster 3, specifically, a downregulation of cell 
cycle, cell division, and mitosis-related genes in both analyses. Additionally, three of the top 5 hub 
genes overlapped between the childhood maltreatment grey60 module and the PTSD grey 
module.  
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4.3.2. REPLICATION DATASET 
4.3.2.1. WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS WITH 
REPLICATION DATA 
In total, 21 modules were generated for the childhood maltreatment analysis and 20 for 
the lifetime PTSD analysis during the clustering step. Of the generated modules, 3 were 
significantly correlated with childhood maltreatment (p≤0.05) (Figure 4.2A). One module was 
negatively correlated with childhood maltreatment and two modules were positively correlated 
with childhood. No modules were significantly correlated (p≥0.05) with lifetime PTSD (Figure 
4.2B).  
Gene enrichment analyses were performed on the modules significantly associated with 
childhood maltreatment; gene enrichment analyses were not performed for lifetime PTSD as no 
modules were significantly correlated. Table 4.5 contains the top 3 annotation clusters for each 
significant childhood maltreatment-related module. The grey module (p=0.01) was negatively 
correlated with childhood maltreatment. Gene enrichment analysis revealed 26 annotation 
clusters with an enrichment score greater than 1 (Supplementary Table 4.8). The grey module 
was enriched in genes associated with glycoprotein, cellular signaling, cellular membrane, 
calcium binding, and synapses. The top 5 genes (PROS2, Protein S (Alpha); ITGB5, Integrin 
Subunit Beta 5; CTDSPL, CTD Small Phosphatase Like; LTF, Lactotransferrin; DEFA1B, 
Defensin Alpha 1B) with the strongest correlations within the grey module were associated with 
neuronal signaling and membrane defense (Figure 4.5A). The second module grey60 (p=0.04), 
was positively correlated with childhood maltreatment and had 3 annotation clusters with an 
enrichment score above 1 (Supplementary Table 4.9). The grey60 module was enriched in genes 
associated with mRNA processing, cytoplasm, and nucleotide binding. The 5 most connected 
genes (CCT7, Chaperonin Containing TCP1 Subunit 7; EEFIA1, Eukaryotic Translation 
Elongation Factor 1 Alpha 1; RBM4, RNA Binding Motif Protein 4; ERP29, Endoplasmic Reticulum 
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Protein 29; EIF3M, Eukaryotic Translation Initiation Factor 3 Subunit M) within the grey60 module 
are associated with translation, RNA processing, and protein folding (Figure 4.5B). The third 
module, red (p=0.04) was positively correlated with childhood maltreatment and had 7 annotation 
clusters with an enrichment score above 1 (Supplementary Table 4.10). The red module was 
enriched in genes associated with a genetic disorder targeting the kidneys and eyes, mRNA 
processing, TPR structural domains, and nucleotide binding. The 5 most connected genes 
(POFUT2, Protein O-Fucosyltransferase 2; FNBP4, Formin Biding Protein 4; C7ORF54, SND2 
Intronic Transcript 1 (alias SND1-IT1); RHOT2, Ras Homolog Family Member T2; POLG, DNA 
Polymerase Gamma, Catalytic Subunit) of the red module are associated with protein binding and 
DNA binding (Figure 4.5C). 
Terms identified from the gene enrichment analysis for the significant childhood 
maltreatment modules from the discovery and replication dataset were compared for overlap. An 
additional comparison of terms between the discovery PTSD modules and replication childhood 
maltreatment modules was also performed. Comparison of the childhood maltreatment terms 
identified in the discovery and replication datasets revealed no overlap in terms. Comparison of 
the significant discovery PTSD modules with the significant replication childhood maltreatment 
modules yielded an overlap between the discovery PTSD tan module annotation clusters 1 and 
2 with the replication childhood maltreatment grey60 module annotation cluster 1 and 3 and red 
module annotation cluster 2. Overlap in terms included RNA binding, mRNA processing, 
nucleotide binding, and mRNA splicing; upregulation of these terms was observed in the 
discovery PTSD tan module and in both replication childhood maltreatment modules, grey60 and 
red.  
 
4.4. DISCUSSION  
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In this study, we set out to examine the biologic impact of childhood maltreatment and 
PTSD on genome-scale gene expression in leukocytes with the goal of determining whether the 
same (or similar) biologic pathways are disrupted following exposure or if there is unique biologic 
embedding of each exposure. Childhood maltreatment and PTSD were analyzed by WGCNA 
separately. We identified one module that was significantly correlated with childhood 
maltreatment and 6 modules that were significantly correlated with lifetime PTSD in our discovery 
dataset. Comparison of the gene enrichment analysis between the discovery childhood 
maltreatment and PTSD results revealed a shared downregulation of cell cycle associated genes, 
however the transcriptomic profiles of each exposure are largely unique. Additionally, we were 
unable to replicate our findings for either childhood maltreatment or lifetime PTSD in an 
independent dataset (GSE42002). However, comparison of the childhood maltreatment results 
from our replication dataset to the PTSD results derived from our primary analysis revealed 
shared upregulation in pathways associated with mRNA processing and nucleotide binding, 
providing additional modest support for biologic dysregulation in similar pathways across the two 
exposures. 
In our primary childhood maltreatment analysis, one module (grey60) was significantly 
negatively correlated with exposure to childhood maltreatment, consisting of 48 transcripts. Gene 
enrichment analysis of the significant (grey60) module revealed genes associated with cell cycle 
and mitosis. Interestingly, previous research has suggested that adverse early life experiences 
such as childhood maltreatment are associated with stunted growth (Abajobir et al., 2017; 
Denholm et al., 2013; Wales et al., 1992). Certainly, dysregulation of the cell cycle could result in 
stunted growth due to a down-regulation of the cell cycle and mitosis. Still, more work is needed 
to fully understand how the cell cycle is dysregulated in individuals with a history of childhood 
maltreatment.  
In the PTSD analysis we identified 6 modules that were significantly correlated with lifetime 
PTSD and of these, three were positively correlated and three negatively correlated with lifetime 
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PTSD. Gene enrichment analysis revealed a variety of networks associated with PTSD. Of 
particular interest are the red and blue modules, both of which were negatively correlated with 
PTSD and enriched in immune function or immune response genes, which is consistent with a 
strong body of work linking PTSD with immune function and response as indexed by gene 
expression analyses (Breen et al., 2015; Glatt et al., 2013; Mehta et al., 2013; O'Donovan et al., 
2011; Sarapas et al., 2011; Segman et al., 2005; Zhou et al., 2014; Zieker et al., 2007). In addition, 
in studies that have focused on immune function of participants with PTSD, increased levels of 
pro-inflammatory cytokines (Cohen et al., 2011; Gola et al., 2013; von Kanel et al., 2007; Zhou et 
al., 2014) have been reported, while research regarding anti-inflammatory cytokines (Cohen et 
al., 2011; Guo et al., 2012) is less clear. In PTSD, dysregulation of immune-related genes is 
thought to be associated with HPA axis dysregulation, due in large part to the bidirectional 
communication between the HPA axis and immune system. When a stressful event is perceived, 
the HPA axis mobilizes to produce cortisol, which functions to downregulate pro-inflammatory 
cytokines and downregulate the innate immune system. Reduced cortisol secretion or decreased 
cortisol sensitivity have been associated with PTSD, and may play a role in the dysregulation of 
inflammatory cytokines (as reviewed in (Gill et al., 2009)). In addition, stressful exposures activate 
the sympathetic nervous system, which upregulates production of pro-inflammatory cytokines 
while downregulating the innate immune system (Irwin and Cole, 2011). In this study, both the 
red and blue modules were negatively correlated with lifetime PTSD, which is indicative of a 
downregulation of the transcripts within these modules. Even though both modules were 
associated with immune function and immune response, the enrichments within each differed. 
More specifically, the red PTSD module was enriched in genes associated with adaptive 
immunity, including T-cell receptor signaling, IL17 signaling pathway, and immune response. The 
blue PTSD module was enriched in genes associated with innate immunity, including regulation 
of innate immune response and natural killer cell mediated cytotoxicity. It is possible the down 
regulation of the innate immune system is in part associated with the sympathetic nervous system, 
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which also downregulates the innate immune response. Interestingly, dysregulation of innate 
immunity was reported in a previous WGCNA study (Breen et al., 2015) that examined the 
RNAseq profiles of U.S Marines pre- and post-deployment; however, that study reported an 
upregulation of genes associated with innate immunity. This difference in effect could be related 
to the all-male sample population or more generally differences in experienced traumas between 
civilians and military personnel. Nevertheless, this finding of innate immunity dysregulation is 
promising as it provides further support for immune dysregulation in participants with PTSD.  
The green module was positively correlated with lifetime PTSD and was enriched in genes 
associated with mitochondrion function and translation. Mitochondrial dysregulation has 
previously been associated with psychiatric disorders (Manji et al., 2012; Murphy et al., 2017; 
Rezin et al., 2009; Tobe, 2013; Torrell et al., 2013; Wang and Dwivedi, 2016) and studies of PTSD 
(Su et al., 2008; Zhang et al., 2012; Zhang et al., 2015). Additionally, reduced mitochondrial copy 
number (Bersani et al., 2016) and mitochondrial genetic variants (Flaquer et al., 2015) have also 
been associated with PTSD. Within the cell, the main role of mitochondria is to generate ATP 
through cellular respiration and regulate cellular metabolism (Sherratt, 1991). However, within 
PTSD, the role of mitochondrial dysregulation has not yet been well characterized. Interestingly, 
one study in blood reported increased expression of a subset of mitochondria genes was 
significantly positively correlated with total PTSD checklist score (Zhang et al., 2012). Within this 
study, we report an upregulation of mitochondrion-related genes in participants with lifetime PTSD 
compared to controls. Results from our analysis support the emerging literature suggesting 
mitochondrial dysregulation is associated with PTSD.  
Additionally, it should be noted that three PTSD modules, yellow, tan, and grey, were 
enriched in genes associated with mRNA processing and transcription. RNA metabolism, RNA 
processing, and transcription have been previously reported in a blood-based gene expression 
study of PTSD showing both up and down regulation of transcription-associated genes in PTSD 
cases (Segman et al., 2005). The genes within the yellow and tan modules were upregulated, 
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while the genes in the grey module were downregulated. Dysregulation of these related processes 
could result in altered protein levels as RNA must be processed and translated to generate 
proteins. This type of broad dysregulation could impact protein levels of genes by increasing or 
decreasing their production. It is also possible that dysregulation of translation and RNA 
processing could result in the production of dysfunctional proteins, as a consequence of 
dysregulation RNA splicing and processing. Further work is needed to explore the relationship 
between PTSD and dysregulated transcription and mRNA processing. 
A replication analysis was performed using gene expression data from an independent 
cohort whose data is publically available on GEO, GSE42002. In the replication analysis, we 
identified 3 modules significantly correlated with childhood maltreatment, however in the 
replication, no modules were significantly correlated with lifetime PTSD. Consistent with previous 
studies examining the impact of childhood maltreatment on genome-scale DNA methylation levels 
derived from several tissues (saliva, buccal, blood, and brain), enriched genes in the grey module 
were significantly associated with synapse and cellular signaling (Cecil et al., 2016; Labonte et 
al., 2012a; Suderman et al., 2014; Yang et al., 2013). The red and grey60 modules were enriched 
in genes associated with RNA processing and nucleotide binding. As mentioned previously, 
dysregulation of RNA processing could result in altered protein levels. Dysregulation of translation 
and RNA processing could result in the production of dysfunctional proteins, as a consequence 
of dysregulation RNA splicing and processing. To our knowledge, dysregulated RNA processing 
is a novel finding for childhood maltreatment however, more research is needed to fully 
understand the extent to which these dysregulated networks impact the individual. Comparison 
of results from the discovery and replication WGCNA analyses revealed no overlap between gene 
enrichments for childhood maltreatment. However, there was an overlap of terms between the 
discovery PTSD tan module and the replication childhood maltreatment red and grey60 modules. 
The overlapping terms from the discovery PTSD and replication childhood maltreatment analysis 
include mRNA processing and nucleotide binding. An upregulation of these terms was observed 
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in both the discovery PTSD (tan) and replication childhood maltreatment (grey60 and red) 
modules, however the replication childhood maltreatment grey60 indicated a downregulation of 
these genes. Despite the lack of replication between the discovery and replication datasets, we 
report dysregulation of pathways previously implicated in PTSD, mitochondria and immune-
related pathways, however, the direction of dysregulation was not consistent for innate immunity.  
As with every study, there are limitations that should be considered. First, we make use 
of RNA obtained from leukocytes rather than brain, the central tissue of interest in psychiatric 
research. Leukocytes are a heterogeneous tissue; the composition of cellular proportions may 
confound or bias results. In this study we estimated and corrected for cellular proportions using 
the R package CellCODE, to alleviate the concern of heterogeneity and potential bias. Second, 
our measure of childhood maltreatment is based on retrospective, self-reported abuse occurring 
before the age of 18. Even though early life experiences have been shown to be long lasting with 
effects that are detectable into adulthood, early life assessments based on self-reported 
measures may introduce recall bias. Previously, retrospective self-reports of childhood 
maltreatment from adults with documented cases were associated with underreporting of physical 
and sexual abuse (Widom and Morris, 1997; Widom and Shepard, 1996). Therefore, our measure 
of childhood maltreatment may well be an underestimate of previous abuse.  
This study also has many strengths, including the inclusion of a replication cohort, even 
though the findings did not confirm our analysis. Second, we employed a systems biology 
approach which allows for the data to be examined at the network level rather than the individual 
gene-level. Examination of data at the network level allows for the identification of pathways that 
are dysregulated in relation to the exposure of interest, rather than focusing on an individual gene. 
Third, this study is novel, in that we examine genome-scale gene expression profiles associated 
with childhood maltreatment and PTSD. To date, only one other study has examined childhood 
maltreatment and PTSD together (Mehta et al., 2013).  
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In summary, the results from our analysis identified modules significantly correlated with 
both childhood maltreatment and PTSD. In our discovery DNHS dataset, we observed an overlap 
of cell cycle and mitosis-related terms between childhood maltreatment and PTSD. Additionally, 
both analyses were associated with a downregulation of these terms. This finding provides a small 
measure of support for the role of cell cycle and mitosis within childhood maltreatment and PTSD. 
Additionally, we observed an overlap between the discovery PTSD and replication childhood 
maltreatment terms associated with mRNA processing and nucleotide binding. This finding 
provides additional modest support for the relationship between childhood maltreatment and 
PTSD; nevertheless, given the greater number and breadth of modules associated with PTSD, 
and the relatively small overlap between exposures, we conclude childhood maltreatment and 
PTSD impact biologic networks largely unique to each exposure. However, the way in which 
childhood maltreatment increases risk for PTSD later in life needs to be further examined. 
Furthermore, several of our reported findings were consistent with previous studies, suggesting 
a role for immune and mitochondrion-associated genes in PTSD. This work contributes to the 
current understanding of how childhood maltreatment and PTSD impact biologic networks 
following exposure or onset. 
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4.5. TABLES AND FIGURES 
TABLE 4.1. Demographic and survey data summary of the replication study participants. Values indicate the counts or mean ± 
standard deviation. P-values are indicated for t-tests unless otherwise indicated by X2. 
            
Measures 
Childhood 
Maltreatment 
- 
Childhood 
Maltreatment 
+ 
p value, 
PTSD- PTSD+ 
p value, 
t-test or Χ2 t-test or Χ2 
Age 40.53±15.97 43.22±10.55 0.335 42.20±15.24 40.88±12.74 0.657 
Sex   Χ
2 0.657   Χ
2 0.294 
Male  13 10  10 13  
Female 42 26  39 29  
Race   Χ
2 0.165   Χ
2 0.087 
African American 52 31  47 36  
Other 3 5  2 6  
Childhood Maltreatment Types  Χ
2 <0.001   Χ
2 <0.001 
0 Maltreatment 
Types 55 0  41 14  
2+ Maltreatment 
Types 0 36   8 28   
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TABLE 4.2. Demographic and survey data summary of the DNHS participants. Values indicate the counts or mean ± standard 
deviation. P-values are indicated for t-tests unless otherwise indicated by X2. 
Measures 
Childhood 
Maltreatment - 
Childhood 
Maltreatment+ 
p value, 
PTSD- PTSD+ 
p value, 
t-test or 
Χ2 
t-test or 
Χ2 
Age 55.82±14.26 50.15±10.45 0.039 55.68±14.60 52.94±12.43 0.33 
Sex   Χ
2 0.037   Χ
2 0.410 
Male  35 7  22 20  
Female 32 19  22 29  
Race   Χ
2 0.170   Χ
2 0.154 
European American 14 3  5 12  
African American 53 22  39 36  
Other 0 1  0 1  
Childhood Maltreatment Types  Χ
2 <0.001   Χ
2 <0.001 
0 Maltreatment Types 67 0  40 27  
2+ Maltreatment Types 0 26   4 22   
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TABLE 4.3. Enrichment results for the WGCNA module significantly associated with childhood 
maltreatment, grey60.  
Grey60 Module     
Annotation Cluster 1     
Enrichment Score: 12.61     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Cell cycle 23 9.31E-23 17.339 9.22E-21 
Cell division 17 1.22E-17 21.470 1.21E-15 
Mitosis 14 2.14E-15 26.184 2.09E-13 
GO:0051301~cell division 13 2.56E-11 14.850 7.98E-09 
GO:0007067~mitotic nuclear division 11 3.09E-10 17.733 9.64E-08 
GO:0005829~cytosol 15 1.08E-02 1.963 6.74E-01 
     
Annotation Cluster 2     
Enrichment Score: 3.46     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0006260~DNA replication 7 1.93E-06 18.056 6.03E-04 
DNA replication 5 3.63E-05 26.065 3.59E-03 
hsa03030:DNA replication 3 5.71E-03 25.036 2.00E-01 
GO:0000784~nuclear chromosome, telomeric 
region 
3 3.45E-02 10.013 9.73E-01 
     
Annotation Cluster 3     
Enrichment Score: 2.90     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
hsa04114:Oocyte meiosis 5 3.44E-04 13.781 1.33E-02 
GO:0031145~anaphase-promoting complex-
dependent catabolic process 
4 9.39E-04 20.244 2.54E-01 
GO:0042787~protein ubiquitination involved 
in ubiquitin-dependent protein catabolic 
process 
4 6.14E-03 10.453 8.53E-01 
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TABLE 4.4. Enrichment results for the WGCNA modules significantly associated with lifetime 
PTSD. 
 Grey Module     
G
re
y
 M
o
d
u
le
 (
-0
.4
6
, 
p
=
5
x
1
0
-6
) 
Annotation Cluster 1     
Enrichment Score: 2.00     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0006355~regulation of 
transcription, DNA-templated 235 8.52E-04 1.212 9.88E-01 
Transcription 344 1.48E-03 1.159 5.69E-01 
Transcription regulation 333 2.39E-03 1.153 7.44E-01 
GO:0006351~transcription, DNA-
templated 293 2.65E-03 1.162 1.00E+00 
Nucleus 688 3.56E-02 1.060 1.00E+00 
DNA-binding 277 6.17E-02 1.091 1.00E+00 
GO:0003700~transcription factor 
activity, sequence-specific DNA 
binding 140 6.63E-02 1.135 1.00E+00 
GO:0003677~DNA binding 234 8.49E-02 1.089 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 1.71     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
IPR004092:Mbt repeat 6 7.73E-03 4.306 1.00E+00 
repeat:MBT 2 5 1.90E-02 4.392 1.00E+00 
repeat:MBT 1 5 1.90E-02 4.392 1.00E+00 
SM00561:MBT 5 2.07E-02 4.281 1.00E+00 
repeat:MBT 3 4 4.77E-02 4.517 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.67     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
IPR000859:CUB domain 16 2.76E-03 2.296 1.00E+00 
SM00042:CUB 14 6.66E-03 2.248 9.66E-01 
domain:CUB 1 11 1.16E-02 2.415 1.00E+00 
domain:CUB 2 11 1.16E-02 2.415 1.00E+00 
domain:Sushi 1 9 2.02E-01 1.581 1.00E+00 
domain:Sushi 2 9 2.02E-01 1.581 1.00E+00 
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TABLE 4.4. (Continued) 
 Blue Module     
B
lu
e
 M
o
d
u
le
 (
-0
.2
8
, 
p
=
0
.0
0
7
) 
Annotation Cluster 1     
Enrichment Score: 4.34     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0004842~ubiquitin-protein 
transferase activity 65 4.54E-07 1.909 7.11E-04 
Ubl conjugation pathway 102 1.46E-06 1.613 7.80E-04 
GO:0016874~ligase activity 46 8.70E-04 1.646 7.45E-01 
GO:0016567~protein ubiquitination 53 7.59E-03 1.429 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 4.23     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Immunity 78 6.81E-06 1.677 3.63E-03 
Innate immunity 47 1.70E-05 1.936 9.03E-03 
GO:0045087~innate immune 
response 65 1.73E-03 1.463 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 3.38     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Cell cycle 104 4.76E-08 1.720 2.54E-05 
Cell division 60 1.11E-04 1.663 5.75E-02 
GO:0051301~cell division 55 1.73E-03 1.521 1.00E+00 
Mitosis 36 1.85E-02 1.477 1.00E+00 
GO:0007067~mitotic nuclear division 34 7.73E-02 1.327 1.00E+00 
 
     
 Red Module     
R
e
d
 M
o
d
u
le
 (
-0
.2
7
, 
p
=
0
.0
0
9
) 
Annotation Cluster 1     
Enrichment Score: 1.92     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Helicase 12 3.18E-03 2.874 6.77E-01 
GO:0004004~ATP-dependent RNA 
helicase activity 
8 4.81E-03 3.812 9.72E-01 
domain:Helicase C-terminal 10 5.00E-03 3.101 1.00E+00 
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TABLE 4.4. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
IPR011545:DNA/RNA helicase, 
DEAD/DEAH box type, N-terminal 
8 5.17E-03 3.768 9.96E-01 
IPR001650:Helicase, C-terminal 10 6.05E-03 3.010 9.98E-01 
SM00490:HELICc 10 6.31E-03 2.974 7.89E-01 
IPR014001:Helicase, superfamily 1/2, 
ATP-binding domain 
10 6.80E-03 2.955 9.99E-01 
domain:Helicase ATP-binding 10 7.10E-03 2.938 1.00E+00 
SM00487:DEXDc 10 7.11E-03 2.920 8.27E-01 
IPR014014:RNA helicase, DEAD-box 
type, Q motif 
5 2.61E-02 4.392 1.00E+00 
short sequence motif:Q motif 5 3.06E-02 4.187 1.00E+00 
GO:0010501~RNA secondary 
structure unwinding 
5 5.37E-02 3.495 1.00E+00 
GO:0004386~helicase activity 7 5.64E-02 2.551 1.00E+00 
short sequence motif:DEAD box 4 9.12E-02 3.722 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 1.64     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Zinc-finger 75 1.23E-03 1.442 3.55E-01 
Zinc 88 1.11E-02 1.283 9.81E-01 
Metal-binding 129 1.15E-02 1.214 9.84E-01 
GO:0046872~metal ion binding 76 1.49E-01 1.138 1.00E+00 
IPR007087:Zinc finger, C2H2 29 2.56E-01 1.180 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.64     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0042101~T cell receptor complex 6 1.80E-04 10.639 7.97E-02 
h_tcraPathway:Lck and Fyn tyrosine 
kinases in initiation of TCR Activation 
5 9.24E-04 10.118 1.35E-01 
h_tcrPathway:T Cell Receptor 
Signaling Pathway 
7 1.14E-02 3.541 8.33E-01 
GO:0031295~T cell costimulation 8 1.32E-02 3.154 1.00E+00 
h_il17Pathway:IL 17 Signaling 
Pathway 
4 2.59E-02 5.936 9.84E-01 
h_tcapoptosisPathway:HIV Induced T 
Cell Apoptosis 
3 6.92E-02 6.678 1.00E+00 
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TABLE 4.4. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
h_cskPathway:Activation of Csk by 
cAMP-dependent Protein Kinase 
Inhibits Signaling through the T Cell 
Receptor 
4 7.02E-02 4.047 1.00E+00 
h_thelperPathway:T Helper Cell 
Surface Molecules 
3 9.59E-02 5.565 1.00E+00 
h_no2il12Pathway:NO2-dependent IL 
12 Pathway in NK cells 
3 1.72E-01 3.928 1.00E+00 
GO:0004888~transmembrane 
signaling receptor activity 
6 8.24E-01 0.868 1.00E+00 
 
     
 Tan Module     
T
a
n
 M
o
d
u
le
 (
0
.7
3
, 
p
=
9
x
1
0
-1
7
) 
Annotation Cluster 1     
Enrichment Score: 2.40     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
mRNA processing 10 1.94E-05 6.595 3.16E-03 
mRNA splicing 7 1.17E-03 5.895 1.74E-01 
Spliceosome 5 2.64E-03 8.620 3.50E-01 
GO:0000398~mRNA splicing, via 
spliceosome 
6 6.22E-03 5.099 9.66E-01 
GO:0008380~RNA splicing 5 1.13E-02 5.683 9.98E-01 
GO:0005681~spliceosomal complex 4 1.16E-02 8.429 8.91E-01 
GO:0006397~mRNA processing 5 1.45E-02 5.270 1.00E+00 
GO:0071013~catalytic step 2 
spliceosome 
3 7.74E-02 6.459 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 2.25     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
mRNA processing 10 1.94E-05 6.595 3.16E-03 
IPR000504:RNA recognition motif 
domain 
7 7.64E-04 6.387 1.50E-01 
SM00360:RRM 7 1.10E-03 5.826 6.40E-02 
mRNA splicing 7 1.17E-03 5.895 1.74E-01 
IPR012677:Nucleotide-binding, alpha-
beta plait 
7 1.70E-03 5.468 3.04E-01 
domain:RRM 1 5 2.73E-03 8.537 6.33E-01 
domain:RRM 2 5 2.73E-03 8.537 6.33E-01 
domain:RRM 3 4 2.86E-03 13.996 6.49E-01 
GO:0000398~mRNA splicing, via 
spliceosome 
6 6.22E-03 5.099 9.66E-01 
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TABLE 4.4. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
IPR003954:RNA recognition motif 
domain, eukaryote 
3 6.86E-03 23.794 7.69E-01 
SM00361:RRM_1 3 9.08E-03 20.358 4.22E-01 
GO:0008543~fibroblast growth factor 
receptor signaling pathway 
4 9.14E-03 9.204 9.93E-01 
RNA-binding 9 1.04E-02 2.963 8.19E-01 
GO:0000166~nucleotide binding 7 1.13E-02 3.691 8.77E-01 
GO:0010494~cytoplasmic stress 
granule 
3 1.39E-02 16.507 9.29E-01 
GO:0003676~nucleic acid binding 12 1.67E-02 2.235 9.55E-01 
GO:0003723~RNA binding 8 2.82E-02 2.684 9.95E-01 
Ribonucleoprotein 5 4.53E-02 3.698 9.99E-01 
GO:0006396~RNA processing 3 9.19E-02 5.835 1.00E+00 
GO:0030529~intracellular 
ribonucleoprotein complex 
3 1.48E-01 4.370 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.31     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Ubl conjugation pathway 9 1.18E-02 2.898 8.56E-01 
GO:0000209~protein 
polyubiquitination 
5 1.59E-02 5.127 1.00E+00 
GO:0016567~protein ubiquitination 5 1.20E-01 2.628 1.00E+00 
GO:0004842~ubiquitin-protein 
transferase activity 
4 2.62E-01 2.231 1.00E+00 
 
     
 Green Module     
G
re
e
n
 M
o
d
u
le
 (
0
.5
2
, 
p
=
1
x
1
0
-7
) 
Annotation Cluster 1     
Enrichment Score: 7.65     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Transit peptide 49 1.13E-10 2.872 3.78E-08 
transit peptide:Mitochondrion 46 2.56E-10 2.923 4.07E-07 
Mitochondrion 75 1.74E-09 2.106 5.81E-07 
GO:0005739~mitochondrion 85 2.94E-08 1.865 1.49E-05 
GO:0005743~mitochondrial inner 
membrane 
38 5.06E-07 2.517 2.57E-04 
GO:0005759~mitochondrial matrix 26 1.58E-04 2.322 7.69E-02 
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TABLE 4.4. (Continued) 
Annotation Cluster 2     
Enrichment Score: 3.79     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Ribosomal protein 21 1.92E-06 3.567 6.42E-04 
GO:0070125~mitochondrial 
translational elongation 
14 1.03E-05 4.564 2.18E-02 
GO:0070126~mitochondrial 
translational termination 
13 5.74E-05 4.189 1.16E-01 
GO:0003735~structural constituent of 
ribosome 
19 9.96E-04 2.404 5.21E-01 
GO:0005762~mitochondrial large 
ribosomal subunit 
8 1.15E-03 4.868 4.42E-01 
GO:0005761~mitochondrial ribosome 5 1.44E-02 5.215 9.99E-01 
     
Annotation Cluster 3     
Enrichment Score: 3.75     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Ribonucleoprotein 32 6.55E-09 3.397 2.19E-06 
Ribosomal protein 21 1.92E-06 3.567 6.42E-04 
GO:0006364~rRNA processing 22 3.21E-05 2.849 6.64E-02 
GO:0006413~translational initiation 17 3.44E-05 3.438 7.10E-02 
hsa03010:Ribosome 17 5.05E-05 3.284 1.16E-02 
GO:0006614~SRP-dependent 
cotranslational protein targeting to 
membrane 
13 1.38E-04 3.832 2.56E-01 
GO:0003735~structural constituent of 
ribosome 
19 9.96E-04 2.404 5.21E-01 
GO:0005840~ribosome 15 1.72E-03 2.639 5.83E-01 
GO:0022625~cytosolic large 
ribosomal subunit 
9 2.17E-03 3.865 6.68E-01 
GO:0019083~viral transcription 12 2.37E-03 2.969 9.94E-01 
GO:0000184~nuclear-transcribed 
mRNA catabolic process, nonsense-
mediated decay 
12 3.80E-03 2.794 1.00E+00 
GO:0006412~translation 19 4.80E-03 2.081 1.00E+00 
GO:0002181~cytoplasmic translation 5 1.16E-02 5.542 1.00E+00 
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TABLE 4.4. (Continued) 
 Yellow Module     
Y
e
llo
w
 M
o
d
u
le
 (
0
.2
9
, 
p
=
0
.0
0
5
) 
Annotation Cluster 1     
Enrichment Score: 5.65     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0006413~translational initiation 31 2.05E-09 3.535 7.00E-06 
GO:0006412~translation 41 9.65E-08 2.531 3.28E-04 
GO:0003735~structural constituent of 
ribosome 
37 2.28E-07 2.600 2.72E-04 
GO:0006614~SRP-dependent 
cotranslational protein targeting to 
membrane 
22 3.71E-07 3.656 1.26E-03 
GO:0019083~viral transcription 24 5.23E-07 3.347 1.78E-03 
Ribosomal protein 30 1.23E-06 2.761 5.70E-04 
GO:0000184~nuclear-transcribed 
mRNA catabolic process, nonsense-
mediated decay 
24 1.60E-06 3.150 5.42E-03 
Ribonucleoprotein 40 1.93E-06 2.300 8.93E-04 
GO:0022625~cytosolic large 
ribosomal subunit 
17 3.42E-06 3.983 2.27E-03 
hsa03010:Ribosome 26 3.82E-06 2.805 1.04E-03 
GO:0005840~ribosome 26 4.00E-05 2.495 2.63E-02 
GO:0006364~rRNA processing 29 2.45E-04 2.117 5.65E-01 
GO:0022627~cytosolic small 
ribosomal subunit 
9 9.37E-03 2.987 9.98E-01 
     
Annotation Cluster 2     
Enrichment Score: 3.85     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Nucleus 399 1.36E-09 1.295 6.29E-07 
Transcription 185 6.43E-05 1.313 2.93E-02 
Transcription regulation 174 6.16E-04 1.270 2.48E-01 
GO:0006351~transcription, DNA-
templated 
159 9.76E-04 1.270 9.64E-01 
GO:0006355~regulation of 
transcription, DNA-templated 
121 6.27E-03 1.257 1.00E+00 
DNA-binding 142 2.42E-02 1.179 1.00E+00 
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TABLE 4.4. (Continued) 
Annotation Cluster 3     
Enrichment Score: 3.80     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Glycolysis 11 6.67E-06 6.040 3.07E-03 
GO:0006094~gluconeogenesis 13 1.37E-05 4.615 4.57E-02 
GO:0061621~canonical glycolysis 10 2.01E-05 6.008 6.60E-02 
hsa01200:Carbon metabolism 21 6.27E-05 2.726 1.70E-02 
hsa01130:Biosynthesis of antibiotics 31 8.99E-05 2.145 2.42E-02 
hsa00010:Glycolysis / 
Gluconeogenesis 
15 1.29E-04 3.285 3.45E-02 
GO:0006096~glycolytic process 10 2.12E-04 4.594 5.13E-01 
h_glycolysisPathway:Glycolysis 
Pathway 
6 4.58E-04 7.738 9.43E-02 
hsa01230:Biosynthesis of amino 
acids 
13 3.89E-03 2.577 6.55E-01 
hsa00051:Fructose and mannose 
metabolism 
7 1.91E-02 3.209 9.95E-01 
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TABLE 4.5. Enrichment results of the replication analysis for the WGCNA modules significantly 
associated with childhood maltreatment in the replication dataset.  
 Grey Module     
G
re
y
 M
o
d
u
le
 (
-0
.2
7
, 
p
=
0
.0
1
) 
Annotation Cluster 1     
Enrichment Score: 5.63     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Glycoprotein 613 6.38E-10 1.234 3.46E-07 
glycosylation site:N-linked (GlcNAc...) 584 7.33E-10 1.242 3.82E-06 
signal peptide 460 1.55E-07 1.237 8.07E-04 
Secreted 275 6.53E-06 1.282 3.53E-03 
disulfide bond 389 3.67E-05 1.200 1.74E-01 
Disulfide bond 441 7.23E-05 1.176 3.84E-02 
Signal 520 2.02E-04 1.145 1.04E-01 
GO:0005576~extracellular region 215 3.65E-03 1.190 9.34E-01 
     
Annotation Cluster 2     
Enrichment Score: 4.03     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Glycoprotein 613 6.38E-10 1.234 3.46E-07 
glycosylation site:N-linked (GlcNAc...) 584 7.33E-10 1.242 3.82E-06 
GO:0005886~plasma membrane 540 1.20E-05 1.168 8.90E-03 
topological domain:Extracellular 364 3.40E-04 1.176 8.30E-01 
Membrane 886 1.07E-03 1.083 4.39E-01 
topological domain:Cytoplasmic 437 1.29E-03 1.138 9.99E-01 
transmembrane region 621 1.46E-03 1.106 1.00E+00 
Transmembrane helix 673 2.31E-03 1.094 7.14E-01 
Cell membrane 393 3.03E-03 1.134 8.07E-01 
Transmembrane 673 3.23E-03 1.091 8.27E-01 
GO:0016021~integral component of 
membrane 612 5.13E-02 1.056 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.72     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
IPR009030:Insulin-like growth factor 
binding protein, N-terminal 32 8.85E-05 2.095 2.05E-01 
domain:EGF-like 4; calcium-binding 13 1.79E-04 3.442 6.07E-01 
EGF-like domain 43 1.16E-03 1.655 4.67E-01 
domain:EGF-like 1 26 1.38E-03 1.950 9.99E-01 
domain:EGF-like 5; calcium-binding 12 2.15E-03 2.842 1.00E+00 
IPR000742:Epidermal growth factor-
like domain 41 2.39E-03 1.616 9.98E-01 
domain:EGF-like 7; calcium-binding 10 2.44E-03 3.215 1.00E+00 
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TABLE 4.5. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
domain:EGF-like 8; calcium-binding 9 3.27E-03 3.375 1.00E+00 
SM00181:EGF 36 3.65E-03 1.629 8.33E-01 
domain:EGF-like 6; calcium-binding 9 5.67E-03 3.116 1.00E+00 
IPR013032:EGF-like, conserved site 34 1.04E-02 1.555 1.00E+00 
domain:EGF-like 11; calcium-binding 6 1.42E-02 3.858 1.00E+00 
domain:EGF-like 2 18 1.76E-02 1.820 1.00E+00 
domain:EGF-like 3 16 1.88E-02 1.895 1.00E+00 
domain:EGF-like 12; calcium-binding 6 1.94E-02 3.600 1.00E+00 
IPR000152:EGF-type 
aspartate/asparagine hydroxylation 
site 20 1.95E-02 1.734 1.00E+00 
IPR001881:EGF-like calcium-binding 23 2.04E-02 1.648 1.00E+00 
domain:EGF-like 3; calcium-binding 10 2.08E-02 2.369 1.00E+00 
domain:EGF-like 9; calcium-binding 6 2.57E-02 3.375 1.00E+00 
SM00179:EGF_CA 23 3.91E-02 1.541 1.00E+00 
domain:EGF-like 10; calcium-binding 5 4.77E-02 3.462 1.00E+00 
IPR018097:EGF-like calcium-binding, 
conserved site 18 5.22E-02 1.606 1.00E+00 
domain:EGF-like 2; calcium-binding 12 5.22E-02 1.862 1.00E+00 
domain:EGF-like 13; calcium-binding 4 1.14E-01 3.273 1.00E+00 
domain:EGF-like 15; calcium-binding 4 1.41E-01 3.000 1.00E+00 
domain:TB 1 3 1.78E-01 3.858 1.00E+00 
domain:TB 4 3 1.78E-01 3.858 1.00E+00 
domain:TB 2 3 1.78E-01 3.858 1.00E+00 
domain:TB 3 3 1.78E-01 3.858 1.00E+00 
IPR026823:Complement Clr-like EGF 
domain 6 1.88E-01 1.950 1.00E+00 
IPR017878:TB domain 3 2.59E-01 3.034 1.00E+00 
domain:EGF-like 16; calcium-binding 3 3.50E-01 2.455 1.00E+00 
domain:EGF-like 14; calcium-binding 3 3.91E-01 2.250 1.00E+00 
      
 Grey60 Module     
G
re
y
 6
0
 M
o
d
u
le
 (
0
.2
1
, 
p
=
0
.0
4
) 
Annotation Cluster 1     
Enrichment Score: 2.60     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0003729~mRNA binding 5 5.11E-05 23.284 4.28E-03 
RNA-binding 8 5.93E-05 7.503 5.55E-03 
Methylation 9 1.13E-04 5.607 1.05E-02 
SM00360:RRM 5 2.18E-04 14.825 3.70E-03 
GO:0003723~RNA binding 7 2.31E-04 7.449 1.92E-02 
IPR000504:RNA recognition motif 
domain 5 4.58E-04 13.245 4.12E-02 
GO:0000398~mRNA splicing, via 
spliceosome 5 5.45E-04 12.607 1.12E-01 
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TABLE 4.5. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0071013~catalytic step 2 
spliceosome 4 5.55E-04 24.011 5.40E-02 
IPR012677:Nucleotide-binding, alpha-
beta plait 5 8.20E-04 11.339 7.27E-02 
domain:RRM 4 1.40E-03 17.484 1.50E-01 
GO:0044822~poly(A) RNA binding 8 2.00E-03 4.125 1.55E-01 
GO:0000166~nucleotide binding 5 2.46E-03 8.364 1.87E-01 
GO:0008380~RNA splicing 4 2.87E-03 13.488 4.66E-01 
mRNA splicing 4 7.54E-03 9.595 5.09E-01 
mRNA processing 4 1.46E-02 7.514 7.49E-01 
hsa03040:Spliceosome 3 2.50E-02 11.133 5.07E-01 
Ribonucleoprotein 3 7.71E-02 6.321 9.99E-01 
GO:0005654~nucleoplasm 9 1.04E-01 1.785 1.00E+00 
GO:0003676~nucleic acid binding 4 2.22E-01 2.364 1.00E+00 
Transport 4 6.06E-01 1.261 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 1.80     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0005737~cytoplasm 19 9.78E-04 2.009 9.32E-02 
Nucleus 15 1.86E-02 1.784 8.29E-01 
GO:0005634~nucleus 13 2.17E-01 1.326 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.05     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Nucleotide-binding 7 5.46E-02 2.442 9.95E-01 
nucleotide phosphate-binding 
region:GTP 3 9.19E-02 5.711 1.00E+00 
GTP-binding 3 9.91E-02 5.455 1.00E+00 
GO:0005525~GTP binding 3 1.33E-01 4.548 1.00E+00 
      
 Red Module     
R
e
d
 M
o
d
u
le
 (
0
.2
1
, 
p
=
0
.0
4
) 
Annotation Cluster 1     
Enrichment Score: 1.83     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
Senior-Loken syndrome 3 1.03E-03 60.003 2.02E-01 
Nephronophthisis 3 8.73E-03 21.001 8.55E-01 
Leber congenital amaurosis 3 1.25E-02 17.501 9.37E-01 
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TABLE 4.5. (Continued)     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0032391~photoreceptor 
connecting cilium 3 2.98E-02 11.027 9.96E-01 
Ciliopathy 3 2.25E-01 3.333 1.00E+00 
     
Annotation Cluster 2     
Enrichment Score: 1.82     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
GO:0006397~mRNA processing 7 1.59E-03 5.565 5.76E-01 
GO:0005681~spliceosomal complex 5 4.98E-03 7.234 5.93E-01 
GO:0008380~RNA splicing 6 6.12E-03 5.144 9.64E-01 
mRNA processing 8 9.62E-03 3.374 8.81E-01 
mRNA splicing 5 1.14E-01 2.692 1.00E+00 
Spliceosome 3 2.28E-01 3.307 1.00E+00 
     
Annotation Cluster 3     
Enrichment Score: 1.80     
Term 
Number of 
genes in 
term 
p-value 
Fold 
Enrichment 
Bonferroni 
repeat:TPR 4 6 7.74E-04 8.302 3.48E-01 
repeat:TPR 3 6 4.57E-03 5.535 9.21E-01 
repeat:TPR 2 6 6.64E-03 5.062 9.75E-01 
repeat:TPR 1 6 6.64E-03 5.062 9.75E-01 
repeat:TPR 6 4 1.40E-02 7.907 1.00E+00 
repeat:TPR 5 4 1.86E-02 7.096 1.00E+00 
IPR011990:Tetratricopeptide-like 
helical 6 2.36E-02 3.675 1.00E+00 
TPR repeat 5 3.13E-02 4.192 9.99E-01 
IPR013026:Tetratricopeptide repeat-
containing domain 4 7.56E-02 4.046 1.00E+00 
IPR019734:Tetratricopeptide repeat 4 8.38E-02 3.870 1.00E+00 
SM00028:TPR 4 9.13E-02 3.700 1.00E+00 
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FIGURE 4.1: Module-trait relationship. Heatmap shows the correlation and respective p-value 
(in parentheses) between each module eigengene (indicated by color) and exposure of interest, 
(A) childhood maltreatment and (B) PTSD. Black boxes indicate significant module significantly 
correlated with exposure. Correlations are considered significant if p<0.05.  
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FIGURE 4.2. Module-trait relationship of the replication analysis. Heatmap shows the correlation 
and respective p-value (in parentheses) between each module eigengene (indicated by color) 
and exposure of interest, (A) childhood maltreatment and (B) PTSD. Black boxes indicate the 
module significantly correlated with the exposure. Correlations are considered significant if 
p≤0.05. 
 117 
 
FIGURE 4.3: Visual representation of the top 150 connections within the module (grey60) significantly associated with childhood 
maltreatment. Top connections were determined based on correlation strength. Nodes represent genes and edges represent 
correlation. The top 5 most connected genes are shown in larger size and blue shading. 
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FIGURE 4.4 
 
  
 119 
FIGURE 4.4 (Continued) 
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FIGURE 4.4 (Continued) 
 
FIGURE 4.4: Visual representation of the top 150 connections within the modules significantly associated with Lifetime PTSD (A. 
Grey, B. Blue, C. Red, D. Tan, E. Green, F. Yellow). Top connections were determined based on correlation strength. Nodes 
represent genes and edges represent correlation. The top 5 most connected genes are shown in larger size and blue shading. (A-C) 
Modules that are negatively correlated with PTSD, (D-F) modules that are positively correlated with PTSD. 
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FIGURE 4.5 
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FIGURE 4.5 (Continued)  
 
 
FIGURE 4.5: Visual representation of the top 150 connections within the modules significantly associated with childhood 
maltreatment in the replication dataset (A. Grey, B. Grey60, C. Red). Top connections were determined based on correlation 
strength. Nodes represent genes and edges represent correlation. The top 5 most connected genes are shown in larger size and 
blue shading. (A) Module that is negatively correlated with childhood maltreatment, (B-C) modules that are positively correlated with 
childhood maltreatment. 
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CHAPTER 5: EPIGENETIC PROFILES ASSOCIATED WITH MAJOR DEPRESSIVE 
DISORDER IN THE HUMAN BRAIN 
 
ABSTRACT 
Major depressive disorder (MDD) is a debilitating mental illness affecting over 30 million 
adults in the US. Known risk factors for MDD include genetic factors, environmental exposures, 
and psychologic (personal or familial) history of mental illness. Despite these identified risk 
factors, studies have been largely ineffective at understanding the underlying molecular 
mechanisms and pathways disrupted by MDD. We sought to examine the epigenetic impact of 
MDD within brain-derived DNA at the genome-scale level using two analytic approaches, a 
standard differential methylation approach and a systems biology approach, weighted gene co-
methylation network analysis (WGCNA). DNA methylation data from Illumina’s 
HumanMethylation450 BeadChip array corresponding to GSE41826 was identified from the 
public repository GEO datasets. Data was downloaded, preprocessed, and analyzed in R version 
3.2.5 using packages available through Bioconductor. The two analytic approaches, differential 
methylation and WGCNA, were separately applied to the data following the preprocessing steps. 
Differential methylation analyses controlled for age, sex, suicide status, and post-mortem interval 
(PMI) within the regression model. WGCNA was used to detect gene co-methylation modules 
associated with MDD. Differential methylation analyses revealed 4,652 probes showing nominally 
significant (p<0.05) differential methylation, however, no probes remained significant following 
multiple test correction (all FDR>0.05). Gene enrichment analysis of nominally significant probes 
revealed such probes were significantly enriched in genes associated with transcription, DNA 
binding sequence domains, and synapse function. WGCNA revealed one module that was 
significantly correlated with MDD and enriched in terms associated with transcription, DNA 
binding, and mitochondria. Comparison of probes identified by the differential methylation and 
WGCNA methods revealed an overlap of 7 probes. Comparison of gene enrichment analyses 
 124 
revealed an overlap in genes associated with transcription. Overall, these results provide 
additional support for dysregulation of genes involved in synaptic and mitochondrial function 
among individuals with MDD. 
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5.1. INTRODUCTION  
Major depressive disorder (MDD) is a debilitating mental illness with an estimated lifetime 
prevalence of 16.6% in the USA (Kessler and Wang, 2008). MDD is typically characterized by 
depressed mood or a loss of interest or pleasure in daily activities which can negatively impact 
many aspects of life, making many normal day-to-day interactions challenging and resulting in 
impaired social, occupational, and/or educational functioning. Diagnosis of MDD according to the 
Diagnostic and Statistics Manual of Mental Disorders version V (DSM-V) requires the possession 
of at least 5 of 9 symptoms with persistence of symptoms occurring for two or more weeks. These 
symptoms include: depressed or irritable mood, decreased interest or pleasure, significant weight 
change (≥5%), change in sleep (hypersomnia or insomnia), change in activity level (psychomotor 
agitation or retardation), fatigue or loss of energy, feelings of worthlessness or guilt, diminished 
ability to concentrate, and lastly, suicidal thoughts or ideations; at least one of these symptoms 
has to be depressed mood or loss of interest or pleasure (Association, 2013). MDD is a 
heterogeneous disorder, meaning many individuals diagnosed with MDD present different 
symptoms which may vary greatly in symptom severity, making it a challenging disorder to study. 
Additionally, there is a high prevalence of co-morbid anxiety, substance abuse and personality 
disorders (Hirschfeld, 2001; Melartin et al., 2002) in those diagnosed with MDD. Despite these 
challenges, studies of MDD have identified risk factors for the disorder, including genetic variants, 
environmental exposures, and personal and familial psychologic history (Hammen et al., 2000; 
Sullivan et al., 2000). In particular, stressful life events are strongly implicated in depression onset 
based on data from twin and population based studies (Kendler et al., 2011; Kendler et al., 1999; 
Tennant, 2002; Wigman et al., 2011). 
Epigenetics is a powerful tool which can be used to elucidate the interplay between 
environmental exposures, including stressful life events, and genetic factors. Epigenetics can be 
broadly defined as biologic mechanisms which alter or regulate gene expression without 
modifying the underlying DNA sequence. DNA methylation is one type of epigenetic modification 
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that, in vertebrates, is typically characterized by the addition of a methyl group to the 5’ position 
of cytosine when it is coupled to guanine on the DNA backbone. DNA methylation is a chemical 
modification that does not alter the underlying DNA sequence (Whitelaw and Whitelaw, 2006), is 
tissue specific (Ghosh et al., 2010; Lokk et al., 2014), stable over time (Heijmans et al., 2008), 
and responsive to environmental exposures (Fraga et al., 2005). Initial work has shown that early 
life adversity and other environmental exposures can alter DNA methylation levels (Beach et al., 
2010; Klengel et al., 2013; McGowan et al., 2009; Tyrka et al., 2016; Tyrka et al., 2012) and 
increase susceptibility for mental illness (Afifi et al., 2008; Green et al., 2010; Hussey et al., 2006; 
Kendler et al., 2004; Kessler et al., 1997). Additionally, work focusing on mental illness has shown 
altered DNA methylation levels are associated with MDD (Na et al., 2014; Nantharat et al., 2015), 
bipolar disorder (Dempster et al., 2011; Sugawara et al., 2011), borderline personality disorder 
(Martin-Blanco et al., 2014; Prados et al., 2015), and schizophrenia (Dempster et al., 2011; 
Nishioka et al., 2013) among others. Taken together, these studies demonstrate the ability to 
detect differences in DNA methylation associated with environmental exposures and mental 
illness. Detection of these differences provide additional motivation to further examine the 
epigenetic impact of mental illness.  
Previous epigenome-scale MDD studies have largely focused on peripheral tissues such 
as blood (Byrne et al., 2013; Malki et al., 2016; Numata et al., 2015; Oh et al., 2015; Prados et 
al., 2015; Walker et al., 2016a; Walker et al., 2016b), with only a few studies examining 
epigenome-scale profiles in the brain (Murphy et al., 2017; Oh et al., 2015; Sabunciyan et al., 
2012). An initial study by Sabunciyan et al (Sabunciyan et al., 2012) examined the impact of MDD 
on post-mortem frontal cortex tissue samples compared to controls. They identified over four 
hundred nominally differentially methylated regions (p≤0.05), however these findings did not 
withstand correction for multiple tests (Sabunciyan et al., 2012) (FDR<0.1). A second study by 
Oh et al. (Oh et al., 2015) examined epigenetic differences associated with MDD in blood and 
post-mortem brain tissues from different individuals. Their initial locus-by-locus analysis in post-
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mortem brain revealed 22 nominally differentially methylated loci, however none of the detected 
loci survived multiple test correction. In addition to the differential methylation analysis, Oh et al., 
performed a network analysis to examine the epigenomic profiles of personality traits associated 
with MDD (anxiety, neuroticism, and extroversion), which revealed gene enrichments associated 
with post synaptic membrane, synapse, and postsynaptic density, lipid metabolic process, and 
glycolipid metabolic process (Oh et al., 2015). Lastly, Murphy et al. (Murphy et al., 2017), 
examined post-mortem cortical brain tissue from MDD suicide completers and non-psychiatric 
controls. No probes reached genome-scale significance in their initial differential methylation 
probe analysis. However, they detected 3 differentially methylated regions (PSORS1C3, TAPBP, 
and ATP5G2), which remained significant following Šidák correction. Their final analysis was a 
network-based approach which revealed genes enriched in mitochondrial function and nervous 
system development associated with MDD suicide completers (Murphy et al., 2017). 
Current genome-scale epigenetic studies have failed to identify specific probes associated 
with MDD as significant results typically have failed to replicate across studies (Byrne et al., 2013; 
Malki et al., 2016; Murphy et al., 2017; Numata et al., 2015; Oh et al., 2015; Sabunciyan et al., 
2012; Walker et al., 2016b). This lack of consensus is not unique to genome-scale epigenetic 
studies, as genome-wide association studies (GWAS) have also failed to identify SNPs 
associated with MDD that not only reach genome-wide significance but also replicate in other 
cohorts (Aberg et al., 2010; Power et al., 2017; Rietschel et al., 2010; Shi et al., 2011). 
Additionally, many MDD genome-scale DNA methylation studies have used peripheral tissues 
such as blood (Byrne et al., 2013; Malki et al., 2016; Numata et al., 2015; Oh et al., 2015; Prados 
et al., 2015; Walker et al., 2016a; Walker et al., 2016b), rather than the ideal tissue of interest, 
brain (Murphy et al., 2017; Oh et al., 2015; Sabunciyan et al., 2012); mainly since peripheral 
tissues are easier to obtain from living individuals with the disorder. Currently, the extent to which 
findings from peripheral tissues can be extended to central tissues (brain) is not well understood. 
Therefore, direct assessment of DNA methylation from brain-derived tissues provide a point of 
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reference for how well results from peripheral studies reflect what is going on in the brain. Given 
this gap in the field, we sought to examine the genome-scale epigenetic impact of MDD on brain-
derived DNA using two analytic approaches, a standard differential methylation approach and a 
systems biology approach weighted gene co-methylation network analysis (WGCNA).  
The goal of this work is to explore the biologic pathways that are affected by MDD in neural 
tissue making use of publically available high throughput post-mortem brain methylation data 
subset for transcription start site (TSS) associated probes. The TSS is typically located at the 5’ 
end of the gene, within an important genomic region, just downstream of transcription factor 
binding sites (TFBS), where transcriptional machinery binds specific DNA sequences to initiate 
transcription and produce a variety of RNAs (Jones, 2012). Additionally, adjacent to or just 
upstream of the TSS is the promoter region, which typically overlap with CpG islands—stretches 
of DNA that are dense (greater than 50%) in CpG sites—providing more potential sites for DNA 
methylation (Saxonov et al., 2006). The presence of DNA methylation within this genomic region 
may inhibit the ability of the transcription machinery to bind the specific DNA sequence, resulting 
in decreased transcription (Deaton and Bird, 2011). Indeed, increased DNA methylation within 
the promoter region, specifically at TFBS, has been previously associated with reduced levels of 
gene expression or transcription (Brenet et al., 2011; Eckhardt et al., 2006). Therefore, selecting 
TSS-associated probes allows for the most biologically meaningful interpretation of the data. More 
specifically, these regions are more likely to alter downstream gene expression and impact protein 
levels or observed phenotype. We hypothesized (1) both approaches will identify distinct 
epigenetic profiles associated with MDD and (2) some degree of overlap will exist between the 
pathway-level findings of the two methods (differential methylation and WGCNA).   
 
5.2. METHODS 
5.2.1. GENE EXPRESSION OMNIBUS DATASETS 
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Data for this study was retrieved from the public repository Gene Expression Omnibus (GEO) 
(Barrett et al., 2013; Edgar et al., 2002) using the following criteria: Homo sapiens, brain, DNA 
methylation, and major depression. GSE41826, produced by Guintivano and Kaminsky 
(Guintivano et al., 2013), characterized the specific DNA methylation patterns associated with 
glial and neuronal cell types in 58 post-mortem brain prefrontal cortex tissue samples by first using 
fluorescence activated cell sorting (FACS) followed by Illumina’s Human Methylation 450 
microarray. From this dataset, the data pertaining to neuronal cell type was selected for inclusion 
in our analysis due to their direct involvement in electrical and chemical signal transmission and 
previous research suggesting a link between neuronal dysregulation and MDD (Lopizzo et al., 
2015; Rajkowska et al., 1999; Villanueva, 2013). Demographics of the 58 participants (30 female, 
28 male) are summarized in Table 5.1. Participants with a history of MDD did not differ significantly 
(p>0.05) from those without a history of MDD diagnosis in terms of age, sex, race, or Post-Mortem 
Interval (PMI). There was a significant difference (p<0.05) between participants with a history of 
MDD compared to controls in the number of suicide victims (Table 5.1).   
 
5.2.2. PREPROCESSING OF DNA METHYLATION MICROARRAY 
Raw data was downloaded from GEO using the R package GEOquery (Davis and Meltzer, 2007), 
preprocessed using an established pipeline from the psychiatrics genomics consortium (PGC) 
epigenome-wide association study (EWAS) work group (Ratanatharathorn et al., (In Press)), and 
analyzed in R (www.R-project.org) version 3.2.5 (Team, 2016) using a variety of packages 
available in Bioconductor (http://bioconductor.org) (Huber et al., 2015). Briefly, probes with low 
signal intensity, CpG sites with more than 10% missing data for a participant, and detection p-
value above 0.001 were removed using CpGassoc (Barfield et al., 2012). Next, potentially cross-
hybridizing probes were removed from the dataset, this included both CpG and non-CpG targeting 
probes (Chen et al., 2013). Data was then normalized using Beta MIxture Quantile normalization, 
BMIQ (Teschendorff et al., 2013) available in the R package wateRmelon (Pidsley et al., 2013). 
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A total of 455,190 probes passed the preprocessing and quality control (QC) pipeline. The QC’d 
data was sequentially adjusted for batch effects (chip, then position) including the covariate MDD 
using ComBat (Johnson et al., 2007) as implemented in SVA (Leek and Storey, 2007).  
Data was examined using principal components analysis (PCA) to detect any significant 
associations among known technical artifacts (chip or batch) and potential study variables (age, 
sex, race, suicide status, and PMI) with calculated principal components (PCs). PCs were 
examined at every stage of data QC and pre-processing: Raw data prior to QC, post QC and 
BMIQ normalization, post ComBat for chip, and lastly post ComBat for position. Visualization of 
PCs confirmed the effects of chip and batch were removed following ComBat correction.  
Data was then subset to select probes annotated to the transcription start site (TSS), 
specifically probes with an annotation of TSS200 or TSS1500. In total, 70,515 probes met the 
criteria and were included in the analyses. TSS-associated probes were selected as they are 
more likely be informative in regards to the potential impact of DNA methylation on downstream 
gene transcription and function (Jones, 2012).  
 
5.2.3. DIFFERENTIAL METHYLATION ANALYSIS 
Differential methylation analyses were performed in R version 3.2.5 using the preprocessed 
ComBat corrected data. Beta (β) values were converted to M-values using the function “beta2m” 
within the R package lumi (Du et al., 2008). M-values are the preferred input for differential 
methylation analyses as the distribution of values is approximately homoscedastic and does not 
contain the same biases as β values (Du et al., 2010). M-values are the logit transformation of 
the ratio of the methylated to unmethylated probe intensities and unlike β values are not bound 
between 0 and 1. M-values near 0 indicate the probe (CpG site) is half methylated, half 
unmethylated. Positive M-values indicate the probe is more methylated than unmethylated, while 
negative M-values indicate the probe is more unmethylated than methylated (Du et al., 2010). 
Generalized linear regressions were used to examine differences in DNA methylation levels (M-
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values) of participants with and without MDD at each TSS-associated probe, controlling for 
potential confounders including age, sex, suicide status and PMI. To address the concern of 
multiple hypothesis testing and potential Type I errors, the false discovery rate (FDR) was 
calculated using the Benjamini-Hochberg approach (Benjamini and Hochberg, 1995). Results 
were accepted as significant when FDR≤0.05.   
 
5.2.4. WEIGHTED GENE CO-METHYLATION NETWORK ANALYSIS  
Weighted gene co-methylation networks were generated for MDD using the R package WGCNA 
(Langfelder and Horvath, 2008; Zhang and Horvath, 2005). Similar to the differential methylation 
analysis, M-values for the 70,515 TSS-associated probes were used as input for WGCNA.  Data 
was subjected to unsupervised hierarchical clustering to detect gene clusters (modules) from 
correlation patterns observed in the data of each probe. In this analysis, WGCNA creates a 
correlation matrix by performing a Pearson correlation for each probe with every other probe to 
account for all possible probe pairs. This correlation matrix was transformed into an adjacency 
matrix by use of a power function (β=4), creating the weighted network. Automatic network 
construction was then used with the function “blockwiseModules” with minimum module size set 
to 30 probes, the recommended minimum. Modules were ultimately created using the default 
setting for mergeCutHeight 0.25, with each cut branch or newly created module indicated by a 
unique color identifier. Several iterations of the network construction were performed using 
alternative values for mergeCutHeight to ensure the optimal parameters were used. Each newly 
created module was then correlated with the clinical trait of interest, specifically the presence or 
absence of MDD, using the module eigengene. Module eigengenes can be defined as the first 
principal component of an individual module, and is considered to representative of the module 
DNA methylation profile (Langfelder and Horvath, 2008). Therefore, a positive correlation 
between module eigengene and MDD is indicative of increased DNA methylation of probes within 
the selected module, while a negative correlation is indicative of decreased DNA methylation of 
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probed associated with MDD. Modules significantly (p≤0.05) correlated with the exposure of 
interest, MDD, were selected for further examination of module members (probes) and gene 
ontology using DAVID (Huang et al., 2007a; Huang et al., 2007b).  
As an additional test to ensure there was no effect of potential confounders on modules 
significantly associated with MDD, we performed a regression analysis using module eigengene 
as the outcome with MDD, age, sex, suicide status, and PMI as the predictors, and verified the 
covariates did not show a significant relationship with the module eigengene that was significantly 
correlated with MDD.  
 
5.2.5. GENE ENRICHMENT ANALYSIS 
Significant findings from each analysis were further examined for enriched genes using DAVID 
(https://david.ncifcrf.gov/) (Huang et al., 2007a; Huang et al., 2007b). Briefly, individual probeIDs 
(CpG site identifiers) were converted to gene symbols and used as input for the enrichment 
analysis. Within the differential methylation analysis, the enrichment analysis was performed for 
the top 1000 probes with p≤0.05, as no probes reached FDR significance. Within the WGCNA 
analysis, gene enrichment analysis was performed using the list of probes from the module 
significantly associated with MDD.  
 
5.3. RESULTS  
5.3.1. DIFFERENTIAL METHYLATION ANALYSIS 
A total of 4,652 TSS-associated probes were nominally differentially methylated (p-value 
≤0.05) prior to FDR correction. However, no individual probe survived multiple test correction, 
FDR≤0.05 (Figure 5.1). One probe, cg00600684, which is annotated to intron 1 of WD repeat 
domain 11, WDR11, was nominally significant following multiple test correction, FDR≈0.065. The 
full list of nominally differentially methylated probes based on the unadjusted p-value (p≤0.05) is 
listed in Supplemental Table 5.1. 
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 In order to gain a better understanding of the function of genes that are nominally 
differentially methylated, we performed a gene enrichment analysis of the top 1000 nominally 
significant probes. Gene enrichment analysis of these nominally significant probes revealed 14 
annotation clusters had enrichment scores greater than 1. The top 5 annotation clusters were 
significantly enrichment in terms associated with myotubularin, homeobox, synapse function, 
transcription, and sequence specific DNA binding domains (Table 5.2); the full gene enrichment 
output is available in Supplemental Table 5.2. DNA methylation levels of genes associated with 
synaptic function had increased DNA methylation in MDD cases compared to controls, whereas 
the reverse pattern was observed for genes associated with transcription and DNA binding (i.e. 
average DNA methylation was reduced for in these genes in MDD cases vs. controls).  
 
5.3.2. WEIGHTED GENE CO-METHYLATION NETWORK ANALYSIS 
5.3.2.1. CO-METHYLATION MODULES 
Next, we employed a systems biology approach, WGCNA, to examine the impact of MDD 
on TSS-associated DNA methylation levels. In this analysis, 16 modules were generated from the 
clustering step. Of these, one module (salmon) was significantly negatively correlated (p=0.03, 
ρ=-0.29) with MDD (Figure 5.2). The significantly correlated module contained 69 probes, listed 
in Supplement Table 5.3. 
 To identify the underlying role of the probes in the MDD-associated module, an enrichment 
analysis was performed. Gene enrichment analysis revealed none of the identified annotation 
clusters had an enrichment score greater than 1. The top 5 annotation clusters were significantly 
enrichment in genes associated with oxioreductase (oxidative-reduction process), transcription 
regulation, DNA binding, and mitochondrion (Table 5.3), the full gene enrichment output is 
available in Supplemental Table 5.4, however none of the annotation clusters had an enrichment 
score greater than 1. Decreased DNA methylation was observed in genes associated with 
oxioreductase, transcription regulation, DNA binding, and mitochondrion in MDD participants 
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compared to controls. Further examination of this module revealed several probes map to genes 
directly related to mitochondrial function or structure (cg23210309, DNA Replication 
Helicase/Nuclease 2 (DNA2); cg20010369, GABA Type A Receptor Associated Protein Like 1 
(GABARAPL1); cg07126281, Sorting and Assembly Machinery 50kDa (SAMM50); cg05387146, 
Malic Enzyme 1 (ME1); cg15419313, Mitochondrial Ribosomal Protein S26 (MRPS26); 
cg09989883, Mitochondrial Ribosomal Protein S22 (MRPS22); cg04453241, 
Phosphatidylglycerophosphate Synthase 1 (PGS1); and cg00030423, Ubiquinol-Cytochrome C 
Reductase Rieske Iron-Sulfure Polypeptide 1 (UQCRFS1)).  
 A post hoc analysis was performed to confirm that no covariates included in the differential 
methylation analysis (age, sex, suicide status, and PMI) were significantly correlated with the 
MDD-associated module eigengene using a linear regression. No covariates were significantly 
associated with the MDD-associated module and do not confound the WGCNA results. 
 
5.3.3. OVERLAP OF DIFFERENTIAL METHYLATION AND WEIGHTED GENE CO-
METHYLATION NETWORK ANALYSIS RESULTS 
Results from the differential methylation and WGCNA analyses were compared for 
overlap. From the identified 4,652 nominally significant probes identified in the differential 
methylation analysis and 69 probes from the module significantly correlated with MDD, 7 probes 
were identified in common between the lists. To determine if the overlap of 7 probes was more 
than expected by chance, a hypergeometric probability was calculated using the total pool of 
70,515 probes. Results from the hypergeometric probability calculation determined the probability 
of an overlap of 7 probes is 0.085, more than would be expected by chance. The list of overlapping 
probeIDs and their corresponding gene name and symbol are listed in Table 5.4. Genecards.org 
was used to determine the function of the genes associated with the 7 overlapping probes. Using 
the UniProtKB/Swiss Prot function as well as the listed gene ontologies with experimental 
evidence, associated functions include transcription, histone demethylation, and vesicle transport.  
 135 
A comparison of the gene enrichment analyses from each approach revealed consistency in gene 
ontologies related to transcription. 
 
5.4. DISCUSSION 
 In this study, we set out to examine the epigenetic impact of MDD on post-mortem brain-
derived DNA focusing on TSS-associated probes using two analytic approaches, differential 
methylation and WGCNA. In the first analysis, using standard differential methylation approaches, 
we identified 4,652 probes that were nominally differentially methylated (p≤0.05), however no 
probes survived correction for multiple tests (FDR≤0.05). In our second analysis, using WGCNA, 
we identified one module that was significantly correlated with MDD (p≤0.05). Comparison of the 
results from both approaches revealed an overlap of seven probes. Furthermore, comparison of 
gene enrichment results from both analyses revealed consistency among the gene enrichments, 
suggesting a role for DNA binding and transcription in MDD.  
Although no probes survived multiple test correction in the differential methylation 
analysis, some of the nominally differentially methylated probes (p≤0.05) have been implicated in 
previous neurologic and psychiatric studies. For example, cg00600684 (p=9.17×10-7), located 
upstream of a TSS of WD repeat domain 11 (WDR11), is a protein coding gene whose function 
has not yet been characterized, however WDR11 is known to interact with EMX1 a transcription 
factor involved in olfactory neuron development (Kim et al., 2010). Recently, mutations of WDR11 
have been implicated in schizophrenia (Xu et al., 2011) and Kallmann Syndrome (Kim et al., 2010; 
Kim and Layman, 2011), a disorder characterized by delayed or absent puberty and an impaired 
sense of smell (Dode and Hardelin, 2009). Additionally, cg27241907 (p=7.59×10-5), located just 
upstream of a TSS for Ubiquitin Conjugating Enzyme E2 E2 (UBE2E2) is involved in selective 
protein degradation, and has been previously associated with Parkinson’s disease (Ramsey and 
Giasson, 2010; Zhang et al., 2000). A GWAS examining the association between type 2 diabetes 
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and psychiatric disorders found a SNP within UBE2E2 was associated with schizophrenia, 
however, this result did not survive multiple test correction (Kajio et al., 2014).  
Another probe of interest, cg06927864, located upstream of the TSS for Interleukin 1 
Receptor Accessory Protein-Like 1, IL1RAPL1, was nominally significant (p=0.052) in the 
differential methylation analysis and has been implicated in a previous MDD DNA methylation 
study (Walker et al., 2016b). Three additional probes (cg18230558, cg20350671, cg26791231) 
for IL1RAPL1 are also nominally differentially methylated (p≤0.05) in this analysis, and all 4 
probes show increased methylation in MDD cases compared to controls which is consistent with 
the findings of Walker et al. (Walker et al., 2016b). The function of IL1RAPL1 is to mediate 
excitatory synapses with a potential role in the release of neurotransmitters that have an effect on 
synapse structure and function. Given the consistent direction of methylation across the 4 probes 
both within this analysis and with the previous study by Walker, and the presence of several 
predicted transcription factor binding sites around the probes, it is plausible that these DNA 
methylation differences may be associated with differences in IL1RAPL1 expression. Additionally, 
mutations of this gene has been previously been implicated in studies of autism and mental 
retardation (Bahi et al., 2003; Butler et al., 2015; Nawara et al., 2008; Piton et al., 2008).  
A gene enrichment analysis of the top 1000 nominally differentially methylated probes 
revealed genes whose functions relate to transcriptional activity, DNA binding, and synaptic 
function. There is some evidence linking DNA binding and transcription-related genes to MDD 
(Kerman et al., 2012; Mellon et al., 2016; Subaran et al., 2016; Xu et al., 2015). For example, 
transcriptional regulators exhibited reduced expression in MDD cases compared to controls 
(Kerman et al., 2012), while another study reported increased expression of transcription 
regulators associated with MDD cases (Mellon et al., 2016). Dysregulation of genes associated 
with transcription and transcription regulation may have downstream effects on transcriptional 
efficacy in terms of the ability of transcriptional machinery to locate and bind to the correct DNA 
 137 
sequences, impacting the production of transcripts (gene expression), and even impact protein 
function.  
Gene ontologies related to synaptic function (including post synaptic membrane, cell 
junctions or synaptic cleft, neurotransmitter-gated ion channel and GABAergic synapses), and 
cellular adhesion are all integral components of normal cellular functioning in the brain and 
throughout the body. Synapses are responsible for passing electrical or chemical signals from 
one neuron to another. Dysregulation of genes associated with synaptic function have been 
previously associated with MDD and may be related to altered levels of neurotransmitters within 
the brain (as reviewed in (Lopizzo et al., 2015; Villanueva, 2013)). Previous studies of MDD have 
shown altered gene expression in synapse-related genes compared to controls (Duric et al., 2013; 
Forero et al., 2017; Hori et al., 2016; Kang et al., 2012) and decreased neuronal synapses (Kang 
et al., 2012).  Certainly, altered post synaptic cell membrane function within chemical synapses, 
can impact how the post synaptic cell responds (de- or hyper-polarization) to the signal from the 
presynaptic cell, thereby affecting the efficiency of synaptic transmission. Similarly, dysregulation 
of neurotransmitter-gated ion channels and GABAergic synapses can also impact the efficiency 
of post synaptic transmission by improperly responding to neurotransmitters within the synaptic 
cleft or even impact the number of receptors present on the membrane thereby altering sensitivity. 
Additionally, the synapse-related genes as identified by DAVID had increased DNA methylation 
within the TSS among the MDD cases, which is potentially indicative of decreased gene 
expression of these genes. Indeed, previous studies have reported decreased expression of 
synapse-related genes within both brain (Duric et al., 2013; Kang et al., 2012) and blood (Hori et 
al., 2016) tissues, which is consistent with the observed increased DNA methylation reported in 
this study. These results provide additional support for altered synaptic function in MDD, which is 
known to occur in participants with MDD (as reviewed in (Villanueva, 2013)).  
The second analysis made use of WGCNA, a method that is more robust against small 
samples sizes and reduces the burden of multiple hypothesis testing. WGCNA identified a module 
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that was significantly correlated with MDD, consisting of 69 probes. A gene enrichment analysis 
showed that genes in this module were enriched for genes associated with oxioreductase, 
transcription, DNA binding, and mitochondria. Of particular interest is the enrichment in 
mitochondria-related genes, as there is a strong body of evidence linking mitochondrial 
dysfunction with psychiatric disorders (Manji et al., 2012; Rezin et al., 2009; Torrell et al., 2013), 
including MDD (Murphy et al., 2017; Tobe, 2013; Torrell et al., 2013; Wang and Dwivedi, 2016). 
Mitochondria are considered the powerhouse of the cell as they are responsible for generating 
ATP through cellular respiration and regulation of cellular metabolism (Sherratt, 1991). Currently, 
within MDD, mitochondria dysregulation is thought to result in either reduced ATP levels (Gardner 
et al., 2003; Karabatsiakis et al., 2014) or increased levels of oxidative stress (Chang et al., 2015; 
Sarandol et al., 2007). Additionally, a significant negative correlation of mitochondrial activity and 
depression symptoms (fatigue, difficulty concentration, lack of energy, sadness, irritability, and 
traumatic load) has been shown (Karabatsiakis et al., 2014). Furthermore, it has been suggested 
that the downstream effect of mitochondrial dysregulation includes altered synaptic function (as 
reviewed in (Manji et al., 2012)). Results from our WGCNA analysis provide additional support to 
the literature linking mitochondrial dysregulation and MDD.  
An in-depth examination of individual probes within the MDD-associated WGCNA module 
revealed several genes that have previously been implicated in neurologic and psychiatric 
disorders. Of particular interest is cg19727439, which maps to the TSS of Glutamate Ionotropic 
Receptor Kainate Type Subunit 3 (GRIK3), a gene that has been previously been shown to be 
associated with MDD (Minelli et al., 2009; Schiffer and Heinemann, 2007) and schizophrenia 
(Greenwood et al., 2016). GRIK3 is a ligand-gated glutamate receptor that acts as an ion channel 
and has a role in excitatory synaptic transmission. Additionally, two probes, cg11509669 and 
cg07361180, map to Visin Like 1 (VSNL1) and Ral GEF With PH Domain and SH3 Binding Motif 
2 (RALGPS2) respectively, two genes that have been previously associated with Alzheimer’s 
disease (Groblewska et al., 2015; Liu et al., 2007). Other probes map to genes (JAK1, SVIL1, 
 139 
and ANO3 (alias TMEM16) which have been previously implicated in GWAS of bipolar disorder 
(Johnson et al., 2009; Xu et al., 2014), however JAK1 and SVIL1 did not achieve genome-wide 
significance in the GWAS study. These genes highlight the complex nature of studying psychiatric 
disorders such as MDD, which has a high rate of comorbidity with anxiety and personality 
disorders, and the overlap among findings of other disorders.  
With every study there are limitations that should be taken into consideration. First, this 
study makes use of post-mortem brain tissue. There are several concerns when using post-
mortem brain samples, such as any potential effects from cause of death, PMI, and method of 
tissue collection all of which may impact or confound results. Within this study, no significant 
differences were detected for age or PMI in MDD cases and controls, a significant difference 
between cases and controls in relation to suicide status was observed, and as a result, participant 
suicide status was controlled for in our analyses. Second, our sample size is relatively small, 
N=58, which may result in reduced power to detect significant associations that survive multiple 
hypothesis testing. To reduce these concerns, we applied two analytic approaches, differential 
methylation and WGCNA. WGCNA is robust for small sample sizes and reduces the burden of 
multiple hypothesis testing, increasing power. Third, we make use of previously collected data 
and therefore do not have information on co-morbid disease status, which may potentially 
confound our results. Lastly, we do not have available gene expression data for these participants 
and are therefore unable to assess the functional relevance of the identified altered DNA 
methylation patterns within the same individuals.  
Despite the above limitations, this study has many strengths. This study is unique in that 
we are making use of publically available high throughput human brain DNA methylation data, 
but analyzing it in a novel way: specifically, by investigating the epigenetic impact of MDD, which 
was outside the purview of the original study. Examination of DNA-derived from brain tissue 
allows for the direct examination of the primary tissue of interest in MDD. Additionally, by using 
DNA derived from neurons, we avoid the concerns of confounding from cellular heterogeneity 
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within the tissue. Secondly, we conducted analyses of genome-scale DNA methylation data. A 
genome-scale approach allows for the simultaneous interrogation of multiple regions of the 
genome, rather than honing in on one specific region as in a candidate gene study, allowing the 
possibility of multiple findings. Genome-scale studies also provide insight and direction for future 
candidate gene studies. Lastly, we employ two different analytic approaches, differential 
methylation and WGCNA, to analyze the data, which provide the opportunity to compare and 
contrast results from each approach. Standard differential methylation compares methylation 
between defined cases and controls with results focusing on individual CpG sites or genes. 
Conversely, WGCNA results focus on gene networks or pathways generated from the unbiased 
hierarchical clustering of the data based on methylation values, without regard to case or control 
status. Further, by focusing specifically on TSS in our WGCNA analyses, we hone in on networks 
of MDD-associated epigenetic dysregulation that has a higher likelihood of functional effects on 
gene expression. 
 In summary, we report altered DNA methylation associated with MDD from two analytic 
approaches with some overlap between findings. We report a degree of consistency in our 
differential methylation and WGCNA results with the previous literature examining MDD. We also 
report probes that have been previously implicated in other psychiatric and neurodegenerative 
diseases. Overall, our findings provide additional support for synaptic function and mitochondrial 
associated genes in MDD. Future work is needed to examine the relationship between altered 
DNA methylation and downstream gene expression within the same individual. This type of 
analysis will strengthen the findings and provide more evidence for the functional impact of altered 
DNA methylation levels. 
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5.5. TABLES AND FIGURES 
TABLE 5.1. Demographic and survey data summary of the study participants. Values indicate the 
counts or mean ± standard deviation. 
  MDD + MDD- P-value  
      (t-test or Χ2 ) 
Age 32±15.9 32.1±16.1 0.98 
Sex   Χ2 1.00 
Male 14 14  
Female 15 15  
Race   Χ2 0.6 
African 6 6  
Caucasian 22 23  
Asian 1 0  
Suicide Victim 21 2 Χ2  <0.001 
Post-Mortem Interval 
(PMI) 18.10±7.09 16.31±4.96 0.27 
*all information was obtained from the Guintivano 2013 paper (Guintivano et al., 2013).  
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TABLE 5.2. Summary of gene enrichment results for the top 1000 nominally differentially 
methylated probes 
Annotation Cluster 1     
Enrichment Score: 2.20     
Term Count p-value 
Fold 
Enrichment 
Benjamini 
p-value 
IPR010569:Myotubularin-related 5 0.002 9.23 0.63 
domain:Myotubularin phosphatase 5 0.002 8.89 0.59 
domain:GRAM 5 0.003 7.85 0.63 
SM00568:GRAM 4 0.025 6.13 1.00 
IPR004182:GRAM 4 0.040 5.17 0.96 
     
Annotation Cluster 2     
Enrichment Score: 1.84     
Term Count p-value 
Fold 
Enrichment 
Benjamini 
p-value 
IPR017970:Homeobox, conserved site 18 0.001 2.45 0.76 
DNA-binding region:Homeobox 16 0.006 2.23 0.73 
Homeobox 18 0.019 1.85 0.45 
IPR009057:Homeodomain-like 22 0.021 1.69 0.96 
IPR001356:Homeodomain 18 0.022 1.82 0.95 
IPR020479:Homeodomain, metazoa 9 0.026 2.53 0.96 
SM00389:HOX 18 0.026 1.77 0.97 
GO:0043565~sequence-specific DNA binding 29 0.053 1.43 0.99 
     
Annotation Cluster 3     
Enrichment Score: 1.56     
Term Count p-value 
Fold 
Enrichment 
Benjamini 
p-value 
GO:0030054~cell junction 30 0.006 1.70 0.93 
Synapse 24 0.008 1.81 0.46 
GO:0045211~postsynaptic membrane 16 0.017 1.97 0.83 
Postsynaptic cell membrane 12 0.070 1.81 0.58 
Cell junction 29 0.290 1.16 0.85 
     
Annotation Cluster 4     
Enrichment Score: 1.48     
Term Count p-value 
Fold 
Enrichment 
Benjamini 
p-value 
IPR008993:Tissue inhibitor of 
metalloproteinases-like, OB-fold 
5 0.017 4.97 0.97 
SM00643:C345C 4 0.030 5.77 0.94 
IPR018933:Netrin module, non-TIMP type 4 0.030 5.74 0.96 
domain:NTR 4 0.047 4.85 0.97 
IPR001134:Netrin domain 4 0.057 4.50 0.98 
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TABLE 5.2. (Continued)     
Annotation Cluster 5     
Enrichment Score: 1.36     
Term Count p-value 
Fold 
Enrichment 
Benjamini 
p-value 
GO:0030203~glycosaminoglycan metabolic 
process 6 0.005 5.25 0.96 
GO:0006024~glycosaminoglycan 
biosynthetic process 7 0.006 4.23 0.94 
Heparan sulfate 4 0.020 6.73 0.42 
GO:0043395~heparan sulfate proteoglycan 
binding 4 0.031 5.68 1.00 
GO:0006027~glycosaminoglycan catabolic 
process 4 0.081 3.90 1.00 
Proteoglycan 5 0.107 2.75 0.64 
GO:0043202~lysosomal lumen 7 0.109 2.14 0.95 
GO:0005796~Golgi lumen 7 0.165 1.89 0.97 
GO:0001523~retinoid metabolic process 5 0.219 2.08 1.00 
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TABLE 5.3. Summary of gene enrichment for the WGCNA module significantly correlated with 
MDD. 
Annotation Cluster 1     
Enrichment Score: 0.99     
Term 
Number of 
genes in term 
p-value 
Fold 
Enrichment 
Benjamini 
p-value 
Oxidoreductase 5 0.056 3.40 1.00 
NADP 3 0.078 6.38 0.84 
GO:0055114~oxidation-reduction 
process 
4 0.249 2.27 1.00 
     
Annotation Cluster 2     
Enrichment Score: 0.85     
Term 
Number of 
genes in term 
p-value 
Fold 
Enrichment 
Benjamini 
p-value 
IPR011993:Pleckstrin homology-like 
domain 
4 0.112 3.34 1.00 
domain:PH 3 0.129 4.72 1.00 
SM00233:PH 3 0.157 4.08 1.00 
IPR001849:Pleckstrin homology 
domain 
3 0.171 3.95 1.00 
     
Annotation Cluster 3     
Enrichment Score: 0.83     
Term 
Number of 
genes in term 
p-value 
Fold 
Enrichment 
Benjamini 
p-value 
GO:0005743~mitochondrial inner 
membrane 
5 0.029 4.22 0.94 
GO:0005739~mitochondrion 7 0.135 1.96 0.99 
Mitochondrion 6 0.143 2.12 0.93 
transit peptide: Mitochondrion 3 0.348 2.40 1.00 
Transit peptide 3 0.385 2.22 0.98 
     
Annotation Cluster 4     
Enrichment Score: 0.73     
Term 
Number of 
genes in term 
p-value 
Fold 
Enrichment 
Benjamini 
p-value 
GO:0005730~nucleolus 6 0.074 2.60 0.98 
GO:0010628~positive regulation of 
gene expression 
3 0.178 3.85 1.00 
mutagenesis site 7 0.489 1.23 1.00 
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TABLE 5.3. (Continued) 
Annotation Cluster 5 
Enrichment Score: 0.51     
Term 
Number of 
genes in term 
p-value 
Fold 
Enrichment 
Benjamini 
p-value 
GO:0045892~negative regulation of 
transcription, DNA-templated 
5 0.057 3.37 1.00 
Transcription regulation 11 0.058 1.87 0.98 
Transcription 11 0.067 1.82 0.96 
GO:0005730~nucleolus 6 0.074 2.60 0.98 
GO:0006351~transcription, DNA-
templated 
9 0.205 1.55 1.00 
GO:0005634~nucleus 18 0.236 1.24 0.99 
DNA-binding 8 0.242 1.54 0.96 
Ubl conjugation 6 0.417 1.39 0.98 
Nucleus 15 0.425 1.13 0.97 
GO:0003677~DNA binding 6 0.543 1.21 1.00 
GO:0046872~metal ion binding 7 0.566 1.14 1.00 
IPR013087:Zinc finger C2H2-
type/integrase DNA-binding domain 
3 0.588 1.50 1.00 
SM00355:ZnF_C2H2 3 0.617 1.41 1.00 
IPR015880:Zinc finger, C2H2-like 3 0.625 1.41 1.00 
GO:0006355~regulation of 
transcription, DNA-templated 
5 0.650 1.12 1.00 
IPR007087:Zinc finger, C2H2 3 0.651 1.34 1.00 
Zinc-finger 4 0.829 0.89 1.00 
Zinc 4 0.941 0.67 1.00 
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TABLE 5.4. Overlap of probes between the differential methylation and WGCNA analyses. 
IlmnID Gene Symbol Gene Name 
cg07980947 ZNF263 Zinc Finger Protein 263  
cg15932787  C6orf115 (ABRACL) –ABRA C-Terminal Like  
cg23487015  OSBPL11 Oxysterol Binding Protein Like 11  
cg20010369  GABARAPL1 GABA Type A Receptor Associated Protein Like 1  
cg20873046 KDM4A Lysine Demethylase 4A  
cg17543520 DENND5A DENN domain containing 5A  
cg25283338  PTPN9 Protein Tyrosine Phosphatase, Non-Receptor Type 9  
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FIGURE 5.1. Manhattan plot of differential methylation results. Scatter plot shows the distribution 
of individual probes across each chromosome (x-axis) by the negative logarithm of the p-values 
(y-axis). Horizontal red bar indicates FDR-based cutoff for significance and the horizontal blue 
bar indicates nominal significance (p<0.05). Black arrow indicates top probe cg00600684 
(WDR11) p= 9.17x10-7, FDR=0.065. 
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FIGURE 5.2. Module-trait relationship. Heatmap shows the correlation and respective p-value 
(in parentheses) between each module eigengene (indicated by color) and Major Depressive 
Disorder (MDD). Correlations are considered significant if p≤0.05. 
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CHAPTER 6:  GENERAL DISCUSSION  
 
There is a strong body of work demonstrating early life is a critical developmental period 
where the risk for or resilience to mental illness later in life is shaped (Afifi et al., 2008; Espejo et 
al., 2007; Green et al., 2010; Kendler et al., 2004; Kessler et al., 1997). More specifically, 
individuals with a history of childhood maltreatment are more likely to develop mood and anxiety 
disorders (Duncan et al., 1996; Kessler et al., 1997) such as major depressive disorder (MDD) 
and post-traumatic stress disorder (PTSD). Despite this well-known association, the biologic 
mechanisms contributing to this relationship are poorly understood. The overall goal of this 
dissertation is to further explore and characterize the impact of childhood maltreatment, MDD, 
and PTSD on DNA methylation and gene expression both at the locus-specific and genome-scale 
levels, in order to contribute and deepen the current understanding of the biologic dysregulation 
associated with each exposure (childhood maltreatment, MDD, and PTSD) and, in particular, how 
the childhood maltreatment-associated dysregulation may mediate later risk for PTSD or MDD. 
Within this dissertation, I performed four empirical investigations (Chapters 2-5), findings of which 
are summarized below; each of the studies contributes to the goal of characterizing the impact of 
childhood maltreatment, MDD, and PTSD on both DNA methylation and gene expression, and 
the larger goal of elucidating the biologic mechanisms contributing to the relationship among 
childhood maltreatment, MDD, and PTSD. 
In Chapter 2: Glucocorticoid receptor DNA methylation, childhood maltreatment and major 
depression, I reported both childhood maltreatment and MDD are significantly associated with 
altered NR3C1 promoter region DNA methylation levels, however in opposite directions and at 
adjacent CpG sites. Additionally, I found childhood maltreatment alone was associated with 
significantly decreased NR3C1 gene expression levels. This study demonstrated childhood 
maltreatment and MDD impact NR3C1 DNA methylation in an independent manner. In Chapter 
3: FKBP5 does not mediate the relationship between childhood maltreatment and depression: 
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findings from the Detroit Neighborhood Health Study, I reported childhood maltreatment does not 
predict FKBP5 DNA methylation at any of the four regions tested. Additionally, FKBP5 DNA 
methylation did not predict depression symptom severity at any of the four regions examined. A 
secondary analysis found no genotype-dependent effect of FKBP5 SNP rs1360780 on Intron 7 
DNA methylation levels and no interaction effect between childhood maltreatment and genotype 
of FKBP5 SNP rs1360780 on FKBP5 intron 7 DNA methylation. Interestingly, FKBP5 gene 
expression was significantly decreased in participants with MDD compared to controls. This study 
highlights the complex relationship between exposure to childhood maltreatment and depression. 
In Chapter 4: Altered transcriptomic profiles associated with childhood maltreatment and post-
traumatic stress disorder, I characterized and explored genome-scale gene expression networks 
dysregulated by childhood maltreatment and PTSD separately using a systems biology approach, 
weighted gene co-expression network analysis (WGCNA). I reported childhood maltreatment-
associated networks were enriched in genes associated with the cell cycle and mitosis, while 
PTSD-associated networks were enriched in genes associated with RNA processing, the cell 
cycle, immune system, and mitochondrion-related genes. However, the findings from the 
discovery dataset were not replicated in the independent cohort used for the replication analysis. 
Interestingly, relatively little overlap of dysregulated networks was observed between childhood 
maltreatment and PTSD, suggesting the impact of childhood maltreatment and PTSD on biologic 
pathways is largely unique to each exposure. In Chapter 5: Epigenetic profiles associated with 
major depression in human brain, I provide evidence for the dysregulation of genes associated 
with synaptic function and mitochondrial function among individuals with MDD by employing two 
different approaches, standard differential methylation and WGCNA. Together, these four studies 
provide evidence of the impact of childhood maltreatment, MDD, and PTSD on DNA methylation 
and gene expression at specific hypothalamic-pituitary-adrenal (HPA) axis genes and at the 
genome-scale level. 
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The results of the studies within this dissertation highlight the complex relationship 
between childhood maltreatment and mental illness and their respective impacts on DNA 
methylation and gene expression levels both at the locus-specific and genome-scale levels. 
Results from Chapter 2 are consistent with previous literature reporting altered DNA methylation 
levels of NR3C1 given a history of childhood maltreatment (Martin-Blanco et al., 2014; McGowan 
et al., 2009; Tyrka et al., 2012) and MDD (Na et al., 2014). However, contrary to previous work 
(Klengel et al., 2013; Tyrka et al., 2015), this dissertation detected no significant effect of 
childhood maltreatment on FKBP5 DNA methylation (Chapter 3), interestingly we report increased 
FKBP5 gene expression levels associated with MDD. Chapter 3 results suggest that either 
another region of FKBP5 may be differentially methylated and that is what contributes to the 
altered gene expression, or perhaps another epigenetic mechanism is at work. Results from 
Chapter 4 are novel and suggest there is relatively little overlap of networks associated with 
childhood maltreatment and PTSD. Additionally, results from Chapter 4 are consistent with the 
literature linking PTSD with immune dysregulation (Bam et al., 2016; Breen et al., 2015; Glatt et 
al., 2013; Neylan et al., 2011; O'Donovan et al., 2011; Rusiecki et al., 2013; Sarapas et al., 2011; 
Segman et al., 2005; Smith et al., 2011a; Uddin et al., 2010; Yehuda et al., 2009; Zhou et al., 
2014; Zieker et al., 2007). Lastly, Chapter 5 results are consistent with previous reports of 
mitochondrial and synaptic function dysregulation in MDD (Duric et al., 2013; Forero et al., 2017; 
Hori et al., 2016; Kang et al., 2012; Murphy et al., 2017; Tobe, 2013; Torrell et al., 2013; Wang 
and Dwivedi, 2016). These results all provide support for altered DNA methylation and gene 
expression associated with childhood maltreatment, MDD, and PTSD and also highlight the 
complexity of the relationship between childhood maltreatment and mental illness. Future studies 
should examine the impact of these exposures on DNA methylation and gene expression of other 
HPA axis genes. 
Although the majority of studies presented within this dissertation make use of peripheral 
tissue, whole blood (Chapters 2-4), rather than the central tissue of interest, brain (Chapter 5), it 
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is important to comment on the use of peripheral tissues compared to central nervous system 
(CNS) tissues. Use of CNS tissues, specifically brain, is ideal since as it allows for the direct 
assessment of the biologic impact of the exposures of interest; however CNS tissues in living 
humans are largely inaccessible. Although post-mortem tissues provide the opportunity to assess 
the biologic impact using CNS and peripheral tissues within a single individual, studies using this 
approach are relatively rare (Byun et al., 2009; Hannon et al., 2015). Even though central tissues 
are preferred, the overwhelming majority of studies use peripheral tissues, namely whole blood, 
due in large part to the ease of sampling from study participants. Studies of peripheral tissues to 
assess the biologic impact of environmental and/or mental illness serve as an index for the 
potential changes that occur within the central tissue, brain. The main goal of using peripheral 
tissues is to identify potential biomarkers of disease risk, however the profiles of central tissues 
must be characterized in order for this to successfully occur. It is important to note that biomarkers 
do not need to “mirror” the actual biologic effect in the central tissue, however, a consistent 
correlation should be observed. It is important to assess global gene expression and DNA 
methylation levels within both healthy controls as well as cases across multiple tissues of the 
same individual, in order to create a baseline or benchmark dataset from which inferences can 
be made. To this end, several studies have examined genome-scale DNA methylation (Farre et 
al., 2015; Hannon et al., 2015; Kaminsky et al., 2012; Walton et al., 2016) and gene expression 
(Kohane and Valtchinov, 2012; Rollins et al., 2010; Sullivan et al., 2006) patterns from central and 
peripheral tissues. DNA methylation signatures are known to be tissue specific (Gama-Sosa et 
al., 1983) and responsive to environmental exposures (Fraga et al., 2005), therefore it is 
imperative to characterize the methylation profiles of both central and peripheral tissues in healthy 
individuals and in the exposure/disease of interest. Hannon et al. (Hannon et al., 2015), examined 
DNA methylation profiles from both central and peripheral tissues from the same individuals and 
with matched controls. They found that although there is great variability in methylation signatures 
across tissues, a subset of CpG sites are strongly correlated across tissues (Hannon et al., 2015). 
 153 
 
Consistent with the Hannon study, another group reported high levels of correlation between 
blood and brain tissues in a subset—roughly 8%—of CpG sites (Walton et al., 2016). Another 
study examined the genome-scale methylation patterns of 11 tissues derived from the same 
individuals and report a high level of correlation in 807 of the 1505 CpG sites across all 11 tissues 
(Byun et al., 2009). In addition to the above mentioned studies, several public datasets or 
browsers exist that allow for the simultaneous examination of DNA methylation profiles of central 
and peripheral tissues, for example the UCSC genome browser tool (genome.ucsc.edu) (Kent et 
al., 2002), MARMAL-AID (marmal-aid.org) (Lowe and Rakyan, 2013), and the blood brain DNA 
methylation comparison tool (http://epigenetics.essex.ac.uk/bloodbrain/) (Hannon et al., 2015). 
Together, these studies and tools provide resources to examine DNA methylation levels across 
both central and peripheral tissues. Specific to the studies within this dissertation, in Chapter 2, I 
used the publically available tools, UCSC genome browser and MARMAL-AID to examine the 
NR3C1 DNA methylation in available central nervous tissues. I report similar DNA methylation 
levels across the available central and peripheral tissues. In Chapter 3, no effect childhood 
maltreatment was observed on FKBP5 DNA methylation at any of the regions examined, 
additionally, the regions examined do not overlap with the available 450K data, so potential 
comparisons would need to be made based on adjacent regions.    
In addition to the aforementioned studies examining correlation and concordance of DNA 
methylation levels across tissues, a relatively strong body of work has examined this issue using 
gene expression data derived from healthy individuals as well. A seminal genome-scale gene 
expression study by Sullivan et al. (Sullivan et al., 2006) examined 79 different human tissues 
and found overall gene expression patterns were highly correlated between blood and brain 
tissues; however, similar to DNA methylation, great variability of expression can be observed in 
some genes (Sullivan et al., 2006). Following up on this work, Rollins et al. (Rollins et al., 2010), 
examined the relationship between blood and brain-derived gene expression in the same 
individuals as well as a group of matched participants. They found a subset —roughly 20%—of 
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expressed transcripts had similar expression patterns between blood and brain tissues (Rollins 
et al., 2010). This work was furthered by Kohane and Valtchinov (Kohane and Valtchinov, 2012), 
as they compared expression signatures of white blood cells to other tissues (19 in total) and 
found a high rate of correlation between white blood cells and other tissues examined (Kohane 
and Valtchinov, 2012). Together, these studies of both DNA methylation and gene expression 
demonstrate that a certain level of correlation exists between central and peripheral tissues. 
These studies also provide evidence and support for the use of peripheral tissues as a proxy for 
changes occurring in the brain, however, careful consideration of concordance across tissues 
must be employed when selecting the tissue and gene region of interest. Still, more work is 
needed to profile the DNA methylation and gene expression profiles of central and peripheral 
tissues in a variety of exposures and illnesses.  
The studies within this dissertation provide support for the role of mitochondrion 
dysregulation in stress-related mental illness, specifically PTSD (Chapter 4) and MDD (Chapter 
5). Mitochondrial dysregulation has been implicated in several mental illnesses including MDD, 
PTSD, schizophrenia, and bipolar disorder (Manji et al., 2012; Miller and Sadeh, 2014; Rezin et 
al., 2009; Shao et al., 2008; Su et al., 2008). It is thought that dysregulation of mitochondrial 
function results in impaired energy production and may disrupt other cellular processes including 
apoptosis, synaptic activity, calcium regulation, and regulation of reactive oxygen species (Manji 
et al., 2012; Rezin et al., 2009). Additionally, there is evidence that mitochondrial dysregulation 
can impact the immune response (as reviewed in (Galluzzi et al., 2012; West et al., 2011)). 
Interestingly, studies have suggested glucocorticoids and glucocorticoid receptors can influence 
mitochondrial function (Demonacos et al., 1996; Lee et al., 2013; Psarra and Sekeris, 2011), as 
glucocorticoid receptors and glucocorticoids are capable of translocating into the mitochondria 
(Demonacos et al., 1996). Once in the mitochondria, glucocorticoid receptors can modulate 
mitochondrial gene expression by binding to mitochondrial glucocorticoid response elements 
(Psarra and Sekeris, 2011). Additionally, glucocorticoids can influence mitochondrial biogenesis, 
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ATP production, and oxidative phosphorylation (Lee et al., 2013; Scheller and Sekeris, 2003). 
Despite the strong body of evidence linking mental illness with HPA axis dysregulation and, 
separately, with mitochondrial dysregulation, no one has directly investigated the relationship 
among mental illness, HPA axis activity, and mitochondrial function. Specific to the studies in this 
dissertation, I report mitochondrial dysregulation in association with both MDD (Chapter 5) and 
PTSD (Chapter 4), in different tissues; and in Chapter 2, I demonstrate the significant impact of 
MDD on DNA methylation of HPA axis gene, NR3C1, the glucocorticoid receptor. Future studies 
examining these three aspects together (HPA axis, mitochondrial function, and mental illness), in 
a longitudinal setting would provide insight into this relationship and how dysregulation of these 
systems is established over time.  
Numerous studies of PTSD have reported a dysregulation of immune response and 
immune function genes using genome-scale approaches (Bam et al., 2016; Breen et al., 2015; 
Glatt et al., 2013; Neylan et al., 2011; O'Donovan et al., 2011; Rusiecki et al., 2013; Sarapas et 
al., 2011; Segman et al., 2005; Smith et al., 2011a; Uddin et al., 2010; Yehuda et al., 2009; Zhou 
et al., 2014; Zieker et al., 2007). Other studies examining immune dysregulation in individuals 
with PTSD have employed a more targeted approach and examined specific pro- and anti- 
inflammatory cytokines (Cohen et al., 2011; Gola et al., 2013; Guo et al., 2012; von Kanel et al., 
2007; Zhou et al., 2014) in participants with and without PTSD, finding increased levels of pro-
inflammatory cytokines (Cohen et al., 2011; Gola et al., 2013; von Kanel et al., 2007; Zhou et al., 
2014) and conflicting reports regarding anti-inflammatory cytokines (Cohen et al., 2011; Guo et 
al., 2012). Furthermore, individuals with PTSD show an increased prevalence of inflammatory 
diseases such as cardiovascular disease, diabetes, and autoimmune disease among others in 
people with PTSD (Boscarino, 2004; O'Donovan et al., 2015; Tsai and Shen, 2017). Consistent 
with previous studies, I report a dysregulation of immune-related networks associated with PTSD 
(Chapter 4), more specifically a downregulation of both the adaptive and innate immune systems. 
As described in Chapter 1, the sympathetic nervous system and HPA axis are activated during a 
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stressful event and both systems have roles in regulating the immune response (Charmandari et 
al., 2005; Irwin and Cole, 2011; McEwen, 2007). When activated, the sympathetic nervous system 
upregulates pro-inflammatory cytokines and downregulates the innate immune response (Irwin 
and Cole, 2011). Activation of the HPA axis results in the release of glucocorticoids, such as the 
stress hormone cortisol, inhibiting the transcription of immune response genes, namely 
upregulating anti-inflammatory cytokines and downregulating the innate immune response (Irwin 
and Cole, 2011; Savage-Dunn et al., 2003). Additionally, decreased cortisol levels have been 
reported in participants with PTSD (Boscarino, 1996; Labonte et al., 2014; Yehuda et al., 2015b) 
and observed following exposure to stress (MacMillan et al., 2009; Roelofs et al., 2009; Simeon 
et al., 2007), suggesting increased cortisol sensitivity. This increased cortisol sensitivity together 
with the sympathetic nervous system may contribute to the observed dysregulation of the immune 
response and more specifically the innate immune response. However, further work is needed to 
more completely characterize immune dysregulation within individuals with PTSD. 
Overall, the studies presented within this dissertation provide support for altered DNA 
methylation and gene expression levels, both at the locus-specific and genome-scale levels, in 
childhood maltreatment, MDD, and PTSD. Together, these studies contribute to our current 
understanding of the biologic impact of childhood maltreatment, MDD, and PTSD on DNA 
methylation and gene expression levels. Future studies should explore the impact of these 
exposures in more central tissues (Chapters 2-4), further explore the relationship between mental 
illness, HPA axis regulation, and mitochondrial function (Chapters 2, 4 and 5), and lastly further 
examine and characterize the role of inflammation in PTSD. 
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APPENDIX A: SUPPLEMENTAL TABLES 
 
The supplementary file “Bustamante_Dissertation_Supplementary Tables.xlsx” contains excel 
spreadsheets for all supplemental materials/tables referenced throughout the dissertation. 
Supplemental Tables correspond to Chapters 3, 4, and 5. All supplemental tables are listed 
below.   
 
SUPPLEMENTAL TABLE 3.1. Mediation results of the Upstream promoter. Linear regression 
results showing the results of each step of the mediation analysis. The β value, 95% confidence 
interval (CI), unadjusted p-values, and FDR adjusted p-values are shown for each variable within 
the model. Age, sex, race, PBMC count, and antidepressant medication use were included as 
covariates. Bold values indicate the variable is a significant in the model following correction for 
multiple hypothesis testing. 
SUPPLEMENTAL TABLE 3.2. Mediation results of the downstream promoter. Linear 
regression results showing the results of each step of the mediation analysis. The β value, 95% 
confidence interval (CI), unadjusted p-values, and FDR adjusted p-values are shown for each 
variable within the model. Age, sex, race, PBMC count, and antidepressant medication use were 
included as covariates. Bold values indicate the variable is a significant in the model following 
correction for multiple hypothesis testing. 
SUPPLEMENTAL TABLE 3.3. Mediation results of the Intron 2. Linear regression results 
showing the results of each step of the mediation analysis. The β value, 95% confidence interval 
(CI), unadjusted p-values, and FDR adjusted p-values are shown for each variable within the 
model. Age, sex, race, PBMC count, and antidepressant medication use were included as 
covariates. Bold values indicate the variable is a significant in the model following correction for 
multiple hypothesis testing. 
SUPPLEMENTAL TABLE 3.4. Mediation results of the Intron 7. Linear regression results 
showing the results of each step of the mediation analysis. The β value, 95% confidence interval 
(CI), unadjusted p-values, and FDR adjusted p-values are shown for each variable within the 
model. Age, sex, race, PBMC count, and antidepressant medication use were included as 
covariates. Bold values indicate the variable is a significant in the model following correction for 
multiple hypothesis testing. 
SUPPLEMENTAL TABLE 4.1.  DNHS Childhood Maltreatment Grey60 Module. DAVID 
Enrichment Analysis output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.2.  DNHS PTSD Grey Module. DAVID Enrichment Analysis output. 
Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.3.  DNHS PTSD Blue Module. DAVID Enrichment Analysis output. 
Contains all annotation clusters with an enrichment above 1. 
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SUPPLEMENTAL TABLE 4.4.  DNHS PTSD Red Module. DAVID Enrichment Analysis output. 
Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.5.  DNHS PTSD Tan Module. DAVID Enrichment Analysis output. 
Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.6.  DNHS PTSD Green Module. DAVID Enrichment Analysis 
output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.7.  DNHS PTSD Yellow Module. DAVID Enrichment Analysis 
output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.8.  Replication Childhood Maltreatment Grey Module. DAVID 
Enrichment Analysis output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.9.  Replication Childhood Maltreatment Grey60 Module. DAVID 
Enrichment Analysis output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 4.10.  Replication Childhood Maltreatment Red Module. DAVID 
Enrichment Analysis output. Contains all annotation clusters with an enrichment above 1. 
SUPPLEMENTAL TABLE 5.1. Full list of nominally significant differential methylation analysis 
results, p<0.05. 
SUPPLEMENTAL TABLE 5.2. Full output from gene enrichment analysis of top 1000 nominally 
differentially methylated probes, p<0.05. 
SUPPLEMENTAL TABLE 5.3. WGCNA Results, list of probes within the MDD-associated 
module. 
SUPPLEMENTAL TABLE 5.4. Full output from the gene enrichment analysis of WGCNA 
module significantly associated with MDD.  
 
